var title_f28_1_28688="Urine sediment showing a waxy cast";
var content_f28_1_28688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F83885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F83885&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine sediment showing a waxy cast",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 342px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Ringsrud KM, Linne JJ. Urinalysis and Body Fluids: A Colortext and Atlas, Mosby, Amsterdam 1995. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28688=[""].join("\n");
var outline_f28_1_28688=null;
var title_f28_1_28689="MCL grade1 injury MRI";
var content_f28_1_28689=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    MRI of Grade 1 medial collateral ligament injury",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MCL is macroscopically intact, but there is overlying bright signal (arrow heads), reflecting superficial edema associated with the presence of torn fibers. In Grade 1 sprains, the edema is seen only superficially. The MCL is of normal thickness and is closely applied to the cortical bone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28689=[""].join("\n");
var outline_f28_1_28689=null;
var title_f28_1_28690="Coyne spoon assisted delivery";
var content_f28_1_28690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1124px;\">",
"  <div class=\"videoplayer\" h264=\"./images/OBGYN/67734/Coyne_spoon_assist_delivery.mp4?title=Coyne+spoon+assisted+delivery\" style=\"width:480px;height:288px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Coyne spoon assisted delivery",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28690=[""].join("\n");
var outline_f28_1_28690=null;
var title_f28_1_28691="Safe bedding for infants";
var content_f28_1_28691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52080&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Safe sleep position and bedding to reduce SIDS risk",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 562px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     To reduce the risk for sudden infant death syndrome (SIDS), the following practices should be used for every sleep:",
"    </p>",
"    <ul>",
"     <li>",
"      Place the infant to sleep on his or her back.",
"     </li>",
"     <li>",
"      The sleep surface should be firm. Infants should not sleep on sofas or beds designed for adults.",
"     </li>",
"     <li>",
"      Avoid soft objects in the crib, including pillows and stuffed animals.",
"     </li>",
"     <li>",
"      If a blanket is used, the infant's feet should be placed near the bottom of the&nbsp;crib (\"feet to foot\").&nbsp;The blanket&nbsp;should be thin, and tucked around the mattress, reaching only as far as the infant's chest.&nbsp;",
"     </li>",
"    </ul>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28691=[""].join("\n");
var outline_f28_1_28691=null;
var title_f28_1_28692="Urofollitropin (purified human follicle stimulating hormone): Patient drug information";
var content_f28_1_28692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Urofollitropin (purified human follicle stimulating hormone): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/60/32708?source=see_link\">",
"     see \"Urofollitropin (purified human follicle stimulating hormone): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3878204\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bravelle&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F248402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bravelle&reg;;",
"     </li>",
"     <li>",
"      Fertinorm&reg; H.P.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691380",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help you get pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help make sperm.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029383\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to urofollitropin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703455",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Cancer where hormones make it grow, ovarian cysts, adrenal gland disease, thyroid gland disease, or vaginal bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697565",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Limit working out while undergoing ovarian stimulation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698292",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ovarian cyst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696435",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pimples (acne).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698354",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697923",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Enlarged breasts.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Over stimulation of the ovaries.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain or soreness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696011",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696360",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give the shot.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10984 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-71A5527948-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28692=[""].join("\n");
var outline_f28_1_28692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3878204\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F248402\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029384\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029383\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029388\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029389\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029391\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029386\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029387\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029392\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029393\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?31/60/32708?source=related_link\">",
"      Urofollitropin (purified human follicle stimulating hormone): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_1_28693="Psoas hitch ureteral reimplantation";
var content_f28_1_28693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60514&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    Psoas hitch ureteral reimplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 420px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Figure A represents mobilization of the bladder, with fingers inserted into the bladder to assist with anchoring the bladder to the psoas muscle with nonabsorbable sutures. The cystostomy is performed away from the dome. The ureter is reimplanted into the dome of the bladder.",
"    <br/>",
"    Figure B represents the reimplanted ureter, anchored bladder, and the closed cystostomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28693=[""].join("\n");
var outline_f28_1_28693=null;
var title_f28_1_28694="Intradural nerve sheath tumors";
var content_f28_1_28694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Intradural nerve sheath tumors",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Mark Bilsky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Robert Maki, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Jay S Loeffler, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Patrick Y Wen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Alberto S Pappo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28694/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/1/28694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal tumors are classified as extradural, intradural and extramedullary, or intradural intramedullary based upon their anatomic location. Nerve sheath tumors (NSTs) constitute about 25 percent of tumors arising in the intradural extramedullary space [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the majority of NSTs are confined to the intradural extramedullary space, some of these tumors extend into either the extradural compartment or the spinal cord. In addition, occasional spinal NSTs are confined to either the extradural or intramedullary spaces [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NSTs are derived from the Schwann cells and perineurial cells of the peripheral nervous system. Approximately 65 percent of intradural nerve sheath tumors are schwannomas, and most of the remainder are neurofibromas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/4\">",
"     4",
"    </a>",
"    ]. Malignant NSTs are rare, constituting about 5 percent of such tumors.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment of NSTs will be reviewed here. Peripheral extradural nerve sheath tumors, intramedullary spinal tumors, and meningiomas of the spinal cord are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H7#H7\">",
"     \"Spinal cord tumors\", section on 'Intramedullary tumors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link&amp;anchor=H16#H16\">",
"     \"Spinal cord tumors\", section on 'Meningioma'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intradural, extramedullary nerve sheath tumors (NSTs) may be either sporadic or associated with an inherited disorder. Sporadic NSTs are most common in the fifth to seventh decades and have a similar incidence in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/3\">",
"     3",
"    </a>",
"    ]. In addition, spinal NSTs are manifestation of both neurofibromatosis type 1 (NF-1) and neurofibromatosis type 2 (NF-2):",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     NF type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromas are a characteristic component of NF-1. Although the majority of these lesions are located in the periphery, they also occur within the spinal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/5\">",
"     5",
"    </a>",
"    ]. Most of the spinal neurofibromas are asymptomatic, but 2 percent of patients with NF-1 have neurologic symptoms from a spinal lesion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=see_link\">",
"     \"Neurofibromatosis type 1 (von Recklinghausen's disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     NF type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Spinal tumors are found in up to 90 percent of patients with NF-2. The tumors are often multiple, consisting primarily of schwannomas, but including some meningiomas [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/7\">",
"     7",
"    </a>",
"    ]. About 2 percent of all spinal schwannomas are seen in patients with NF-2, while the rest are sporadic [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=see_link&amp;anchor=H9#H9\">",
"     \"Neurofibromatosis type 2\", section on 'Spinal tumors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomas are thought to be predominantly a proliferation of Schwann cells, while neurofibromas are derived from a mixture of Schwann, perineurial, and fibroblastic cells [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/9\">",
"     9",
"    </a>",
"    ]. This observation is based upon histopathologic and immunochemical analyses of these tumors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Schwannomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomas arise from macroscopically recognizable nerves and generally occur as growths that are closely associated with, but relatively circumscribed from, the nerve. Immunochemical staining for the S-100 protein shows that the neoplastic proliferation consists almost exclusively of Schwann cells. Neurofilament stains demonstrate few or no axons within the neoplastic proliferation.",
"   </p>",
"   <p>",
"    Microscopically, spindle cells are arranged in short, intersecting fascicles. Nuclear palisading is a typical feature; when pronounced, this results in the formation of Verocay bodies [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/9\">",
"     9",
"    </a>",
"    ]. Two different histologic patterns have been described that coexist within schwannomas (",
"    <a class=\"graphic graphic_picture graphicRef51535 graphicRef58208 graphicRef71091 \" href=\"UTD.htm?40/44/41674\">",
"     picture 1A-C",
"    </a>",
"    ). The Antoni A regions consist of compact areas of spindle cells with pink cytoplasm. These alternate with looser Antoni B tissue, which is comprised of cells showing clear, vacuolated cytoplasm due to lipid accumulation. Myxoid change is not prominent, except in myxoid variants [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Neurofibromas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurofibromas grow as fusiform expansions of the involved nerve with tumor cells intermingling with axons. Histologically, there are several features that help to distinguish neurofibromas from schwannomas:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurofibromas are less compact and less cellular.",
"     </li>",
"     <li>",
"      Tumor cells are spindle-shaped with a wavier or buckled nuclear profile, compared to cells in schwannomas.",
"     </li>",
"     <li>",
"      Neurofibromas often contain crisscrossing bundles of collagen, a moderate amount of myxoid matrix, and readily identifiable mast cells, features that are uncommon in schwannomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Malignant nerve sheath tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant nerve sheath tumors (MNSTs) arise sporadically as sarcomas or from dedifferentiation of neurofibromas in patients with NF-1. Although MNSTs more commonly arise from peripheral nerves, they comprise up to 6 percent of intradural nerve sheath tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/4,11,12\">",
"     4,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Microscopically, MNSTs are highly cellular and show a fascicular pattern, spindle-shaped nuclei, and scant cytoplasm. Necrosis and a high mitotic index are also frequently observed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=see_link&amp;anchor=H12227065#H12227065\">",
"     \"Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma\", section on 'Introduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Schwannomas and neurofibromas typically are slow growing and often fill a significant volume of the spinal column before causing symptoms. In contrast, MNSTs are relatively fast growing, producing rapidly progressive symptoms, and carry a worse prognosis.",
"   </p>",
"   <p>",
"    The specific symptoms of nerve sheath tumors (NSTs) depend upon the level of the spinal cord involved. NSTs commonly present with pain, which is typically worse at night or in the morning and resolves during the day. Schwannomas and neurofibromas usually arise from the dorsal sensory roots and may present with radicular sensory changes. Radiculopathy with motor manifestations is not common, even with involvement of functional roots in the cervical or lumbar spine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once a tumor reaches a critical mass and causes spinal cord compression, signs and symptoms of myelopathy can progress rapidly. The myelopathy has no distinctive features, and the differential diagnosis includes herniated disc, amyotrophic lateral sclerosis, multiple sclerosis, transverse myelitis, and other epidural and intradural spinal cord tumors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=see_link\">",
"     \"Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contrast-enhanced magnetic resonance imaging (MRI) is the most sensitive and specific imaging modality to evaluate possible spinal column lesions. The majority of nerve sheath tumors (NSTs) enhance diffusely with contrast, but heterogeneous enhancement can be seen when intratumoral cysts, hemorrhage or necrosis are present (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77534 graphicRef56634 \" href=\"UTD.htm?40/30/41446\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    MRI can define the anatomic interface between the tumor and spinal cord, but cannot reliably establish a histopathologic diagnosis. In addition to NSTs, the differential diagnosis of intradural extramedullary tumors includes meningiomas, myxopapillary ependymomas, paragangliomas, ganglioneuromas, hemangiomas, and cavernous angiomas.",
"   </p>",
"   <p>",
"    Once a tumor is identified, MR images of the head and the remainder of the spine are routinely obtained to determine whether other lesions are present. Additional lesions may be found in patients with neurofibromatosis, when another brain tumor has spread to lower levels of the spinal cord (so-called \"drop metastasis\") or with leptomeningeal tumor. If there is a suspicion of leptomeningeal tumor, a lumbar puncture and CSF cytology are indicated prior to open biopsy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    attempted surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=see_link\">",
"     \"Clinical features and diagnosis of leptomeningeal metastases from solid tumors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Determining whether an intradural tumor is extramedullary or intramedullary can be difficult, although the following distinctions may be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The common intramedullary tumors (astrocytomas, ependymomas) expand the spinal cord and often have an associated polar cyst, which makes them readily distinguishable from extramedullary tumors. In contrast, exophytic intramedullary tumors may not be easily differentiated from extramedullary tumors.",
"     </li>",
"     <li>",
"      Extramedullary NSTs can penetrate the pial membrane and infiltrate or become adherent to the spinal cord.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We have not found myelography to be useful in predicting intramedullary extension, and careful intraoperative exploration may be the only means of determining whether or not tumor involves the spinal cord.",
"   </p>",
"   <p>",
"    Approximately 15 percent of intradural NSTs extend through the nerve root sleeve into the epidural space. Although typical, these \"dumbbell-shaped\" tumors are not pathognomonic for schwannomas and neurofibromas. The differential diagnosis also includes exophytic meningiomas, lipomas, chordoma, and chondrosarcoma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=see_link\">",
"     \"Spinal cord tumors\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=see_link\">",
"     \"Chordoma and chondrosarcoma of the skull base\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A \"dumbbell-shaped\" configuration may also be caused by an epidural tumor extending inward through the neural foramen. This distinction from extradural extension of an intradural tumor is important because epidural tumors extending inward can be completely resected with an epidural approach without intradural exploration.",
"   </p>",
"   <p>",
"    In addition to defining the location of the tumor, imaging studies are useful to determine whether there is involvement of paraspinal structures such as the vertebral artery or the brachial plexus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery is the treatment of choice for intradural nerve sheath tumors (NSTs), as the results have improved with advances such as the operating microscope and intraoperative spinal cord monitoring. Gross total resection is often curative, and the majority of tumors can be safely resected. However, NSTs are benign and slow-growing, and function-sparing operations are important, even if this results in a subtotal resection.",
"   </p>",
"   <p>",
"    There is no established role for chemotherapy or for radiation therapy in patients with NSTs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete surgical resection requires sacrifice of a nerve root or nerve root fascicles. Although these are typically sensory and their loss is well tolerated, sensory deficits should be anticipated and discussed with the patient preoperatively. Motor deficits are less common even with neuroforaminal extension of these tumors. Myelopathy from spinal cord compression typically resolves quickly following tumor resection.",
"   </p>",
"   <p>",
"    Neural monitoring is often used during tumor resection. Somatosensory evoked potentials and motor evoked potentials can be used to monitor function with tumors causing spinal cord compression in the cervical and thoracic spine [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/15\">",
"     15",
"    </a>",
"    ]. Electromyography is used to aid in resection of tumors from functional nerve roots in the cervical, lumbar, and sacral spine. Anal sphincter electrodes are helpful in identifying sacral motor roots. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link&amp;anchor=H10#H10\">",
"     \"Clinical neurophysiology\", section on 'Somatosensory evoked potentials'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=see_link&amp;anchor=H16#H16\">",
"     \"Clinical neurophysiology\", section on 'Electromyography'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Resection of intradural NSTs generally uses a posterior or posterolateral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/16\">",
"     16",
"    </a>",
"    ]. Rarely, an anterior approach may be required for midline ventrally located tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/17\">",
"     17",
"    </a>",
"    ]. Intraoperative radiographs are taken to identify the appropriate levels. Following laminectomy, ultrasound may be used over the dura to confirm the location of the tumor. For tumors with epidural extension into the neural foramen, the facet joint may need to be resected followed by instrumented fusion.",
"   </p>",
"   <p>",
"    A biopsy is sent for intraoperative analysis to determine the histopathology of the lesion. If the tumor is large, debulking may be undertaken. As the tumor is mobilized, the nerve stimulator is used to identify motor roots, which are dissected from the capsule. Once the root or rootlet of origin has been identified, it is sectioned both proximally and distally, and the tumor is removed.",
"   </p>",
"   <p>",
"    If the tumor extends into the extradural space, motor stimulation is essential to determine whether there is motor root involvement. If there is no motor root stimulation, the entire root can be sacrificed. However, a functional motor root involved by tumor should be spared to avoid a significant postoperative neurologic deficit, even though this produces a subtotal resection [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Spinal fluid leak is a rare complication. Although this may result from a residual pinhole opening in the dura, it is thought that some patients with hypervascular tumors develop chemical meningitis causing an increase in CSF pressure. Spinal leaks often occur postoperatively while doses of steroids are being tapered. Slowing the tapering of steroids or temporarily increasing the steroid dose may help eliminate a leak or pseudomeningocele.",
"   </p>",
"   <p>",
"    For patients who are not candidates for surgical resection or in whom only a partial resection is possible, fractionated radiation therapy or stereotactic radiosurgery may be used to treat symptomatic tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=see_link\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of treatment is to prevent recurrence or progression and preserve spinal nerve root function. The prognosis is dependent upon the histopathology of the tumor:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Schwannoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sporadic schwannomas generally remain disease-free and can maintain their level of neurologic functioning, even if preoperative deficits are not reversed. In a series of 187 patients with benign schwannoma, one-fifth were symptom-free at follow-up, and the remainder had varying neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/20\">",
"     20",
"    </a>",
"    ]. There did not appear to be any impairment of life expectancy compared with the general population.",
"   </p>",
"   <p>",
"    The neurologic prognosis is not so good for patients with schwannoma secondary to NF-2, since there is a high incidence of new tumors with additional morbidity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Neurofibroma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with sporadic neurofibromas do well, similar to those with sporadic schwannomas. In contrast, patients with neurofibromas associated with NF-1 are often younger at the time of diagnosis, and the lesions are often multiple and can undergo malignant degeneration [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Malignant NSTs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant NSTs have a poor prognosis. The tumor cannot often be completely resected, and intradural resection is complicated and can lead to leptomeningeal spread. Most patients have a recurrence of their tumor and succumb to the disease, often within a year or less [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28694/abstract/5\">",
"     5",
"    </a>",
"    ]. Recurrent or progressive disease may benefit from radiation therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intradural, extramedullary nerve sheath tumors (NSTs) may be either sporadic or associated with neurofibromatosis type 1(NF1) or neurofibromatosis type 2 (NF2). Pathologically these tumors include schwannomas, neurofibromas, and malignant nerve sheath tumors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology and etiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Schwannomas and neurofibromas typically are slow growing tumors, whose clinical manifestations depend upon the level of the spinal cord involved, while malignant NSTs are faster growing. Symptoms can progress rapidly if spinal cord compression occurs. Contrast-enhanced magnetic resonance imaging of the head and spine is indicated to define the presence and extent of tumor involvement. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical resection is the treatment of choice for most individuals with a schwannoma or neurofibroma. For sporadic tumors, the prognosis is generally good; for those with NF1 or NF2, there is a significant risk of multiple tumors. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/1\">",
"      Levy WJ, Latchaw J, Hahn JF, et al. Spinal neurofibromas: a report of 66 cases and a comparison with meningiomas. Neurosurgery 1986; 18:331.",
"     </a>",
"    </li>",
"    <li>",
"     Nittner K. Spinal meningiomas, neurinomas and neurofibromas, and hourglass tumours. In: Handbook of Clinical Neurology, Vinken PH, Bruyn GW (Eds), Elsevier, New York 1976. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/3\">",
"      Klekamp J, Samii M. Surgery of spinal nerve sheath tumors with special reference to neurofibromatosis. Neurosurgery 1998; 42:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/4\">",
"      el-Mahdy W, Kane PJ, Powell MP, Crockard HA. Spinal intradural tumours: Part I--Extramedullary. Br J Neurosurg 1999; 13:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/5\">",
"      Sepp&auml;l&auml; MT, Haltia MJ, Sankila RJ, et al. Long-term outcome after removal of spinal neurofibroma. J Neurosurg 1995; 82:572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/6\">",
"      Thakkar SD, Feigen U, Mautner VF. Spinal tumours in neurofibromatosis type 1: an MRI study of frequency, multiplicity and variety. Neuroradiology 1999; 41:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/7\">",
"      Patronas NJ, Courcoutsakis N, Bromley CM, et al. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. Radiology 2001; 218:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/8\">",
"      Sepp&auml;l&auml; MT, Sainio MA, Haltia MJ, et al. Multiple schwannomas: schwannomatosis or neurofibromatosis type 2? J Neurosurg 1998; 89:36.",
"     </a>",
"    </li>",
"    <li>",
"     Woodruff JM, Kourea HP, Louis DN, Scheithauer BW. Woodruff, JM, Kourea, HP, Louis, DN, Scheithauer, BW. In: Pathology and Genetics of Tumours of the Nervous System, IARC, Kleihues P, Cavenee WK (Eds), World Health Organization, Lyon, France 2000. p.163.",
"    </li>",
"    <li>",
"     Kernohan JW, Sayre GP. Tumors of the Central Nervous System. Fascicle 35, Institute of Pathology; Armed Forces, 1952.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/11\">",
"      Sepp&auml;l&auml; MT, Haltia MJ. Spinal malignant nerve-sheath tumor or cellular schwannoma? A striking difference in prognosis. J Neurosurg 1993; 79:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/12\">",
"      Conti P, Pansini G, Mouchaty H, et al. Spinal neurinomas: retrospective analysis and long-term outcome of 179 consecutively operated cases and review of the literature. Surg Neurol 2004; 61:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/13\">",
"      Saiki M, Taguchi T, Kaneko K, et al. Measuring of the compensation of a nerve root in a cervical schwannoma: a case report. J Orthop Sci 2003; 8:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/14\">",
"      Lohle PN, Wurzer HA, Seelen PJ, et al. Cystic lesions accompanying extra-axial tumours. Neuroradiology 1999; 41:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/15\">",
"      Krassioukov AV, Sarjeant R, Arkia H, Fehlings MG. Multimodality intraoperative monitoring during complex lumbosacral procedures: indications, techniques, and long-term follow-up review of 61 consecutive cases. J Neurosurg Spine 2004; 1:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/16\">",
"      Steck JC, Dietze DD, Fessler RG. Posterolateral approach to intradural extramedullary thoracic tumors. J Neurosurg 1994; 81:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/17\">",
"      O'Toole JE, McCormick PC. Midline ventral intradural schwannoma of the cervical spinal cord resected via anterior corpectomy with reconstruction: technical case report and review of the literature. Neurosurgery 2003; 52:1482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/18\">",
"      Lot G, George B. Cervical neuromas with extradural components: surgical management in a series of 57 patients. Neurosurgery 1997; 41:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/19\">",
"      McCormick PC. Surgical management of dumbbell and paraspinal tumors of the thoracic and lumbar spine. Neurosurgery 1996; 38:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28694/abstract/20\">",
"      Sepp&auml;l&auml; MT, Haltia MJ, Sankila RJ, et al. Long-term outcome after removal of spinal schwannoma: a clinicopathological study of 187 cases. J Neurosurg 1995; 83:621.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5196 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-58.240.98.179-3BFBD2B80D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28694=[""].join("\n");
var outline_f28_1_28694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NF type 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      NF type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Schwannomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Neurofibromas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Malignant nerve sheath tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Schwannoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Neurofibroma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Malignant NSTs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/5196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5196|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/17/26897\" title=\"diagnostic image 1A\">",
"      MRI of nerve sheath A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/54/28513\" title=\"diagnostic image 1B\">",
"      MRI of nerve sheath B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/5196|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?41/45/42711\" title=\"picture 1A\">",
"      Patho nerve sheath A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/40/43654\" title=\"picture 1B\">",
"      Patho nerve sheath B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/28/31174\" title=\"picture 1C\">",
"      Patho nerve sheath C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/40/7815?source=related_link\">",
"      Chordoma and chondrosarcoma of the skull base",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/48/24329?source=related_link\">",
"      Clinical features and diagnosis of leptomeningeal metastases from solid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/27/6585?source=related_link\">",
"      Clinical features and diagnosis of neoplastic epidural spinal cord compression, including cauda equina syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/13/27863?source=related_link\">",
"      Clinical neurophysiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31418?source=related_link\">",
"      Clinical presentation, histopathology, diagnostic evaluation, and staging of soft tissue sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/50/36650?source=related_link\">",
"      Neurofibromatosis type 1 (von Recklinghausen's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/14/20712?source=related_link\">",
"      Neurofibromatosis type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/63/7161?source=related_link\">",
"      Spinal cord tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_1_28695="Elbow ossification";
var content_f28_1_28695=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73818%7EEM%2F79600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73818%7EEM%2F79600&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Secondary ossification centers of the elbow",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 437px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The appearance of the secondary ossification centers of the elbow proceeds in an orderly fashion, usually occurring approximately one year earlier in girls than in boys.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright &copy; 1994 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fusion of elbow ossification centers",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 408px; height: 401px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The secondary ossification centers fuse to create the mature bony elbow. The lateral epicondyle, trochlear, and capitellar centers fuse first; this unit then fuses with the distal humerus; the last fusion occurs at the medial epicondyle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from DeLee, JC, Drez, D (Eds). Orthopaedic sports medicine: Principles and practice, W.B. Saunders, Philadelphia 1994. Copyright &copy; 1994 W.B. Saunders.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28695=[""].join("\n");
var outline_f28_1_28695=null;
var title_f28_1_28696="Pulmonary capillaritis DAH I";
var content_f28_1_28696=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76904%7EPULM%2F56943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76904%7EPULM%2F56943&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Early pulmonary capillaritis in diffuse alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing early pulmonary capillaritis. There is neutrophilic infiltration of the alveolar wall and hemorrhage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary capillaritis in diffuse alveolar hemorrhage",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDmPB9gdGsILQOZomQXEqQkr5QwdpwAWJJAJwe+eAa09CvrO1W6WJTMHl81HilRh0O5MgZbGWwDkHoabdvaBmMUMFyJG4uTfLEkbOBgjOcOMqSFyG6+1Z93q91HcR6a8TqokQKBuYvnOAvfPzdupzjBFfptPCpR9npaOuttEvndOz8tPI8atU5teV+9/S/rdmpPa6VrgjnuIvMl05wApy4JbgAgckkjgDpgnpV9GiRpWSTzHIDO+R0Bzt6DORjI5z0yMVXktLNFvbO2uITe25druHzN7F8bc5Q4XGDg4P32z1zVLUJI7exMumwz3U6/LKmcySEkBioH8ODxjPAPpQpOdk/l2tv/AMH5+pmoxlFxi3b+l/XTe3lpaqLqSwuksZ44LuNGbzBG2AONxAG7Ix2xxmsqxEmkLDp9xLJKZNjSYhUpcuR1UbiWHIwflHHrnCTXesW/iKygsLBprUIC7upyrn7/AD1AHQ9ifWrL6vp2nanKYLKZjYsFd4yEjLc4HKkDqx+Urk5FdThUUOWFnfXp+P6ebME4wbU13/r+vu7y6RpUPh6/nu7W4uJEkZsCV8FFJ5ABzuHIB6Ee54q5qtpC6tPokEKlY5JZbaGZk2JtBdol6KMEsVHoQBTmkh1XTwbA7ouuxFIO0HJAAyCVOM84P61UWWfSbn7SfNaIc+V5mONuRjJ5PXnjr2rmquUn7SprJEUXJSsnb9f61+W73Mp7iO90eP7EAksIMribcWCsmVcMCAu4AkcZPfGas+HL24v7O+t5py3mRrtmcHdu3DIYYyc4wc9OeuKzrS50+2m+z6OypbuBLHFNuYOQDwXbJ+XJAHTjP13dGFrBEEgSZbiTaW85wzknopwcjqf++vetIScafs6q1vdb+t9fy17enTi6cf4lL5/1v+u19TJvLW70uO5uJTBHJPi0tWiXzBI7EksAOQdv8JGTn0FWL3w/ZXtzHqsxuIb026+X5cm3ycAgEDHVRznPGPUVvyiWLTrn7NKIpZZA+wOAzoeqg9PfBIGBWfYKvlEsSNwYiNCQep5JPDDnOcelRS9pD3lL+tPw0/P0JniPbU/e0l/w+/8An2KfivSBd6VZWv8AacqCAiW8dAS0ihezHoQM9epPNUtGksbOzFpb6fCLQnzZg4Ds7Z6sP72Dx+ldFpqz6lYo+pacbOSWVoxCWLny+5bg7fqc+uKyYNMV3e3uZnQMWTbCxZEHVWBPJ6dPwropySi4VNbf10/rocU5v4EzYuLdJdPMivaW6ud0TIo+6TyePUcEdcilk06O/sI7PWIYrwBdo80EHaOVw5OQRyAcg4FVrtP7PsRbWxkCojK+3h2Jz39Pp1wan0W8tb3TyscjtsBYgISDkc59MHgg9jmuZwly862uDrSStf8AMZH4VtdP0+OG3gAt0dpGhZ95cEjrnGBxjp65J61yfiHwius319NDLbWzXhV8vuZ/MySx4425r0RZWZmZpgSckEcEj1Oen+elZBtNNuZ5WtblHdgFCjgrx8w44IqqFSUZSnLd9bXJWIqLd7en9f8AB284rmyun1R7SQCLTbcRW6tK7bGjSNBkKMgncGfPXOOaqeE7C6t1vZ7pr0STMu0zmM73UnaUGMhiG5JJPXNHinTdVeSK407VJ7a2t4Hb7PG2GeUA7duM5OcDBxxWLfX2s/8ACNWc2qq8d4yE/ufk8ptxxu44baAQPeqpUHVShzJ3/T8/mdUq8uRcqt89f0sbGiXOlPdX02j4MlszQTloyNrOGD446HBHAH071R03VoNR8ZatZmRLrTLhFiw/ILDgonYg5Nb2lasL/R4BdzRNP+8kngAAZgBnewA6kcZJrlrZo9M1XWZzay29hDbhRbgA7pZQFCRtjAx83zDP0rahRS54tWey+/Tt1+Rl7R1Lt6v+ux0VpD4eXRboW0Fq2j/NFNDGhdHYHqSeSR2IOeh9jaknP9iTTaTbmbyrcm2tgoUDauMFcegyBwSawNF8KT6dol9YvrMkUFxKskYSP5oOc4JOOT0Prit2x057bV57m1Z1geMRs5mVg5yDnaBlWHPJ9eKxcaSu09fP5Clo2r3OU8K2mrazr669qyzLZrAYdsxCmfI2lNvBCj5j07Guih0bQxbizj0mBLdJDNH5sOfm4yw3ZIzgdcjjoa17W/stRuDbxO8Use7MJHPy8HHU9ycEgnOK5bTrPxPBeH7ZdRmKS78sJkNmEAnJIGQMcYODnFW5Ou25NRstFtoOUp3dtDqmeSFRO6Iyvj5eMknjaMADA9MYqSEtPGBgORg4bhPp/wDq5rC8StNHeWLRyO0czsnlDOWYYIPQdjW+hltLVoUfaegZv7x5wB6DJNc84WhGXVmF3fUwtWv7UXIjMaXLwEq7ODgMW+4B0J6cdQeppjXDanFf2upLm2lVkcxFo2AUg4yenT/OaLbSbq0BntpYZbhW37ZnEakE/ePbjPPfrV5Lyz1HSp7iLd5UrNCkg6SAZXcP9kkY/wD18bN04u0FfzLcpKKbZgNpdqujvF4TuJtOvtm0Nu3F8HcN79fbI9q19JgvY7UDVZ4brVMFGuIo1zlugU8HtjPU8+tYui6dLaSxusrqWbMZXLBjg8jB6deldNbTmTYqtEJ3O8IkqtI4J+YleoUnuODyfSrxNk7J83rv95cKknojjj4gvrzUzHYRyS20ByzvCN5Oef8AIHeumXe0BVkUTmI/eOz5jxnaMZx+WMVfjtDfeQvlq7SsVzs3jIHIbPt+We9ZOoatBZXyw26JM4XEroREseOiZwR0568VTmqrUaUbNf1q9CZvsT2dpHK212O4MSowWbb7nsD1xz0FaF1a6e+nOLuISMzhEVid4OMnAHPXcTnr09qyNI1LTNTgmaN2hkQO7JKFIIA+8rAkYHcnp75qzFq9lfWjyWcq3P2IGV3j5Y9zt3gAg8896wrUZydpJ6f1uZJyWt/6/q/y+4W0YBgVUldxddqkIcYBxn8eBVjVJrXxBGbS0me2vdMlNyPNXCS7VwxyPQE8HB54rl7GTV9Z1TzbeJLWHG6TYflUHoW/vseRjHJFdPcLa29hqzeWTO9pMfNUfvMsQWB9R8udv1xWeLpOmk5brXR3t28jak4+0T6tr8f+H/pGNp2kPolvfSWF2b+6uZlcs/ygc5K/Ucj0781pXKLPJ5LyBo0Xb8rhGHUnrg4JON2eAah0vbd2iRxSxjzCUBkbkYUE85AAx1PAFQjSrGa3triTU5EZ7gsAkLGNkAIxvxtyCc7sYPHpzdWtJTvJNv0+XT0/M6XGEm+eVn/Tv/X5l7U7vVUtlt9KtJJxM4ChY9zlV7EL0znqTjr3q1b29xdLGnEVxKjM8edxQ7jkEnqB27A/lWQhGlXL2coQ3EQcHa5UljyVCnPAHr168A1EviqCZ7m1tftU1yqsEtmQKrSqcbevPJHGAM04wlOP7tee356mNTDumkktNv6+/wD4JsMUjn8iSRIZSxBiYqpLDp15PHT2z1rJv5+ViF29khbeWiQFjGoB3FsZ+9tx7uOvNUdE0qbWfsWo69bS2V3byeaixybWmxyN6kcc4x06+9aWq6Mtxp0lpBqQc5VllK/whiPmxk8kk+gK4q+WMaig366XX6/0rDUlFO716evf8v8AhtCvpviHToTJEss5mCZX5BHjPAIwcFuvPHt6UVX07w2dGt7vybxZb+RdyPJHtXAOcOBkgHH6detFXKnS5nyNW820/wAjSlShVXM036f8Cxm2dtpGn2ENvc30k9rbx+bJhdrsw424bGFK9uvy8Vf8O3Ju7ye6EjvrMwkurRJmAiRG4J5Hy459hnPpWnY6hYNaWbpZuLXBRoJnYeXGCF4Ue5JyT04oks9J8Pvc6tLJgbN2/AbapBAAX+6fyORg4rFKMueFWPvyt538vS+/dGtavJ2cb26f1+Xbfe5Bo3hmz0SfUL2KSd7u7jMas4XbGp5woXk9PvY9MA1o2EVpAsck0tvLJI4CzCVcE8kDccHODgjgc471Ri1K0122NzY3UkKQMkcyToysNx+UhgdoyOBnGDjntVW0f7cFtor3zpQiLLZGNka3OcElcY645zgg+9KopOTVS976+X/A/DbuVThKdO7dv6e33fn0IJNXtNI1m1tSFubyOZU8qJmUdSRgt688k4zkg1qS+FpUl1CW81K5ksb6UTbXh8lfLGTjGevI9sjvVm622j2azWfltFE0hm8lC0KjoQeuM56ZI7CqMbtbXPlyos1vdLuXypO//PVcAh+wJOME/lXtHFKpF2vv1vr9yt/XQXJKs7XXb1/4JPYi10ONFtFUwqQDmNldAAcfKwGMg5Bz6+lbLpZQ2U3nu8rA/uoowoGc5yQBj8CfeudfSw5hkvvOQhNjfZrlljxyclsYYgknIyABgetXvEWoJaaYqHDsSJIirDfznpjJCkEnnpnms+V1ZKMOv9f8OY4lJNO/z+75fc391r5Gk+C7qbV7e/WQW9uxY7w2ZAGHGTlgTzjg5PfFa8ei6r/wkNrJHps0FoZwzxC3kwkfPJkIwSDhs55IxVvw5INWsJdKgxZzIgkV4WdDgLjGQdx/h5rmo9XvSZ7DUNZ1C4QqYZpHuDNFJzghSTkDpzg98VOIliK8vZy320V7J9dH/X3lUausuWSsu7t+f/A++1upE8JZkhn853by0dGJ8wbuQCOAcY49iKzbnWHtrmS5hSGUQlS68jcSeEHXJGQOfxNWNPsbu1vZFvWt50IEiGJ2JUjsCecFScfQEVNNpto19Lcy9F5Cj7pA5Bb8R6dsVVKdN6zTOSpFQfKnfz/r+rhJeLayve3UkchgIlnWXafLHPDjjA+vbgDmkJW6WCRjCljGGuN8a5yhGf5dugNczeeGPLl1C4jkNzNdzpcSQtISgiDFjnjB5xznjBHPWtKwu20LSrK0mg+0yGJmlWThBGSTgZ4IwT+Q9K29hFxTg7y+7prb8iZtW93b+vk/66CJqk2r3U1vY2QjjTLu0zAqvTqRk546Z/Kta20qOCwuPnGWwWcLs3seigdv/rVHY6hY/YFuLSKOC3bOUC5JYkDn6gdzirMt7D5UZuFmlVyZAVIGCRyST3wP50qjlflhGyM3J/1/X9feWYEWKKNQyvtXHynkdOfp/jWPc2YW/dbaKJY2IYKW6P3IFSC5Qs6qTasqgs+7eWyOu5ehxjPFWraCcSw3MLjywwKSFh6e/HeoV6d23uFkZup38UUpluJRHBEOWbJRRwAT39KgvLzUdpisdF/tG3VBK0gYgOnUhcY+bJ/GtG50fdFI3ylJSTIJBksM89Dnr7VPaWqW0GUnh2KmCXfCgY7DGf0rT2lNRXLq/wCu1tRxaW5l23h7T7nS72CPT7pluFBlQNunTIBAX0wc5wD6HrU+laDD4a01tOZrlkkKzKlwN21uBlQQMYH+e1Pg1/yPMttL/wBJuJ5F/eAFIouMDGevGc/0q5Chd45JCr3Ez4Z5nwWHc+46cVnOVa79o9H06/mX7V/D0/ry/W363Le9VArRwKozgybvmZSMYLHrnjI4FJFayeZGrKfKwf3QBIYjHJ4ycY6DA7Vg614jl0fUEtEaKPzLd5VlkT/WyjcETPOAQBgAd+1V/wC1tUI025vbm301J4GmktGBQh1ByMH125ojhZ2UlontuCi7XXX0L2heK7HXVvotEaQ6oqvuiuYlh8wrjbyucjPBzyAe3JGZ4PuNZhC2/iKORrq7cGCIRg+Uu4hgzc4J7L26+lZWn6zYy+KNPuYrOP7VckRTsgOWDnBZegA+vcmu/lkt4LYvbSi2kiO6aQup3gYwO5GPUDPYjFXWpfVvcUfi/P8Ar7/y0ld6Jb/f/X9XFkuY/KaOMoy+bt8zjPXHB/zwOKrmYJMM/PK+NqEjJYnAC9u+T/kVVu7yOytFuraOPYMyBlyEbjrjnaBz+J/CsnT7y91HUriMSFTHEXTklVdzhMtnA5O78MAcVEKDcXLoRGn/ADM6VESRFieWGSY7gY0kUttyckqD09R781nealhawrBDHGi5EcYjO1Tn7oGPlA5HTvxXEafaPa+J9Isjps1nfaY8zTXqfOl1zuHYDGON2Twa795ZodFa8RJ5riLDfZomG9x03LgcFSewzV1KKpSVne//AAfXR/8AD2FOHLaN/wCv6/yMm48SaTZau1oBMdQ5U3KxbVSXHILA5zkqCeOPzqfUtDt7nVb/AFdTcx3Oo20duWjmUbQoXO0/w7tqj6E9K5vQLPS/EVhHDJHcW81jOZLhJZCGMjEckkdcDHY8d663cWnKRKsRJI2Z5A79/ToParq04U5Lk+Jblq60X9f15nK+IvCU9qkFz4YaexvUnSRfMmJQRnjkkdQfc5zXWLYW+rXkl6LaJpJSplwSySPj5m8snGTjPTHtSX+of2fp9teyzytPMwVIQxVVbnk8HHAznk9MdaTSNcgvGa0ZDaXYUvG8b45ABAyOQcD8azk68o8+rtpe7+ZlKtzJP+tRNQ0WG51a0nm+zuEBjuVYAb4zz83HXBIH4U1tM0zTpZksmkgFynlgSPn5cfcyfz4x1702/wBRtbWQpcNs8jqittZiTkt0wM5UcnnOeakintb9HDIvmRkShnQb4CSQMn+LnqRx0+ojnqWWun9f1+Bp7KfLzPb+v6vt6HE3d9PtmsoZvscTyfvWjHzyYyBk+nsPWtXw9a3Vtbzx3MrtZuDsSZ+QMYOR78cfnWtqlvJDbXd7bRQPPEgced0cdTz9Og4rH8Oa62rxy3gtU+xQW4V3UFHkuCDwgzwvXgdevevQnVU6TaSt1HCD+JdP63Ojjhy0ts7wPldk8Xy7ghP3SoPy5yR7Cm6vZxiIGQYjiQErHg7kxwqj1wKqWW2e/lvDGIZdqSSqAwH7wld4HqcDPPJPvUF3rU0VxJYyIjSy20rR5wN00bsCmB1BVcjJPNcUYyc1bf8Ap/lqbVYyTbi9t/w/r9TltW1W98V3dxMggs7yPbH5MreXvQKFXafZQAea2/AmlT2oefU44or25LNLNEm1tnP3SOOcYHHYnBrFWR9RuhDFB5d+jZZ4AWYgHJI44GPfqetb3iTUrm2lito7wwMYTMzwMru8uSCM57Dr/LFbywCp1LUnbmvpfbb8OwVMVKVP2Vtjeu7l/tKQJG8CBSy7FKbiO+4EEdunYe9UPE11d6Pa2bw4uDd3SQqHIYBWP7zDAnjhOTnGe1WNB1DUriyWTUXguJo5CIptm7ev8JwcgEHK/KOcVqzKWLNKCGk7NtBx/dyME884PX8K5XenJKy038/6/wCBocULqXvf1/X6lKSyW6nE8VoTK6E7o03b1DAYZSQAeVOT+JzxRVqGI48oY8w4jYQqEyBkgZJzxnqT1z7UVnKS6tfM6oYmpT0pyaXk7GFdxi8tkkQkwptjdJE2tu/2lUcD1xnORUE1t/bOjX8SS2rMiJsYurlARwCy52sFUnHbHqMVokyWYjgtgwdT5QlYtuRmGRkDksQMbj8vp1qGCJLORL2IBJGCgbDsaItkHjaBx835jPHNWpVE4yjuv+B/Xd6fPvSUotdHt/VuvTqlpvoQaVo9v4atbiTUU+3T3yt9oiSXYpQD725sYXp75PHStCWcw26W+hXUC28ojBNwPOlkeRA+CQMgBWHPBJB7CsW+lmvZZJFZWwu6MyRLvyGBIZc7cjIBwCAecYNWb6L+1YLfXoWNrq9l5VheyA+WiMq43jaAcMuWHJA5UgACscRUVSfM/ee//b2ltHpte3nbrY1p0HFL2jtfTyt96/4bvqid4722tLaNpnV5N0uxAUC55IDtxwBksSPvHiptBuLWa78tVgYT2rOrox3yBVDMHbgBeCcggEnmqlpaS3sVypL2oRgqbSWUkjgZwMbTjDfhzUV1dxaZp0Tk2sEq24gNxcYkViFIUkgHcp29QM5we1aJSqytB3vdb9bp9N/x7X1JqKMYOLVn5enX8NjoNQubO1hklniaOHnzNkILEfdzsBHGOce3ANSaz4abVpFn07ULEebCmGcHY6lfkZTz1XkZ55rik1l9T8PWk8gaOcxGRjFGDJJtfHyD+Ek8g8gHnHar+natPc6Ybm0A0y3sZUsWMrM8UhCkkopUs7AAFl4wWBBw3Ezm6NRRpy95XXfX9e+hyTwMvZ87evn/AF3djqtE0yz8J3Xm3l6ZbqRFikUAHaHbALEnCrnH/wCquAhtLS78RzaPY6tZ3FuCXaSMFzEm/wCYM2NobnrnGM812XjHTrfV7GDVLS/kS1kHltbTYCbxHs80855AAbHTIrBs0t/C9tp2mXcEFjHcuwZ4ziFHCq6tI3fIwD259sU8Nia7q/3pLW/l5eV2v87oxhQh7JVU730/r+th1t4kupPEbWN/aXEMcxC2sgQny0VdvJ6YODyMY+tdT8gicxlQd2RIMHjnGDjjP61xttoWqW1+kkU8UcZfzROGJDqw6lRgMMZPTnNdeIJFiaRQBGp2op5JGcZz6dcg/hXVio0k17No556b6CRxMQMKduCQg+U8Y5wOOBn86q69qHkW9zPKnmSRq2IxEG6AjJA6HnnHB7it+2jtP7P8y4YsQm4yL0bJ7Y646e+DWNPcQ28D3BkWKIHa3O7dnuO39a5aU+eV7XsQpa27HBaWjwMbiKOQ25ByJH+RmPIVSPQHp2ragjvrt4oZpDHbhsplSWx2UY/nWgNWgjuobQW8ghYIAx4ALDK4THTJwTxVf4mXt+s9osOLdDFuBhfaSx5C55yMfnivU9pOrVjDls31Y7pyNW10y2h3ySxXU8sz7mkBAyewA6DrnFW1ZVCJCWkgiPyhlJUHPbtnnt61leB5LxdExdrIsfmfugWzuxgEr+IODUd9d3T6jNbrG/lISIQiEA+gOOPTnNcUqc5VZQbvYHvr/X5E9haSW2rXGp6ncxzTPEYUihDKgTtu7kgAAAd6ZrNpqV/pMp09reG6bG1JDgMvQpnB2n/PFaktjMbSMmP98yDJxz9c44Gf50WULhAtwWQf3igJx2OOf19KiVS/vJ6/1sjWOnvdexk2+nSafbxXF2beW6iVlVYRiGPuTz949snHbiqdr597rDq0qTEruO0/6pQ37tenGepx+dbeoajYWU4hup23kfNtTzAn1PQfgTTklWKGT+zpLdfMkXDBlKn13Y56c44rWNSajeS1ezM3rq/6/r/gGBrvjGy0W9itL7SLoRiRUN5LEMdOWj3Ke/vyK04dJge2eDVLp9Sk3mbzJFAIV8bce3Trj8K1rGASWzW2pstzuYlwF2IQCBkr0z0NU5FZ7v8AePsjV/3m08sp4yT/APqrNVFe0NLde/8AXyHKaS00JrSC2ht2EX2OONQdjKgIDLkAIeT/ABYxkYJ5rFvNIeLU5b+6u7dNMUgLHIGJWXHUkdcqcd6yo2Fhqlp9nISYTBTHuO24TOMlcEH8ql8QXt1eX9tCLSOYoWXCsQGlIGeeuBjoe2TW6w0nNe9oy6VWpB80P6/r+vLXtotOs7QWsbm6lngyYopgyFdxO48YX0GD2OBUtmYmtnieEwDfloxk7+P4mPJ79e3pVrQ9Ot7YW4vIpLy5hQgPBxjOWIXBBK9f1J7VFf3D2ljNdwwrNPG7PtkYhX4AAK99qjOOvXFcrkotpPRF83tWo2vJ/wBdCzp9jIIYUm3rnmIuxAkGeVjQ8n6gYq1qH2DTbWCPUb21tGnysbTybWfAG4jA4xxyeOneuG0u6aOzfxSblLi+lu5NPtmDPiOWRSDIWycxqgO1V7uMn5eca71FW0gmCOee/soN1xM8g8oo7D5Ru5BGByDnLN6DEwjPETtTu19y+9/LvfsdDwSWrlp9+vy/4ZaanbarrFtb3t3pt5JtaNlAYFdsg2hlYY++CCp45xVuytzdQRsqDawMiJtwpU9Bg49O4GMVQ1DWUhXT7aOaPTr+SwikSFbfzHESoAse88jgDBOfesnT1HifxeZJ5bi2UsjxXEfzlGSNfvDcDuOAccAfMT0qn7SEOZxsl2/MznTpyjdSt6/0zsfFmmPf2dvDbSJA8R+1RPJhuQMEHHX/ABrE0zQr211YXupIsQCGVUSQP5hxgHjpya273V/Nuo4U2qEO9WbGT71eljubqy89Swt1X5yeWIGOlKFarSpqm7JP9TzOdo5me1kubpLmeVMpD5QRAWGw5znPUksx4HB6HirdnZCxsLpVaGBLiPy1AclgVUkMxIAA7Y9yalQmGUyM6oA2CCwBVD6+nHesmb+0Xv7l/NKfuJkDqu6L/VkoFHuQo/Hk1Vl006nqRnOpDlb0QaLcKumWzLs8uNVSXa+WGCN5wvU+xHOateHYtSC3kmrQEWvmAWqPH5YJ+Y5iB5CBcfNgZPHUGuP8DalqFzEbbUVis722QKg8kRTTrkcPhQXx6t09eK27nUTa+Jbx5pHX94PMCIchcAHAz1HBrpq4ec5uz6X2eu1iJNwjKnbXTX+v66nSeQsdxI0UauGwfuFi3ykc/TJ69MVht4ftrnVYL66lciIEKvOS2SQWI64J68HgZ6VnR67danPIun3kkEm8yGQIV3oDyBn179vWupvHjjZZUkKwvkqwUbvvdSvY5qJUqlCSvu/v2/4JnGcknBvf/gf1oZeveHLn+yJl0O4OnXMz75CvyC5XA+VmzwOhz+dV9D8Hzw6e76qhdWYOke0ybD3YuRg/nXQRXIa3hUiQBNzmRgOBwAPYcfnmo7OO8EMrXsm8SglTIdoJJzg5HcZHNJYitGDhzdfmYucmrP8Ar8P0/wAiE+VbQpFFsSNMljG+zAPHLDp1PTHWprGB5XYxptjCYeVgI16kdfTA9q0dPsXbc0c6RPEfleUAjOOoBU9Mjn9KgngOoaLqFgbiL7ao+UhhjJO7A9jt5PPXmuZ1U5W+9+vX+mN1E17v6f8AB/H8Shb31lPKIoL6F33eXkJtBb0BGFOcHgiisiw8O6lFqAkubSa1jWZXkdowFfGTwBnP4etFbV1CDShK/wCP5GftGun4GzJbJPJDPOomkZFhMkzo5ZecqdhyFHQEE4PGKz5Y59QvxbrLbIkTjzIDMMKgXgBFYsWI4ORx1OKgTxR5PiHT9OvZowt/K1sgB8sxMVATcwGdu7aPoc84rn3025s9b0p7jR/7MnguWkkvYnNx9ow33EGeTweM55JOBTglNTg5WaXTs77a+XTyZ66jUp1Emt9h2rWFxq08Wm2eox2SLEXnS6CqpDc5wDw2445xn5TnFdVFBDPLYbpmext87pg4JaLbtc44DNuLHphvU1RFw97cO9m3kxGV2xmMnaq45Uc/LyONwPaho2uLy7u7Z7l5BH9kaGYKxj/ujIzhSQcY71EX7S8HKyW3bXR+V/P5WOipGXutbvf89fLVf8PayNLb2l8dLSYeRDai5RUAUuHf+EZxgfKcZyAfao7x9NbcmpWkRslxtimdWR+SclgMKP8Ad6bj61PDpS+XbXU8cq36GRLORyC8UBfeh9CQ2Rzx8+PSmaL/AGdbWD6rqFzbqY70wW6lOIW2BtuHGcEncF6e9TKfuqMFvpbVXfy76u+rFBxjFzm9uv8AXVaK2m2ujuVYv7T1gXA0nT7qaKF/IT7MoERcjmMSNtCgAgEHOAc4rftYdK0nSZYtY83VLuZxLshcrEjIhG2MEHEa7sGT7zHGFwKk1zXINFsI7iSTKllKpakLJN/FwgOEGeTjnpVPV9fj1R7OOzsIpIMZJmjEhz1Krn/axwOOamNHE1WpN2jq9NFp3e76fj1tbkrYyM4+zcXy6f1rp/W+96+p3bavaWgis2tPle2miScrDhcMkiYBI3K2GVu4B57Q6ppl3rHhm10axUSzMEicPISQkYIwePmwOK56TxVq1l4omOopvsi5X7M8TRgIP7m0DBHr3967N7WLU9Lljaa6a1uULNP5mxuSWXHQBhwADwcYPFdX1aWFnGpO34tfnr07X+8mdWPIowVkv6/rcyYdH1ax01fDuk6tPfXAn82eRm2+TbAYVUOeOTyAc9OK6azgmt7OG0v5TNKkaeZIVAEr4weO/GOvpzWZ4ctv+Ec0ow219NMn3jIyqQ65wArbjnaefUHI4qXUP7Xe4821WOWFcmYMM5XGN3t1+nWoknJ8l1bvs2/62XaxyVJ3lb9P6+f9WuG4gvEkit3mnuGDK6ucJnkZ/D8P0rLjvIdG0aT+07cW8Vu/lRAfMZcHqA2MnnPTFXNK1vS921niF2TtZ0zgHH3jxz/9ao/EOiw67ZJJKZGhg3EyRfvFOR90Hjk4z2+lOKUJ8lVNR/rYyg9df6/r+rFyASX15Hd2FxBLawrh3jwfLOMj5h93jnH9adf2wvZEE0UUi7xIA8e7ntjtxjqRznpXN6Lr2l6daQ2OmQ30MFy2GUMMsxOGJxy+fQ9O2K2hAIL2e6kl2gjDCUkLtB6n06cD2onSlTlrp201KcXzEh1G3sLq2tZjH5rOQEZgQ3ZRGBz0yMn3rQSU7DcBCFckKqnBA9B6dsmuCtNIOs65fXM8qT29wgMF6ZS0saqSQFXOB6fhWt4xup7ezTS7TzIriaBj9ozt8tU6t7naDn0H5Vc8NFzjCL957/n/AF10LcItpHQuxicPN5ZDcBSwBftwSeMf0qwJ7eUo26NMvjYxw3XGT7dP1zWT4fvrLV9J86zeSeONxEJBFsZ3wBnA4yevc+vXNO1t5rbTBc2yvh5VQuY2ZVXOGLY4JHHeuf2d5cj32M5XUrMwtV0TVWSeKKIvulbzJQ6sWUc5Hp7fStzwxp8UCQ/bLXCoxZ4k+VpcAYMg7HOc4/8Ar1S8Ka2dUgmglQfaoFz5gQ4ZAdv8XQg44962Z5iUMVqzQh12jIJyx7n1610V6lWzozVgasrGR46t5fECJa2t3HDd+d58kKPs3qRjbx06Dip7aWVbO3i1aN4ZJPldIfmWMcAHr19R7ZqpBZTafclkTcPNRgi8uGzyS3fPv/SrXiPVbDQ9Kku9VTz5ZGCQWMUxE0gz8zMdpwAf60npGNKGq6d/6/y3sOMnK0UWreK3tZGK5uLt0ZI9ybtqkjDbuoI64BrKhs2tNQv7qaGCOKSFmEm3aWbqQS2AARj2O7vSr4gtWS/DJKx0+JZ5XcbcnIGB2zluc56E1JDfWOr2TWMyk3d0hU2qks20qCMnGASCMCk6VRPmkn5/d+Vma0pcl13/AK/r+r4/g/Xp/tMsepSsFITyY58o4lJBZV9gvQ8A8Yrpb0W/m2h+yiYtcxhI2OwEt0BAGCM5PPpXL6R4I/sjxEt6t6t5p8MZECzBklgbGRlcEEAk98HrXcwRol9aB/uM4Uk/w544Ppyee1GIqU3Lnh1XoVUcYu8WO1ix0p9LtbXU7+x06Q7riLzXCuAoLGQIOnAOOBnoOa5Mr4S1GSySDR7rUWVBbte3spt1WXO4M8K5yi7kJOeVyO1KNHm1/WNX1C4umiutzC4iWNdpMeY0Q4GVAVQR1BPJx1qeOwji0YpIJkjlIMsgbaGZV+Xp2wO5PauCjCauk7W7O33W6f8AA06Lvp04U7Kc3J32ObisLq9L3LypbXax+WLgyq+xiSCjBTxkFsAY4Het/wAOXkFhKLSObzVK77i6OAkjDjCjkH8adpWnWbana27QxJppk2tcn5FGE3KXOdqgtwc4yPrVFLi4+0CS2sbG2mA84IlmNkOD8zkEFGJIIyQeTxXY6tWUVTlqv6t0/D/M1q0KVW6t/X4f195vXGi+c0d/ZSo8cpK7w24Jz7fjVieW5tgvnX0Itgm3LNt3njIweue3TpWJbanrElnLfxakgeJiIUtIEVQP4jtwBgd15z1GOlZHiG8vNQ0y0kfR21W8hnG+K0JRdpAG4IpPUAg44HXAzUpuU1Cq7W8tf6/HyPMeCmtdH/XqaGq6Ncy6yt/pk1lJG9sbWdbghwc9GUdCRn1PIJrdZTGr7XQNGvlzMF3AEADBXOeemM5z09ay/BVvDo1rdrdAebH5l4th5gaVIgobG3k9Ac+vWpdLMN1oct+L54Jzfs0kkke7/gAUYGcHO714yBW1Wfv+yvdLr6/p+BSVlzPRItRWkNvcyz29hHHcbQrHYAcAfd9cAeuenOao6jbWMqNe3kMXlqQJJGZgy9gcjrz+OOlXDJtgXyrh7mM52zhgm4Dnb37+p71k32hLqt7FJJPLChygjCquOeCwIJyM559RVUpLmvKVvvJSW/T+v69Nu5Z0yTT7GwuBbPvWRhudP3jFsZ6N8vvyDz681cg1W11VdltNNI8ChJWcAMW/vHHGT7cegrJ8LWFpcWc32S8KxRTMJWvo8bWUnd04II5yemelWdHh0yfxJNPphEVuEYGNF4l7bgOwPXH41dWEOactW11/z9TGTUW01t6Fu8vXtJoordIgWPLOCyr24XocfTFYVzJdefd3NzNJeYxsyx8zkYyfYf4fSuj1qY2skQNsjWUEBaS8VlIz8x2nJx90E89z7Yqkj6dNevIsqiRkV2wv7tS3POO+McYwCaihWjy3Sv8Anv8AejRYeTSnbR6/19//AARfDGoX93poW9txbyuhSaNMtlB/GpbPUen0p2pWFzJqrPE7QsIyG/egZOArHBOQM45wTyAM9a0YJF3rK0nyLG900gxmTYCSA2ACeDwMmqUd3LqDXlzsRWk2iNSA4UkEj5iM8DjPfcPasJLmk2tLf5/I0pJ0m5Jaef4rvt17NM1bPUZX8tiPOjVOCGAIXtleSfr+WelFYVy4hLGWVwjBWSIg71XGBs25PA5wenOKKTwrnrFFRwNBq839zS/P9DIubGCdxNGqaiLYy4t1gyUKj5ixI3kkHdnAGeM8Vq3MUBe3tri4gCXHmEOECechwGIydwbCgMxAP3utY1nrmlwaNa35iurxIt7Oz26Ali5/ebycAdBj29609YvbZLO1u47yGA6lZCZ/NieUlFPVhHg5+c5J+U45zih0ZpN8urutlf79emv/AAdV6Epp1Ixvt1/r7+/3aSR6TDeXTIjoi2scZ83ywqW6AFUKnJzyzdAzMe1WLe00/ck1gs4leRy0qypJcOv3dojBwUGM4OcdQMiquntJaeHLu13+Tbm4DQqZQElLoSWjB54AyRyvzcd6xNVsILiGC5VJFulLtbzQy4ZZASwD8fdIA6HjI9OZpQhNpy0jt5ad/wDg6JabhP2uq5r/APBt+a/ySs7HWTSSw6Y/+jR3f2hCXQsZF8vAG7rweRz64PGK4+5s7S8sb2x1NLu4sLq4ik/tC2CKbbywVZvL5Eh/efMQw+7xnNdJoVxrGp31sZY5rnzYZJprQkkQDBJZQpBVhxg8E528jiuk8OSWnieLUEvLBEuLfyiLmNcRXKMWEbNFwA6hQGGMMOwrlxFX2b5W9t3vu9P8vNWumtVEpqlCTkr+j7f1f7101wdX0jT/AA3DY6NBF9vk02M/6dOwDsWJJ8v0XrjOefpWZZ6JdWWrwLFbsbKLbcJO/BzgfLtbvznpir/jGK6sdYtptRmMkctptSJyrKjh+WX+IjPI7isPUV1bxN4dQ2l7ue0vZUDs5R7lCoZW3nrtJccnnj6V24SvKPLSctHpd3etr3++/wB/ZHPOgp0VVi7rq/8AhvkdRqF/BBZPJOLX7BHMFnHk71BxjbtA68jnp1q+AgtTFbsrW1yAnmJyrZ+UgDtxgfpXCS6VrGo6XpOl2upK9rbqEv1tfmZZC7HIzjd8pA69R712djpsNjZWltpeZooP3a93Y5zuJAJHJ6EY960rQhTSSet/w6X8/wBDj5Ukru/9f195S8Nw3Nvcaha3cZ/sSRfMdm+YLPnAKMOu4dccY9xg19XV7n/jxaa6tY0ZZbaCUK6AH7xH5cAHABrQv4jDY3T7xDPIwUoFwhH19evPArOtNOm32t3A8Vt5DBl2ofmCkHr6nPIPrU4eCg3UT67dNvv+ZNWftJcz7f1+BHpXh+LU7Kzub2Vyc4lSNRhMNhSDjLZ65HpXQWtnFo809xDNPmYmOCDPOM8DrnAxxn8asXV1a3lj5iSeU7P88BXBHJ4AGPbp04PFDPdXU8hthb20oQujzkyKH7A4OSAc/UDmoq16lS/Nou39fn2Md3/X9f5dSgdOtbO/F0ttbJczcSSIvzj1IXHXvkc+tTakILiA288bSxAZxIQGP0x+e3/Jg0+GazEaXd5JqM4Z5GklIKgtt+VB2UbTgH9KyFuZ53cxO/mfNuZujMfT1rSMHOV73t1HJ9v6/r9DSt7fTtNk3JCIflwqxHn24POf88dae1nY+JLB454Y54m/dkZ+ZGPOVYeoI6elOjhjudIaW/2JDHHuKquNzn5QCR2xngY4zVGwuALWQWpHlN8wIwvQAA4HTjoKlqpKV4vbrqaLlUG0/e/r+v6uY3iDStUspY4tHtC9lAI4hbwbQSmOW7fMMck+1Q+MtQ1Ky8ZNfabaXW2zdLeISS5iux0AA7ArycGtSLWfP3GZJS4A2sTneOmCTjHNbpu2vpYTE0pwibIpEDoEAwSnofXoe3pXVKc6dudbJr77epUJXd2tf6/r+kRfZobK6F/MQk8i7JFBLR7+A5zgZ5wM1dF0ocp5ZeXBJZhynsF6Z569sVn63dSWVm15DYTTvbx+XDFL95hk5PHXlqo3OvGHTba7lhPmzpkxAeXweoORnr27iuZUp1Unv0M2ne5uJd7Ht4JZNgQHy1yFZjnkknqOfasrxA2k6MF17UrDebXbGrjLPk5IwCcA5z3PrUOlaoNQS4k+yxxXUDbNj4wUZc9T06dK0bO+e4/cyqByVUPtkDD2O3IzTdOdJ9u+v+Q01F3OWu4tQsIb69uJYdWsdZkiE0V0TE0Nv95QuGBzzyV6bQe9WNDsbLRrppvDenSXjyTqEkkmbzI9zbQWbpjGcDA7Ek1u+ILIXaMyIWuEA8vzDjcP4h0qnFCumWMNrEojit0Z3dyeePmZmA/zwK2hOMqaXV9P6+7p+BUqjloupU0vxfceJPE1zbQ24gs7FWdllXJlAO3IwAFPPv3rY1+S6tbFjpUQllhjeXYV3+a2c7QPp/nNZGq6lrBaBbG1S9tJYijFDtlIIwpQnHc56fWpdSs5dJsoUup57eOSBUd7dt3lyADOB3/AjPrUqlHmjsvLf7+pUkrp20FutRl1KLw14ntra5hluomsrmIrndKOUcnHIZd65bkbF5rUiuFeJFQqN7BVUqWXd6gepB/KqWj6O+peC/sltqNtdym5Nyszs0cLMCflPBwRnuOtWrTTbPQdRmm1O+kvyIsSWdrGdiMwALkEgkKcEc5Oc4AHHG3GnOVJJuzdtPPbU7FOnKnq/eXzYlxpcVxHLDDKIZJJRLKZVID4XGD24PYfX3prq2l6RbWNojSxvK7qV4SRiRvYKcKuAFHTH481o626SaNqV14bYXN5aMss1sYSxKE4d4w3QgcgjI656g1ya6tqCW0Ekmnh3m3CFZQcyRqwyV3jkDnOM4456VFOcJS5dmu/9f0r9tHS56seaWqT9P6/p7kzaddHTZSUFrPITI6bNyRru+VgoyPMbnnpge9aMttJrXhuSwiWSNrm3MfmqN5Dk5DHaMngcg/MB7dcLUbaa6urnR7qW4t57W6eaKaJujej+q4BYEY46HmmaVf3UyfZr/UF1STUpHaQRAxoIs4C7hjnqxHbAz1rrUvaU4z5tdP+B9/3afMueHknZK2v9fd/XlWg8P8AibT7D7Ws1lZ3EMa/Z717gRG4Y8GM5w4+UMMnA4rY1C8ki03SodSLvqLI1x9njA2LFuKklv4m4GAAeBnNVbrRWSRRqEkRgB877fM+2SWJjgZY9COg57Vd+zTa9qK2uvt/Z+qWoeRLx3JVImYBYiGOWHII2nqc5xmlLFylUjOprv01sl0+/VeWhVTDQ5HzPTy/rbT7/LajoV8YZZrmOJjEzjfAWO1uvzL6EdjXUlTcG2ltwXil5Uv8qe3sMGo5/CMUJa0guZIp4U5STDE45Jx7k9umRVbVNQj0O1srf7JcXTZkxAtyIkRUA5yASzHcMZAHuaqvXpVHzU9/+B/X9WPHhCVSXLT1/r+v+HNCWxtH0vFyBIbzduiCb3GQMHHYeh4Ax9K5fU7ePw/a21xH5omeQRtNJkF9uWAweeQec84x7VtW62K6heyWMa/a7qNDNIz7mHcDaM7ccZx1OfSoPFNpp97pq6be3MK3O8T20edsitggt6MDzkE5PaqoylCai78r3X9dv0KTSdpP+v8Ah+36lmzu4ruxs7lLO3Eif6tZIlZ4Rk5G4jnBJwD6n1qxqMgmtru7igtH1XdHFG8kKEgE7WYbhhm2j+LOAM9qg0LTbiysba2mMeVQuzvJtyuckkflwOen1q3emCBAqsZ8YLSCQgOxUhdvqOxHua5q8abnp0ej+f6/jc2pzcZJLT77f0mykqTPIJZppp5lXau7G3OOOmFXHHpwKh1aJ20W7hspmikKfKyRg8gcYAOOeeB61Xu9dtNOFqbou7S4BjQAkBTyfTHBxnrjt1rKm125sNQC3G2SIjc8bx/KyHkbBjOcYNdtPD1JNNL087Fzm27NF20km1DTra41K+aSWODymEj7BuTGACOjc7cngZorVkSeaKOaCVo2H70ZyhBxwpXaQM9ORwSetFcs6SqSbikvuR10MQ6cEt/69UZGo+FrP+xrO0mkigMYRHaB9yLuPzMwzkjjntUV3FptzbWsOpsgtokYlGdpJcqBsBf+BSSemB2o1S7utFmtbh5onhmaRfMtnJQNjHzcAbhx3PSs6LTprmaS/FxkE7G3DOWYckEd+eoruhTlJKpUlZK9rf1oZQnZ8u/9f16dDUNxFJHcxyLFJMkbNbyxFTjJC7HLEY+UjDE5wMdzV3VLaCxjjBKymONJ5No2gAgD1OMNnrgHIpZj5N19k/0ZbJ12OSNrptG7dnGCcHBDdsc8AU3SJNPi1Mx27SogQwRQR4KTlsEK+c/eJLbjgdeAMV56fJL3vht999v12832Oqo5yinD+u/6d9r+Sv8AhXX/AOz7S7is1E0dzJHJGroRhuVAGOBu7bjjI9a63QLqHVbaO8tlggecs80Kbd3mA4PAGSeO5OMmuV0FrM6rbw/Y2nimDI3LEopGWdQABtDAHnPHpVrxJqb6F4fNzYeUklyfswS2LF41Kj/VKcbWOevYn16clal7Wq1BavX9P06fqcGKpxk7WtJ/1/XT7rHY3hjFlcC9lSC1UEyu77An1bsf1rKsLHS7i0e50u9t7y2gXy/3EgcRs2SofPzA5PAIXP4V5l/wm2uXGgjSPJuNaWM+W++1DXDQk4ERlGSXT7ysozkjJIGK3tJ+HY0HXp7yz1W1vmihltna2uHMjB12BnQjOAOcAkA9Olcs4Soy9nLSV9V5aa+T1COCVGD9pVt28yxNoY0uW4a3R0E4DEHKrwf4QM+/fvWjpk5tLhmlDSvIo5ByUHTk/lWTcahqUOoRWUhElsXBhMZ+aLGMhj1xgE81PPO3ls/nrHtJRZOmCRzgZ69OT7ivZnCc4pVHe5xpXVm9AuNb0rU7qeFL+3jEB+YF9keR1AYjDEdwCCKbLPFHGhlxtY7Uxgk85OBjn/6/eua0TQJI9IutIvrwy2rMZkbyR8rkjLJkegxn1zWncwG1t4RZBJLKFFtm3NvKY53Z9+a29jTi+WLLkoxVol+PUrVY3BR1/uvIuRnpz/LFSrHM0iO8sS2pV96gkOxP3cHoAOSQRXM2Ty6hPdRSnzFDYGM5TIOB09v51qQSHT7Mi4lYkRCMRgg5x3FOpQUXZbmdujJJ9TaPVrdNm5nYorgbhvwfvDuMNjpxmmXerkswgt7dQGOGZOT2yR0xyPWsmwv2udd095oo4o3lHCsCxOCMk5+Xjjj0x710FxosUJWU3MIjf7gC54z2OQAMEdaTpxo1LVOu36mlZQtG3z/r+v8AJNcuGvfC8bxRldxVHjQ8blJBx6gjmsvweBILgSlsujRqpJ54weueKm1jW7eO8stLtN0jGbidZAiqc4JUYOVGfvEjJ6DuX2V1dte3MS2IhtJAYxtbdODnrI+RgY/hUAD9TKqqNJwS3f8AX9feVTw0nF39TIntLiCeeFopNuPkI6N2znoMCt2C1mt7JIguJdm5RycjHQ+/ercsMFtZSSSs8MSKGklYfKqj23cnGAO5NLompafqNnINNjdERg7Ek7s8gE89cZ6irqV5ThdLRbkLRpr+v6/rUqx3a2bML+6hEsxVESeYqTg44HHJ6c+3FSahZWmtu0Ms8MFzAQzSGQM0IJwCwbA56c4qnqvhS31+1jYT2QvEwWM74UDOSOvcnrTdf8JfbtJuYtSeEX9xteW7gG1HZBhFPBwACR79Tmo5oJpwlaX9fh/VjVunJ3Tsyey0FNEmDreLKC26QHDmQpxt9gPTFaDT2vn3Rt4WD26eYzEfLH8u4KPwrGg0a9vtDtba/wDIs7qOMoZbfkhVA2sSeM+vbHvWnYaZFJBG8usC/kUBWII57DIXIyRx16UVJJ6zld/12MpRW7Kd94ot4dO0hyoSS9j+03Cs2fssOdpc468jj8PXFcpaR3s1vPZ29xMltqm1QzKRIhY5D47Djn1BrV8eWmn+bZjVLZms5I1jWe2fDhV42N2AywOcc/hWrqVrPZ6bLaaSI/7SW18q3VpF8zC4Gecc4BOf5V0U3CnBcq0l39f0/wCHNIwVk47j/Dml3Gn2NrazpF58MhVJLfcUkHXcST94nn+grYuES+sZbO8ht54ywYxEFiQO24Y2njr1rh/DlvqVtrkF3qypZ+ZEYJmluc/apQPk2rnkjjpgcda2/FGqaxa/av7OtVkt7cgvJj5yucH5ewz6fnWVWjKVVJSTe9/P8RVINyNrT7C30uzNnYxmOMFnBjcv15OGyfb3qEW3navDNJhPPlElyZeBLgjoMcEgYxWPd6q9jb2c00kcCXKb4hMu49MleBnPuePetyC8sptPjuJJooYnUMksjbOOQQdx47n61jKnUh771v1JjOUH6iTSDw9qjX9rdtcQiApGjIB97+Fmzk47dPerOleNYtUkjtNZtlMcpDr5iCRQR0JVgRnvkVm65pX9p6I8UAeVo2WRmicO0q/wsp7j+oxXGXEMP2tnsklNw+EVPmZiRjAwcYz/AEq6WDoYmDVTWXft2/zIk3N3k9T01tU0vX74QwL9i1AyKsF+8KPJIgJ3RsODtZcgZPHH0rgdU0y80XxP/Ytjci5vFmW3jyCPtKzFXRsEfKwQ5JHygqew5t+G7m9bx7ptoqpcRm7BeGeA7ooifusQMLtwSG9se1d34i1DyoobyTU4LPTGY26Xvl72GQxIyFLAbfmP4cYrynH2NXlp9Pz36b37bato9WMp4aXso6qS+7+vwOS8TQ6TffFNrL+3La3stJ+zW0kd4pGPJQFlQAESsxU4J25Y47is7wtbxQ3Vtazw204iea5e6RjJ90lgqLnI6jKjnP0NLex2niB9Xiliit75ZFY/PujmRW8v94/VJQdmSpCE9s/ek0bR7TRLmwhtmuneGcXbsHH7vcNo3MOoOOV9PSuuhSaoJ8zcu3TZa/1+d0bTqcq9lLa3/DnXx+K9DjjKm6EV3KSHVgy7ON2GlI2+2MnGa5HxVqM/iDUbePSIYr6CEELMn+pQEDqx4Zu+MnH1qvf23h2C4bTLizlSNWDNIZWaBD/dHPyjP1xmrus3d7bXS22m6bKLFIVC+XEPLZ242lv4FU8cck5PeunC4ZUmpte89Vfb/g/h5nmKFOnLmpi6Dp97b2TLdy75d2VETjgehK4HJ9zWxBZLJPC+1WfO3zdgzkDJbcecY9Ku+DVu57KSPxJNE2oqQ2I8IsaZPGR1xxzXN3U5837Tvd4BI/kxoASy7eV/qB36UuedapKO3pt8jJzu3FHUaYnnz3BYL5QAK4HyljndjI44255rO1G3XfIdMuPLkG5S3LZBXBAJBIPP5VmXGsHUFkg05DDEYyr7srtbbjgZ/M5rJ8E6hcxalcWF2BuCkgPkgn+Icnjj0NNYOXLKo+i28hQcoS5o9yhrWl3gtg6QxPHBEIHWNixjBO4twBgfMB7DNauhtPdWEMt86ukb+XCTGWaPaAoCgfeHAxyCMHqK37u5sraN5tQmSJNgMrsd2C2AMjpkgYrJjvpLu0urLTI7a3uo4hLYLGy5YEkA4PAzkjnj5vato1JToqDjouv9fp0On2knLmWl/wCvu/ryNC8xFYltPeTy4mUyeZHxHDu+bGcjqVJ4xyfSis3Rrm7ubwx6laizvI0WNiZlxI46jAHyH3+6SSDRXPdUm0/ev5r89bmypuWltV/XclvbNjYNBq0JZmRY5JJH2g7gWRVbBJYKM+gAxyADV7SLKGCyWK28yWAjzkjkVVPIxz068jkgcc9azdKhu7yGRmDi2wnzuWMb4TIIz8zPuHB44cjgZrP0vx5a3XiGTSoAYtOHyCc53Mx5LFec+wHpxkmopSlKHJT2X5229dHouhpXpNv3dZeX9eat1sdfJb2ZxJeI0UTJ5S7VwCp+U8c9+nXoRyK5x8td3JuJZYrYMZZ0cBWklbhQHcDnjcPTkD0FmbVpmlAUMiySeU0LjaWYsAoOBuY+2eDn7uKy/EaXkdorafZzSRQSFJIpgCz5O4h8ZDZHQjtnuaIQVSSg/v7W7eb2/H10oRnQXNJ7/wDA/wCB+GzsbWgXNykso04x3dxOAn2WWPzHZfvbXH3g2Rk9CMAk8ipfHTQXmoW+ni7SBo2aWQo4fywAN3zE9dzAZPpVTw/JaJrFjPs8ueH97boxKr5oGEV2HQbuPwHaubbw5Dqd841K4ZLqaR2uysu5wFJwijoO3BrTD0Wq7qTdrK/336eSX421sc+LjFzTs7Lr/XTW/wDw50C2s/8Awh3/ABSdwVnkkBklt5tksg7nd0DZ7egNaPhTU9at9JuB4guhJPFcAQz3wHmsmz5lyMZAbGGP94+lMsrn7E8jW0ANhDHgxliHbC8An1OOvqaYl1HdahPa3sdvcsHKhHPy5Bx8qgkpjtnr3NZ14Kc+afr5/wCX9fdzwcqtOUUk1+P9f0+5tSOtyIJntoXmiJ2uRtPIx8pxz2/+vXP6nGJNP8zayNBJlmxjcOnzDr17/StTUZfLs7mO3uEjuQoIaVeB/tY9B+nvVOza5uPDxW5vIZnkQfvEGAD7D171pSTglLpfzOSNrXX9f1/XUfoaNcR3IEDxRhgFB5G7HOR1PB6/pVLSYpYdUlWXDM7CMqd2FTr7Hjt6UtxM9nbxJEpAJ2hg3BPfn655rU8Pr9ptZJLqUxWsJZ5HZgZPLH90d8nABxxWk24RlPoyk3/X9f12M5r7T9P117SaSVH1W4UpM8OItxAUIJBwMdfbPNTXltBe3FwIruK6aJB5iAFdgPyjHHI46j+tc9qOvW3ibxFJY/2Y7aXYRtLC1vdHaHQFgwUnazk/LnrzS+H79WtNRuJrK+tLiICJknYuD1ZQOM56VKp10+a3b/L8ux1OinT5m2n/AFYk0rTpbPxFZraQPMI5HdisRnEap9/IHTjjJ/Kpdc0zUdZ1W7FhrIi0MnZ5aDJAzngdM45/H3qK0sL7VLi1vdPuprQ29xHLHfKcGEjGWC55JHGMDk8nFdfBLC2tstrZMsFzLlUVPLEeAxbgYBGfQGo+sT9rKpe9lp/w/cuu4U1GKtf+v6T89LI5u1ES6j/Z66UUt7SIGKUpnoPv78YPTk8jJqDX7nU4r+3a3u5/IkRgqW4JG4DgHrgE+9W9d182GqYktTPHAwBSN+SW6Fs5AHoKbo/iCHV9cvNOgtpY3gQ/6Q6gAnONvC8HByPpXUueCVVx0t6/13Oe05vmG6trMUD2VhqmmtsvoUa8IB2Qsx5BwPXnj8Kd/wAI/BZXMk8s8aT7RHFgiJSFII6H5jjjnPWm6x4ZudRjiX+0ntUhcSKi7nViDk5UDg8H8qt6roz6tJcSTTHzCCsRckKp9COoz/WpjUhFJKVr7/1/kOaUVaLK1nFPHqqLE0jMGAkWRf3aL/ED+WPrXQrNJalhbo+0AskZJ28nGce/HSsXw/f37adcRTmf/Q28vyVH7xuP19j3qloU2oXGoSRxzzi2WVZZGuABwTgqPfBzxngUqtJzcua3u/iY8l3c0fEInvdJuY/3ks/ySkRsQX2nJUr3HTgelc3YaoNNvLd2UtlC90EQRoqkdBge/wBa7/AddqFflHG329h/9aq4ihchDHAz/d3bV3Eeh4z7nmpo4iMIOEo3RUUtmctqLxW/ieN9OvIbnULpdqWRfd+6AzjCnaenGTkjtxTvGOiTavrmnNYW8n2h3Zjqe0sIR12sgHrnn3o8SarbeF7mP+ytEtJ5Gt2mZhFhgpfHzEDgdTjJ69q1dUvNbt7v7QzXi25eN8yIBbfZzg/NKe5XpjnIwBWi524tdtL9f+G/roatuLUo9f6/r/h0Z/iXSru+ulB1LbapabDbMmHyiqXkTGQCxGenA4PFWdAmt9c0tZI4bzyUxCXuX/ePtA5LAdfXit6K8066tzItzMqgFXiQqXHzcZyTxnpzmq95fWlnIkM7TDcNqDHIHuuSO/asVVk4+zs7ozc7xMHV107+3baO4V7jynQvEB3CnCgk8g8flU/ijTDrOl2l3pbSTwiT92gUHyXPBCqAAcDtU3iTS21XybeyktP7QgfzBGZ1EkkeOhAJbI69uKt+H9Pex0+QXbW4kEnn4VyURQvzAFiOPU1p7VRhCpGXvLoSm00zll1S6sLnRoNFha60hZfKnZZU8y6mfG9cAnYRgYC8cZzXYX92VnQysu1ySbqUKhJ4wGYDJY9vrWba6Ro3hvR57/R7ASRpG1ysiv5pbs21+cAD054qDW7eLxFosdtDerE1x5dzCQ2SpXr8oPboaluNVqTjbo3+P4f1sbS5ZSutilD4g1bwve3FzHo+mWNkxC3Aw0wkw2EeSRmDFt7gjawUDqveqnieGS61i08YWJVtP1EtPJatLIfnViJI2wCDH8vyEAYBUEHBJcqXehw3M97qcl/dXw3+S8YaNiDz8p+o6ipvD8cXiDwy9leo9u9u7takDCwE4I2juhb7yH149uergGl7aLvZq76vv+Nvut5HfDGU4O9vL/I2EudB1I6zolpp17a27CFZLt5l8yfySHYALnySWO7gkNz3q5YS2ZmEVhbC0MIEKqpIyvqcnk8nnrzTbXSYhIDcoj3ewI86Ah3KjgDceDjgewAqH7An2loIrhmu4og5dYSNq5JycNyaKcKcYuN/z9L/AHf8A4MTW55twbt/X6kCeE7G31Ka6uc3EL/6uJ/lCHOTux94449K3I/KhnllkjlkRVCxhQuFGBzjseKqXOtW8TFZllkUFUkeJQyKxx155PPQZq5I+YrsIql1QqgcYAYepzxzj14qqkqs7Opf+rGF29yjr12bXSLy++yAW9tCWSJDuDYIzlwORyM4x/Fj1rC0zWV1Xw2Lx7S22eZsYxSlY0HHIzhgQWA4yRn0NVtDm1FPE1+L+3llv5SkLgxj7M8XAYgAbSCpxjoQT0rYtptNW2vrOaC3s9CjkaCKGF9hLcEuCVJ3cA9e1buk6TUUr7O6/wCH18vvZq1FK39f1/wA0iK1lvGjtku2mmDNGXX5CV44PrznGOlZPiDTbmLW7a9tkRbmQrtVs7g3T5vbGSW46VqQ+HpNPvLS8gvTLbM7Slgw3P1AbrnnPIrduQZY7ZzIm54fnO3G0dcYHQY7ZHAp/WFTqKUHdNWM4xu9Opzdyf7SlNveRCfSromF25yjg/e6fu3xgqOQQRyecM0+wj0H7f8A2DE0K+WsbSSRmRn2n5ggwTjg8gH1qveolzJLDp0U+ZyJYYdhzJKxKAqBncOABnhS2T61Nqvi17DxDB4X0ljA9rHHG9xbxgm7kCZdS7ZITJwMDnALE9uPnqW9nHVP7u+vTy89O1z2pU43Stuv6+f5fnbgeF4kkkRpCNp2zhlkBByAwI9O/FFMili8l0ed5rjG7eqr8iA/MSCNzZzgEnOcduKKJqm3ea9CvZuezLifaJLlp5E4ni2lGuN6ySHHIwSQVbIIOAcYxzgTvZQLuaBRbuRuLxxRxyNk8HJyQf6cYpthZrYXE0sc032meBEEkkSq5iPUIAWAQkLtJJI+bBHNM1pbmG3h+y7/ACyCojVlVA52BN7HtgPkk/ex1pwb2W352X9Lf7tjkm1OolF/1f8Ar8SV4UeC4ezV0u0LxI0cSb1JVVKBlYfNjkYA4z68UNMk2JcJds3khVeOV14xkFXBOegyOM9+tVLi8lt5FFzDIQQPPnhjJjjUcCIKOW6gknnB7A1saTZNHaiN7Qq7KRLi1ZXcYJ3bScE5OeMDsabVkntfy9NL/wBfijWo3ThJSd/6fz31X+Y7QrZJbq6uZIpTAItsMrkohk39UZThuOh6HPrU62xuriNUncw5KnzpC2znnvjk9jwM5GK53XZryG+ktvtAghKpEnl5VY1Kj5sdOcZxzin6ZHeQ6c9/M80UC7liIDSPt2kb9v1x2rWWG0dW/wAVrL5aW/ruec6kp1E07L+v+G+7qdaYUUz7WXzFwJEDKeo4Bx1+uKwLvXbbT9Qi06SOeO3kwBLDGPLLZxtCLy2MZPpWd4QSR/EWuzwRztbz4LSS5Uh+DtA4we+OwroUXyCXZ/mDkhm6j+tL2apS5Z66Ly3X6GUoqD5W7oo2Wv22o+Kb3Rbe0Mwt4WkkugcBGXgqQfwGcjnNaFnFZ29rdi0VLaMvulLSqoU9zyQPpz64otLG2tY72O0gSI3jHzpOCzkDOCc8DJ6ep6VxXjrStR1Lw5La2BxMCGeAYzKAfr2rNq6l7P5LvZfqwtGc4x2T6ieP/FFto+kyW0M7SXkyjyGhIZF44bOenTpXmWmePdd05AIZ43coYpJZYw7zQltxicnqhPb9a2tU8NSnw+ljZk301qjXDSop+Rc8huwUc9+9YHhfwfqGvR/aY1CWQYoXBBd2x9xE6lj27V4mb/XY1Kcad43jeyfXrfppp8j3MDTo8knvrv8Akei+FH0i4tEc6OulNfq32eWORpFZQeRkkkEEDjHPHTv0d9oq6baR2DXEkm6drmUzuAYg2BzzgcDJHpVf4f6Ms99bz6lpElpZ6PGv2fLYXO4khl/vnJJOSeOmMVq69cR/ZVN7JGJZpvNmDD5WBOTnH/AccDgD1r6OFZzcaafTXrr5ei/HyPOrycKui/rp/Xr6i6TGsNmPsjiRZHC7U6Eg/dHPbAH510GqXVxbrcSqrRRiMkqqfdGMkD2rk7O51CxtNSfQ2Rr2RI1jebblct85XPAO1uD6CpY18VJpN1EhsNRu45ERJJD8ssL5yWB4B6devPXrUVKN53bVvP5HI4SqNzb3KNlZ2Gp6nd3TQM1rJhzG3DSMcEbiCNo7gHt161rWuji21i91QSOZLkD93tACkEfMMdfTPHGc+8urXEej6SBY2EbFG3GOFsKxyQ21uTgEHHsPrWDqGn3VvK+IZTITujmScqz8ZbODx2zgfjXRGUq3Wy2V7dLefp/SLUmtP6/r+kdZ9pjU7N+cDC57c8/p3qOSUBy5bdKDxgDBXABHH8vaq0Olp5AWSVjK6ATOuMMSoyenf3pLu5h094s7wiDMaogJPHG3J59c/rXKoRbtHViSLRuYUx5gJAAUFIyCfaq0t5bWoe5l35wU3TuFQA9gAMk/U1YheLyDz5iyLuR84HPJ5/Gql7YRalbRQSmVfL3MrK3OSMHPGCMU4KN/e2FvtsLBfx6ipkhlWSADGI1249cjIOT+tXZIxDDvuVaKJl3DCgbh6niuWbRb3StE1RNPu5ZL2SItDJtwUCkHHUnOMgY9aX4d6ZdWejz311qSxrfxNDbC+bylF1ICAisxxnHzZ4GAM9a0qwpxi5xlotvM0jSvFtMua9pGkatbreapdXggsodoW3Gc4PIK8cn3x0rV0zxLpXiC1jS0jaPYSEjugysGwMj5Tk8c5AwD6Vz+mW2taTcR2t7bOblX8lt7jeQoGSy53AfXv04re+zQtd214Ydk8AKpgKoAz3GPU1M1CUVd3XTXb5BWhyvkn0OI8Zw3Fr52mo0xtrhQ0c6Ju8xsDMeR0wV6+w45rZEGoWb6TFd2vm6OlvE8lzJy8BwCwd/ZjjHpjvWj4lubu1FtKhSKM7huAYIX/hDEDOMZAx3otb20v9Pey1VvLlnJjZJIyQQ3Qkjo2T1OD0NdXtJOlGVr9+/r6hzKyizL1fwxY614mTxHpOrQWsG9TK0AMjJIoAzheRnAJ/GujUXc1ukV/e2t+TFiVX2hpYuQxK53YOcZrmvDHhy60jV5LovBawRKyuqsf36AEBm7LjueO9S+PrOIWNpr9lcwQzwsgNxknz4yQVAPsR04PPtWDgueNJSuujtt8/6/Mb95pX9DuPD9rZ2ekW+n6fD5FooJWInfyx+bOeTz/kVh22g6ZYXEl1FAsVwWaRVLFljBOCVHb8AetW9IuRe2ySwRXEfnJ56oykqF7EH09OtO1KZmRxFfR2wTJDbwolyCQu4/TpXIuenOUU3ruc6b5mrnK3coW6W01q0WSIIrtIflZATgbWHQ9Tg5yKsazeWvhtI7ayiLB432M5+5/CD7nJrQ0SySZvtd5c2U88jkbdwYIO7kdCw7dhWVqGsabN5UjWn2i4t5CIPO+6AehPr9KvF5phcJOMMRLe+mvvPyXr9/mell2U4vMVJ4WDko2u+ivezd9lpq3orXZB4f1K+gDzXN3PewyIv2WN0IYyA9B3wPWt8X01mIxdRob2cl5PKwvAwMYx8zAd8mm6ZaRxQx31zNDJdSqGHmHkDP3VGen/66u3Zt5HiE3kuXYBt6/KwORnB4z7/hiuSjKtiK7xNePKnooLp5ytvL8Ft3Zpj6mFowWFwyU3e7n3eukF0j66yersrI5G40+4dJXsE864Lxyxy+ftaJg2Se3Ge2O/Wuomvri2sWuZNqzsCjjGN2Tzj/AD6VgeJ7y50a3WeAhLNQV89IyrB842egGPbt+NSeFry5k0y51W71m8sdMt3wqrEss1zI4OIQrDPJRto4yAckAZHqV6kZUvaSaaXTr0Vuvl0POVKcktP6/r+rG3pGrxzQQ3NsiLIr7RuPXjrgfTrz1rO1bRhNcSXC3yWNw7uo8zBDMck7QSASecgD61m6dquo/wBj+bJdmS8V2kTZaxxbAByNqHBzwe/U1r6pOJ/DiazFbvcXCW+4QIeWLcNnHTt0qXGdGSnBWu7d/wA0KELT5JP/AIdf19xV09bvQvD2qXLM09pAPO+zRncImJ6BMHGMjvgewqDRZ31nQ7e/v5PJu/3jkZKKyjkOqgcEYIIPB4I6cp4b1bxHd3Vo0tnawWNw7NOgjAIXAA468YJyPxz0NHQtM16DXrtI9Pkt1klbz7m4Y5dDnAXkDB6cdsVrOipc3tWlLe6du6t/Xl1OhP2d5RX/AA1/62/U2Yb97jwW914UuRJqQYeYrOI8fN1PTIXk89yTVXQrCTR9NhXUIUvNYs5ncJGrB1Rzk843c846np0qW+8rRr+8TSYIILJpglytxGGQsoyTg9SSccdh+NWZL4PGupXEJimmjIDhSMgfczn7pODjJzwcZrGf7tc6+F/fr0dvmu9vUVJurJw/r5/16lDXdQbTUgtLAQS312Va3tSSu5TwGOOB93ABNFXZrxDDptzcLptmzqSrXa5MBDHzCrk5YHjauP4vaiqg7RsqXN5tN+Wlun9bHROtKlbf5X/R+ehZ1F57SzmFl9mV2j/ckpsicjIzhMjAPrwCRup/hS21qR3XXL61vYtm5DarnZwS24lQFGNvXj8KNRu7SKAx3MrKWxiORH3FxjOAVxyMc5ycd+tS3M9re2yZkDQ4PlgOAUI/hCYBwAc55zjjBrJ8zhbl362/IxtfS2/9f1+pdijtXv1ZJWbc+5ljhVInf+FlzkjgH7pOcc4GKt3KwIGk3PHEhIAwpPPzc4+Y/dHHoSOc1zEN5Alx5lkwjMEhQkRDAZhkEFiw+YZBP+zVxLlL6SQQX0aCLb56tFvKP97JOcZPQ8Y/HisHTbd09v67f1sKrQaUbt28/wCuugy5ubS7eK21FIJ0KrsfzziPceSp43Ln+EkdDgdq3YEO5omDxyRqUYQyoExnjA7Afr1+mabK2kmaNWZ3V2YRq6sIncZJPOAx3HAIHoAKW7s2j0y7gRXtQqFUl2j5yB8wBBIxke2CT25pyfM1G9kZ4j2dvd89+vX+vV9N6d3cTWN/iZwtoR8rHlXPfkZxg4/OrKGaeaN7VozGMNLkZJUcYHTnr1rL8PWN5LaQ22oROY2LOCMboz6r7cAFeQQcdK1IbeDRmdoh/pDkDbHGUjHvyTk+2cDpWtb3ZckbNmS9nyvmb5v6/roGqTWltLapqWoLZrcS7UyOpyPl6cDlap6vN5ME7xm3uHhbE/7xXKDPcoSc/wCTjpV28sLbV3tL26iMslnIWj2HCAgd+ORwD2/pWdp2gabpkt61nZlTdLhyWLhlbnIzxjp+VOm4q1910+f+QouNtdyDWNRsdP8AD0hjlLC83RqkR4LEc5Ix0zx9frWHo2knQ7Ga2XTEUXMCnMvLsPVcDPPf69K7LybQRwxmCJo423IhUAKfXOT/ACp2oXLQ2e6W6aC3hBMh24I7np7VfOtFFa33e/Tb7lc0o1vZv3Tjr6S+0jUho2mTyTrFJuWGAFU3BeQB2PBJ962dat2uVhnu4ExOiK6O7Hy3wcZY9u3WsrV9Nm3NP4Zspbq4kVJTPCWxJDjLHf02n88it7RLaWDSGt7sKijcykuJCNwyCT0G2tnOnGMXDdb93fqXVhd80nv/AF/XfzI92mGG1sWu4We4XdEBn96VyCP9kAjHPpUuneTFapqU+o+e8mYPPBOwgn7uOeRjGSMVX1Xw5LeWWnC3aze8tLgTCVkJLRfewp6MASe/8X56cWlWUMwKQkxAZSAoTGjA/eAI6/X61i6keTVu732/rXQio4rRf1/X9efPa7qet2urTR2ZNmke0WsXkeYL046BsYz1xyPfk1oavc3CaSupXFk9zexRB2tY3KgEjLZ77RjnH9K05b7Ze+U5uAm35yh249PcDr37VL5Sz4hTbIsp2sDyMNwc9ulDqJcrcbW/ElzUklbYpeEdYXxD4cbU3hht5o5WjmSMEICOdy88jaefep57HT7uMT+bFNGxId237I+MoGUHrkjms3xHpUqQaZc6XcQRDTziSMxkRyZ4xx0GMVz8Wo3+hMba3aMwxkZ4JDBsF3x6Dpg56VVHD+0vKlKz7f18n/ww73d4/d/X9ejOxtImsbDZevE2zdMyQclYx0HHrnNY1v4iSa9MdzBFbWhAaGZWLFT/ALR6Y57ZwevFa0l+bK2AgUMTgKFJByQCCR+PT3rHsbjT3umtJ9Kt43Z9u9FU89Qdo5U98/nTpRupSnG/p/l/w5MZI6E4jkUMpCEBmz/C3faw/PrWdr9gdRuIWltHv38l1VJdmyPC/wAIYjluBketbVpZyzSqbZA5UMzM5ICHgE4J5PPTAz1+tby1EqIrI5JZFZpCueNpK4yCOT0x1HIrlUo372NYScZc0N/6/ryJNOkuNNsUti3lwRAqpcl3C54jUncSozjGTjPHFUtcnItEnlfHzbVweW9R6nHXNQ6Nrw1yC92WN5C9phGMgwxXsVxxnIOfrWZqem3tzrl1dG2jS2AEVrcNIo2qcgsQxBySw4HHHtWtGio1Gp2i1/X6ia5pNy3LtpOZ4ARAZrWZQh3kBXIOMtk8emcVONJ06MG7jS7ZkO9rZ23AsOV28nOSOhPpxVeEzWGlttYTzRI0hZXx5hxz36dwAOccCrmk3v8AaGnJeKWDPF5uDkqUVirMPxAIHoa0m5K8oaK9hSpcrM7S9QsfF2ganblbiymWTyZIJdpkRd2SQBjcOcHI4JArn9As7a08Fag+sI0emRXXmWttdfffbu+UgdNxwM+5rp7DRbSw8S3OuJcpAksZWSIKMM7H7wJ9ePlHpWjrlhFrGnvZ6kgltrpBMhRwrcHsecEf196hVVB8sdnb5d/yKU4p2T0/r/OxmaHrV/e6UtzrFlHAxfcgh3AbOxwT0HQY6iofFGmyat5UlgvmRiLymAIVoznO9QeOg9T0A70z+yL1LJoNLD6jukUFryQxR7QNoBOfQDAzzWjb3K6bqMejap5drqsi+YkJBMbBec5zweDj6fStHKNKfPSevby9NzLeV4IwdYtm0W3iTTLh0hvFJuVc/Ox444HQ9/yrP0uzmvGEtu+xFkCGUE/K2Cccc54P5V1slkt7qNpfR3SPZ7Sg2qG3dfuk8ev/ANeoY5NN03Vjpatm4OZViAyuGB/EH9BmvmcdkH9q4v6xi6jfKvdjHR6buT737dLa6H2uV8XvJst+p4GkueV3KUtd9LJdku+j1dtTSuGWCCCN2GxEVE/AdxVP+1xbZjnmt5IScGN4fN2+/wBfrTWvNPdgPMkMWCo3AkOc9VHX8enHSue+wCzubqaWR8ycBVOQFyDuz/nvX01GhFq0z4ZtSu3/AF9x2UEllqEc8IEBtJFB3xIFMUi/dcDswP4EEg8Eiqt5BEmlXWnqtvPCqPLLCy7fPkI2xlSckFcYUjleves3RrYszzSIxh3ZIAIDDpnPftXWWN4olt1cDy5AYHjbGzDKQFU92bHQZzjNceJoqDk4a/1/X4dbG1DEzpSXVJ7f1/W/dnJaLp9hqdrayCyudryBJCXOE9WZuhb1BIIGOO1WtE1K4mKD7BHZ2wVnjUhNsagZALc89Bg/xfSsyT7faeNdSXU724t9PtHZbezt1Yq0W3dGEwOSQQSR1ySTzXQJqOnRPDPO0AnlBmIEqq2FHLAAfN3GDznkEgmtXOVRJp8yavbtc65wUL80d/8AgeXf79WZ9r4oW/1CKFLGDzZFx5xct5XsxA4IxWrd3MMAgSWUhrlmjR3dtoPfBAIyT0zxznNZCT6i9it1a3lvd2cp2meNY4okkHYqcbeMdN2eMcmlvdaknjeOe2R4Ucn57hUKr2JZxkeoGD1696itytpU1y/j8tbf1cKeCcmmtV/S/wCB+BY8XXtj4fsE1dYRefMq7/L3FPZywOBlcdM+lYnh3xfdazpkMRVBcXk7QyjywiFFwxK9RuweBjGQOvSty2kubvTYLdPs9zCjNlVVSdnBHBP3c9WPOTjOBSxabcxSukQtNsKbjDHJsbjkDaAAoPJLc5xjg80Ozp8sld+e9un/AAV/w6ujGFP+J08/6/rpbQwtX0BNQuFurQtPcWypHFFcENEV3DDEjjueOmeO9FTwaQdGnWGJ4LG6ciRYGlVFKkEbkG4qMsQQG+bgZwKK3hjasYqKt8/0Lq0k2pJu3l/wf00LGoaDJqcIuVuytxOA5aJXkAJHIOf7uOCTzn2q4ttpWj6Qlul1eSPGu2Yqv7mUEgnzN2Q/IBwMEY6jvo2jDybZ1JVpY8xnB+bnaQOTkhiFOemeCaxNZ1axs9b07T5lmmubxhCrCQAgZK9AMAZPuT3rG8qkeS7sv+G1v93qc0asnNJ7Lt9+nT/h+xUv0xHYm0laMSqwlaKJRHg8glAcBeAuO45zmpvDxvJv7RVliT7FMkcnzl1Q4G8lh2xjqSTjGeK0VgWUeW0yyDeJH2XKIC2RjK4wQmMEcdz1qlYvcW2prpMUkc1jeT5WNoQ21hgrJvXls4LYP8IbpnI1lWcKXLa9t/v/AK3Nl+92lrfT8v8AgbfIbJpZtTLdz3SyeZGUthFEXc5YsSo53AnI3Z/GtrR/MMILK4OzdIkitEUHzAbuMdNvtVW3tDZi4gdwIWlLLbPKWaPjDEFONuSQAeSMk46VZALafeRiPb5sQRASSdw9x1HfoD17isOW61+8zxdeMqbinf8Aq/Tz/UuW2rQSS7VkAlPA57/h69KTW5RlJAkRdepHOOnH+RXCyOLVfLIKSrgdOn1Nbeq3epT6YkthBHJeQRqAshySDw3v6cZrolg1CcXF6PueYqd3p/X9f13NFZl06NnIcpjEiR7txKnkg4x3Geo71k6lqdw8k968CRWkTDaquGYsc5IYcYJPpzWnpFy93JBFN5Nvq0aK8luHG5Pl/hB5ZSDxjPv6nI1bU9N03UF87S1mmjdHmbcEC56EKchs89sDFPDq87ON5f15/ibShaVl8jVkYtdPA+xDxGyH5lXI7/rXF6Z4l1N9bkOp3EE+nxpIlxbgKI9ijChVP8RIGD9e1dqLAy6h9phlBilfzd54JBGR/n+VZmt6NLKy2+kafBHbTP5tzOrqro6j5SSSBjnoO9aUJ0l7s+q+7uFGSUnoVNP8V3osmaaznt0bC/JlCFI67egA6DvzV/7Kmo6Jc2pu4Ivt0G2EEhGYnHzKmfQc1Y0FLXVlvrJdVtdSkVnDxxNiVSOAeQM9+nHeuR1u4hTxM19pSYktFitEuZuYrdwMYBPAfgnJ98Cqgo1ZuNFWa18vLcuMbz1VhdF8PzwalPogM7aVGDcO+/y2ll2YTBHO3d257966rwFLq1vcf2b4jjjMbENbXBdtz7T9zPTGP5Yqk2qSaR4ctJLy8bUrmRmUTEeYOuG+pGcZ/WtCaSRhZqLg+ZvEhCAZC4GDt9e3Sprc1SPLJJL9V1/z+40qyc/dZY1TxBpsV0UlljSQ9UT5nHPAI6DrknP061NrN4dIe1vHtrmW1By7RgN5S44JBPTntXPXl4NP1ad/scUrQLhpUOJDHjlT33DAwOeDWvq0keueGbS08+4s/OYMxV/nVVOSOT0OOM9MisZUowcNNHv8zKMLctiyL2xuoFMNw0sMsZkDALH8ucZGeR39cdhUC2enMtvcPDbTQRJujk8wsuM5yzD72Mk5xx6CuT0nwrcXUEc2pxxB95RI3kLGOLBGN0fBbnd/+vnp9P063g0eXTLdJGt33B2JCsxb8MD8B+FXOFOnpCb3/AqdOMdEary29/CsjvFNaSkFHtSNoXoCuc557da59fDC2GoLPDNHKiElJk++y9ship9e5+lYtrDpnhm5V5deku7S1kdU0+FFdi7n5twBwBwMk+3Aro7LwjaHWH1zUNQu7hWxPHCx2BcjIRF6Z5xzgDnqeal3w692ej8nr/X3A4Rg73LHiOPUItCtv7FiiuL1HUlZNuZU55weuemRjr3qhop1q6ZF1a1KPODIFij2iA9dpx68nHPWrj+ItDjuXB1GHdGd7BpSx46gAAAkfUj2qzp+oQ6hbR3MM3mWpLYwMEDPOc9MHnp2zmpTnCFnD5tfqKN0rWLZmlkgiSQDbGC67GJG7vg/jwDzXPeJvEGn+Ho4DdW1xf3hXMECKEwSeWZyD2PAAJz3FQeIby8tNWhV2kclEeOMEbZ1PBIIzyOta6iO7iRSkUk0YJi+0RhjE+OCR2GRmmqKglKWz7DhNXu/6/r+vJuk3C3+jWkhtZoLuUebGZm42ZxtYHGCOcMOD6HrU08bKSJSxIJBL52MnBVRjgYHQcfjmq2k6g+oTTW9xaTWd/CoEonbMbKeCQw5wDz3OKtS6zZafBbz6qWMEsiwuqjePZyAARgL/wDWIqZRmptJfLfft/X/AANLtbf1/XzIZCjS+VcKkokztYgKFJ9VHTPGOKuuILTSkt9rmOJtwA+Yj3B9fx7VXv0hNtcSpv8ALJV1woCsDypGOmeCD0q1HO08HlsRuXGT6j06/p3qZO6TMavdHG/EXStZ1cadDpsbzaepbfGr7Asufvt24HrWjrOgWupaFoMmu6g1rqdhbi2aZG3FzngdPm4xj3qS+8Tw2Ovpp+oW9xBZq5QXLYAeQAHhAORyOTz37U/xfpVxd6ZpdxYWcc1/bXDyMvmbQxXAAPqPTBFbw5k6cZe6r3T07P5f0im5pxi9P6RowywWcsGnyIxthGscbQfvGVF43vgYOGxkdepqnrnhmcXb3tnEranGyvHNuZo2HdQe/r3+tc5ZX1x4OshC1jJqMpfzroicssW88RgjuACeepOK6TXfGNzpMqWumQX2ozlPPaHOFjj7ngE8dwDj2olTrU5p0tb/AHPv/XUHCSlaI6406NoI7mEeXcKCJVt/lyWxu4PfqR7ZrJvLy+0vX7EXrMul3KLGseAyhhwUIxkuSRz798V1F3dwyWVnqflSW8V5CjmFlwyE9vzP5c1DBqlpqEdxCkSSmzkG/wCQECTBwwbnOPrmop1J2vKN1qn5f8MyIGXZeKtKn11tEt47tb1GaLeV/dOy5z0IPUdcH6Cl8ZaRNqkEZinl822HyWspOwMTgyID0cccnnAxkVgWb6jPHqtwunLZ6jHJIIbt49sj7z0Gfrwe3rWt4cg1O00QQ6rcPNceYdgdt5jUgfKT35ycVVTDRjacXqvz/wCG/pFufsZc0HbpbcZ411KEa5ZTXvmwHyUgM6r5ryOoXzFIxgDgAYOcNnBrLv4NP1iPTNasUczlpEjuJORGwJKiRMEHnnqB0rvp8GF1uYjtADxvvOEboCccZxxuPIH5VlzXvhvR5zo0+jyXRiWGQzxNGYrdmVTgLgHaFYNux8xJxgc1hCsqcYQitU/W/wCPmv8AI66eJU4u0XotrmBaaY+hWlvDNcxztbBLh/mPloZQcowA+Ulcds8qagttNntRcX0dxd3MSRkRoQFI3dMc7jjlj0rd1yNU8Va6Ybj9z5sm6N0KL54XHyuDwrMAduDjPWqNrqGox+QtrehL2dczqGDb8LkqeCM5yOMYx1qo4ipOPN1kr7d/6fyPRhTvFabf8H5f8HyI5LCK+sZEe4a3u78MY3t14SMSgF8/eGTGQAAepJwKz7DSj4W1WTUtS16J7GA4ljmGZmdgcAqM46Z5OevFX9QjFxBFPLNDK8lsDLPuWQNIXOQ5A+UoMLjPXJHWlGn2t2ktnNDFGiRMIY5ssjMADFuccd2OTx82Dirp1JxTi9E73+/+vnrpsY1qN1zy6/1/X3Lo27xBKG8vU9PtIdQt5R588qjGUA5Ib1KjnjqOlFV9F0650zwumnarJZxTNK0CpGVkWVWPIcA5xnowHYDmit6NfD004yTaWzV/0dtDH2LklzM6ax3MtruBjMK7o1MnmpHuIfoTnOQM5AAxgdKr6j4Ws9TNpe3Vs4FthkAfkDOQCxzlc56DPXmrn2iK7tsohJGFUAA59COuOD1Hqa1nku5kGnFFW4UEqcHBwCUGRnjjqRziuGU509U/X06nl+1k37pzckJuIZDZPaSbSWlhDMDuOCWDYIPIPBUir1gj28TSEg3LK3zBcMqscsC2F4+8ew5x0rjLJbu1vI5ULW8sADSSsfukdcHoVOQffNdfJtlspH8o20dzFl4wSdu8YPB9Mk4z1Y11YijyNa3TLlWlKHL0M2+08aqlnJo17Ez2z5fa+8sBxll4Yd+gPrmtgWz+bmMscuMkoBgnj7x4BP1rlNH0eDw7qUF1dTIwjylsIlCmQsMFic/MoHAGASSc8Ct/S7TUft/228nKwTBdkKnHyHoFHQjsc4xkHmnXSStGV4ra638vP+kS7dHoFzcaXaOsmozKXZ9oYwsSCvXPJ4GB7H0pdS1ezg0+e/svMvLaNNwSyjD4YAcMAOPesLxk27ULdLd0cqDG4ICbMkZLHPP1q3oVi+gwTNcnbJOVDRx8LGRxjjrn1/xpujH2SqNvmfQSSW/9f8Oc0lzeaFr48WX8c8i6lGrRQRuJHSJgrAh+PmUgfLgcfjXoQsrDxRptpqsNvut7hPNTzDtZDuPHX1zxn615j8VdNg8xL6+1+Tzo5ttvYvCy+XGSCSmODg5z06da2rWd9Ru0fR5ZJLVdqWrxJgHg5Crjn0PtXHSg51moyUWle/8AN520att6bdjprrmpqa/4a3Tz/r1Otu5W0u4/00MseQoyMKD6HqOnbrTpr60Wzd4opGkC7jnn5ScKRjqST+lWtfuZoYLVYbS2uHihAknkVywZVxj5T908/eBH0rChhgvxPDFBdW2pi1IYI6tDLGOQFGBtAJznnGT81EZqSTlp/X9egqFCM488v6/A5a8gj0nVY9Xu7K0ht7eQfY/sjgSXbnnGQcAcksSOMYFdTaadb6tpZGo6eYYp28yIqVJ95B2z05I6YIqncaS8+u2U6Q28r20EkC208f7sLg7dg4y2SMYz3Pata0vXm1KQSPJta3SRA/Dn5lB4I425I4Fddau+VNb6a6+i/rX7ttqkLpuGyQyHT7TSNNjtrV0gjacTZmHm/OePvY6ntwK2bZUSRHhlMsgJVdmMKeOmP59s9abLcCO3x87OTgByBz1GR0HrUEN6903zKrMeCMA8Y5479BnjHTr25pOc02zz+Zyeu/zK9y1qb1GKqLqThcDJOBjg+v0GDiql3Nqf22dk1C3FquceZbgOM+2P1yO9Q6rb/aNWs5LaSF5oUeXylkVjJszwBn8KitPE+najfwQta3UV1OywpJtHlq2AdpYHj0yRyOa6YwtFTSvprs7amnK3sa1+Xis1kiePzSAGZEIYKOpGR+X5Vz8fiLVLjW5bG10ljtfCyzBtrAHlmPAUEemea6Jo50vYZbaWIW5wkomAJK5OcN3J6YHT3puleKrfUr+801V/0iHB8q6iC7gOrJx0yeh54zWcXyxuo836FxvZ6Eb6Ho15Cs39jCK4aVm3JlMtxnkEHcR2rkZPEviC31y4+2Q2sEdu6sbCKInfHxwG5xxgZJr0We8SSZLUzQJM3yrCjLtwRnv0z/8ArqF9PtLvY1zaR3JDZT5Nh9eoGR15HTPNKlXUf4yuumv5X/rzIhU5U76mdqPgzS9YZb25tPILxcsh8tnVhna+BgnnrjPFZupapqGgavZaZoljpU0W1FtojKVlkG35gvzY69z+Ga6W+vbVUup5byJIrdTJKnmZ8lMgbivORkj/ABqgdM03xHp813pt7Y3l5EjQxXC5Uwuw+78xyB1wR3JFRTqP/l9rHbrZDhN7z1X9f1/Wl+FrHXYFt0mtHubf52jkKspUjnJA5wR1GQeKfZRxW8JkigRoVcK6+VnnJ3A5OQcY57HFcloWnSWt5ZyNaXFpHYhvPmlPMrFdpRV7jOfwGfQ1U8d6frd7f2l7pzSSRQxiJYYCytuOfnGD6Ecn0Fa/Vo+09nGfuv8Arv8APuiYx5na/wDX9ff1O71GLykEu5/sj55XPynOcHGMc9QQR0I9uXju9O1CaW11Ewxy7/OWGc/KeM7twOCT831rb0+cw21nZX80UN7cBAIZX+eSVRjA5OCTyex561R1fw9Beo7WD7GBMx3xkmMg8kEDpkjI9x9aig4wbjN27NDi3DRjjNFLI0aSpJJlSrA8Zxx07Y/DiqT6p9nd45Aqssm1icAjpx75q5b6KLGGK3uRIGAyG2jaxzk7O5GO3OOtYviGxR7pjKpKO2VxwMHrz2I/rXRRVKc+W90VdNak82j2upzNcOzFpLlZ9rxhth6nDdQDx1rpWJWRVOGIG0DcMke30rk9Cu7rT7loJQxjHPPKnB4INdKluLlRLDE5RhnKhsEZznAHSoxKkmlJ3XQRh614US/nLWuq3VvDK5muYPLO2R+oYY4PTvWnqvh62vpopTd3tvK9qbWQwOCzqe7H17n19qupE8Iw64J5ORnrzkn/AD+NRa7aHV/D91Zxzz27yLuEkS7iwU8Lkdic9/T8cvb1G4rm0X6j53dJMin0S1h0W10lxM8NsjmN5mbJLZ+YnqeTzgc59qp6FYvo4jt5XsILK6LiOOPO+aVRlmDHngEeg9KqaJoQ2WF/Pc3q3UCBGDTBt31A6cdu1aOq6Ve3XiyDUb29jewsSRaWaoUWEkYyT/eJ56ktxWkpcrdJzutW/Xy9WPTZmrEIpijHOeu08gcA9j9Koa5qVhosQvNRlNtG7lYo0GWmb+6o7Y4yT0+tc5q2tapp2r6rahrqZpY9lkIsL5LkZDg56jOMc5rZ09JfEPhiyHiK2Mt9GpV90nzkqThyvc4HIHYVMqDp2nP4Xbbz1/4BPsoqV2TeEfFMWtWNyJ7U2EjTmGNZZMq5IOMMeM8Y470rXGk32oRQrPZXfzKxiLr5hUcEKw5wc42g/hVy8TRZdCttN1aGJt8wKI4H72TkAgdc4JHT1qjP4dttLsv+JLZWcV8oaS2LjJjOACWc98dBjjis4ez53ur7f53/AKsRHlu2tL/r/XzNHWPD51K6n1fQiblprlnubORhGUdscA9yO3QEdKiuNO8MaULi3l8T6d/aZMkE9q1wgbzj/rY8IAw+bKgsTjJ5JqPwjqGs2t3OL8/6dbuoLx8iRByNw+6cEfXmqMmjW41iWWK+P2Wa4a4aGQsbgF23Oh/hYHLDdkcMM9Mninh6tOoqafurtrppp6W8tep20sRKd41Klrbfjv8A8Ppv5mlNpa38D2UDQR3ULEDOUUrjBAY5Axjq3XJ5FVbyyRbmLRbIGG8MYf7aWBh8xgW2bgMiMqQuQcZIPSqnifRdbv7JX0OYjfJmeOQBTKmeBk4BH86ZY61d6Zf2RjhspYYpFhS2dGRpWJxhG/hO7gDBHSul0pSV6cr+XXb8Nf1LoTk4uUXe1/67bLcii0qa2kgkNxZurN5WX3iUHLYTZgZPGFOR9Djkra8Wa/omgWeo3WkG31u5glCzWEkcoEaBsbvM2jeitkBgcDgZORRXOsU0rq6v/XX/AIYdWnVrWbp3t3/4LX9fcqkEMkVozzvsUIpO5uF4zy3HQZNaUAdiN8g3hiHeT5PmOACOTxg9Cc+3NRRPLPbW0zxtHMIkIWTDMXO0cEnnjdg9OD3qxpt0xQrIVldYl3Zkf92o2/eLZBJznJyRzz2rrlNyjc89QaX9f11+b0M/U7y1hAM8attAZWVeEDfd2jJycH8N3rzTNbub5tPgm0G3W4nlzvBQb0GQN3TJGDye2Pei6ggv7uWJL2JJTxI3yhGUcFuhA/HjjPFaMFjDbuY4RzjyxnEgJOcZ5PGOQV4Pp3rTmhTUW9Wuj2FG+/8AX9dDBup73RbRGa2k1a8kl+e4VPLVGyAikAE4HBB4GKuO3iOHWdNtoLBhpzBftexRIiKWO8AnHI4298jvVP8A4SiABW0yO6eSWZrRJmhRV3Ag7S452kMDzjGc9qTXpGlvUtrqMspXeFUlsEYyQeclmyPwrdQk2lOK67/5XSVuhpN8rvYteIvD1q73t40TNdhCE8sgoCo5fGMn1IJxnpxSaBdCW1S3vZGeSOJXDckyKMANjqWHt1HvVjQ5ry30WWSe1lYAiSNJOXC9jkEHv0o8H3NhqEuoi0s5rPYplLbceaoI+U5J554GeMVlKUlSlGeqjbUyV9v66jtU0iK/M8d3BCwMZRn2bsg55U4wOuM9QSO2aPC+i6b4ftk+wxMVdPmkuCD16qO2M9u/PNbl/ZxxwrEzJ56sY/lUrlOdoXngd/cmud1/UZ7ARxWhEc4iZo5TlsYJ529+/wCNYU3KuuSLD2nNGyf9f169O+nRPI0MTMmUUcIHO5B1/FfTuPpWXYvFa363dtFGkq7j5a58vJ6nHQD1NY/hbTruLwxZIL+NrgzTSXTxc5y2Q25jjkcFeCMAjvnQ8Oyi8uL1RZTxR2kxhM2f9aMZJVe2PyNTGFoScvmvw1/pmkYqF0n/AMH+v684tX1a8vLxmW2WK2GGMPFzGUGMnIHXqc5XqK6BdLsS/mWsh2SDciq4ZcnuB1H+6DjP0omWIr5cEYR2OAVJUA49s+vBH9KqyRTb0lTzBICSpzu+YH/ZHORnsDms7J/BoOdTnioxVinrEUxUJAvz84kJ4YDrg9/8mmaVG9pdxtMoiQp91DggEf4dqf4mkaWLTpS+66dyrMox15ySMenXHb61hTOxt91wjvKoDO3ILDOAfYfz4rtpQc6aXcwiv6/r+upFB4OtdM1K2uftCRwpd/aVuRL5bEclYxu4POPwzVaHW7dfFl/JY2a7pSsVyYnypXI/eccZycZrorVjeRrFeRiUZCqrnaeR0JHXI/SsfQbvQrfxNeWun20oZyxluGJAdxyysDyB7Z64raM5y5nUXNZf8E3jKT33MbS5/EF34nNtI11LaeZmcOdsZQnGeuACDxj8K7bT9Lt49UnvbYb550EMrs3zEr0ABHGcAceme9aMLpPaOISI9w+Xk/KMY4Hr9arOU04tPNK4WNGkJ6AKOrbQM7sDGM9fzrGriHVdoq3SyJbctErFO0067Gr3U80CysdsmAMZAx3zz2rQsSxeRJSFBDNg/KD04+v/ANeuNsvFmty6Hr2qQzKZbZka2IXhFORgjnJ6V1HhTWpPEfhew1W/RvtLySQ3McKjBC4wyr2Jz+YPrWeIjVg7VEu2nTRESpTiuZ+hlPY2Vtqd5czMHW5t2t5Pk4AxwxyeSAMgdCar+FtBHhOG8smvkvrq+Ky2sZjZRhQcE898j1HvUFzrd6/iddOewYxzuAskcYIEXTzGPU9c44/pVbx/pT6To0Nxpseovc3Q+yoYmO5VBBYnjODn7oxwa6Jp6RqPdet+q/pG0OZWg3oy1qmqarp+p2NjeR2vlzy+WwMQj3ZI4wDgdveq3ji+1i31GWK4kmbw5KMBIAE4Odo3Y6qV6dwK1kurOaSx8JajE+q3SxKXumbLK6oHAODwVyASTkZwe9WtQ17RHvrjRLy5liaWHc9whUQDn7u71yPp2ohWjzRahe29vXdW2Zd2tbGPomg23iXRdCurGUWA024+eeaX59udwwP4sknH49ea9A1tLfzJneV0bzg2HlKqG45HfG3vXIeI9AnttCkt9K3SWs0sdxcEIWuJGTOzyx0UcnI/U1CunXHiNo7jWVaztI4X2WsY3Tk5xuZvU/Q8Z4rOcI1pe157Ru/Xv66v8DKX7zd/L+v6ubeoT3EmkvDpLWZ1HeEU3DhZAuTlgOckjoT60yeMCwJu5kuAu0CYjaTxyWPfnODWPbP4fXVrKGPUfN1i1xbiMRu/f5csRg9e2QK6JfKkSQH5kLFTkZ+oqJJQta/3WE48qsZX9oQ2Fs7XCYg6MwGWYdqzfEsC4i1g6lPb25RUggXpuOQGzxjp75ro0j0x2e3W4tRK+Ha3Ubi3bnI+vcdKdq114e05Daa5Mss5Uz/Zivy4A4OQMZPOAKuFXlmnGLb9On9dQTtocnq+qa7HPBaWpMnkiNpbYL/rWIBZs45BB6Vf8UXGr28+hWlrbk2Eg23bRR4+boQXHoAeT61h6h8RJWt7K4Xw9tcws8YwWTaGI4PXbweld1ZX8d14etdVmie1t5YhJJu3N5YLYxnqRkjB/nWlRyp8jdNK34t/1/wTTllHVoyvDllNbG/tZ7UwQebuizLvyMYPPGQfbFTXc91b3Co0cMykE5b5WAz2OPp9TWtbMqhZY5BNGRlHjI+YHkEHv/nNMnSGVCLhWIxhT6Z5rndbmm5SRncp29yl2gQTmKSPIMcq/MpHoRyfwPPpTnguU5EUx2r8rR/OQfQ4wf19qZFYRNPC25FXOVQ5BbB6c4GAcZxz9ARU2v3kmj2scvliaSVsAEgEHGevbNG81Gn1M5O+xFPpkOozw3F/bN51u+6IsSue24gZz/PPXirqzJcwG4gYorNgDPzkLwSPx575OTRourR6jYiVR5eCN43ZCn0znn6+lTTRrwbTZt248lto/FTxz9TWUpSvyT0t9wRk5PX+v6/ErQzWccSotxDDJJ+8KSkRF2PTnpj64qIzwRaoltPJKlzLloyRuQY6gNnHGOv6DrWD4q8Jx+InguVuDBdoAEYk7HA4wM9D79PbvWtpc3iHNymqaajGJC8ZtpNomPZcAn5j0J/nWk1CNNzUr73XX5dy3SWlnqzSXU5vtLRSMDCV2t6Hjqfese+vPDs+sLZXV0n2y2nChWD8SMMEjqDz06YJ4rl9Gn8QeJ7q01eJoEaznMDaXl44YDwNzAnLMSTnnPHYYrauPD76beXOqLYw6nrbyqHMjbFRsksxCkDjAH606EIWUpPlutk1fXa/Tbf16jVNUm482v4X/r+u9HXdCtbDVmWC9n0x0WaGJYsyJIsisFUjLYUcA7scZoqe71GVfGVppmvQ2d010qyRwRKzG3fPc5yykjJGT6+1FYVMLhYqLqwu316f13PTjm2No6Up2v6r8jahksLm2i0ucwSSujebp/lhSYiFZmABweoYAc8Zo1/z7fwvKtrM8zZVnmLsXdVHy5fGCqjAHT3Gajs7eCOa01BLcJftbrEsxUK5BT7uO/HU9eQAa1LdjJauyuAMkrujLeWe2R65APPB7GrVoSjPfb+vQ8+pF2a/rf8Aq/fQ4fR9Elu7TUZ2ZobOW3aBOcZkK7lPOMkMF6eppmiXl7pltZz61LcWkNlIIYoTFuEq4zhkyCMcEt6cCuymnghn23Mc000Y+Tc/mFGJPJJ5XnPAPSnrbadcaza30szSPA6yiPh/MZMlS27J2qSMKMHuQcZHTXxdSUJWjq9r/d57r+luOjWgpe/t/X9dipoWm2mjW0wsI5lWecSs/O6M4I2gFSU4JwT2PXIxTtbstNS4hne6jjnQKJEjbcWxyuSAAG+nJ711N3m8iN2xErqm52jILlOuc56jGefTjrXINoTfabgwNtnPLSiEyE7uc/MMBe+Tx+Nc9Crzy56krPqc/Pzu+39f1+fVmvbh5JZRvUksCeBzx8pyDxzzgc8VZZDEIp45EXGMH5ywB7j5vfpg+/NYlhpj2Nm1m07OJHyDtChQRyUPboCQQD+dTfaJpSFn78HcRwP/AEEH1xxSlTu/degXfR/1/X+Remvt0bHBjcrj94ASMYHfp6DjGc1WuLdNUt2XUYzOEYshkzvjYKTgHqM4P1ovo443ZVwkZ+d84BbkhTjjAwSuBwODg8GqltP5LG3kjXY7PJCgjOSAAWAI6kctj0JPUckY2XNDc6FS5l7v9f1v2IFt5dJvrea0JkglwrRSMTnBzgf7WDwe1autzW2naXhmiMsjguBkbsDOCQcc4HfmixvDPYLdsjRLIdqRqysTjphhwwPrgd+KNXns10i4vJUZ5woKq0jgNzgBgCMjPsKUpyqtNLXb59LmSXs5+/0HXtwdN0JpClzeSWsXzRxAb5WJOQODheTk8HGMdai8OXks+j29xfR4Lqzg5BUoe3y8ZAxxyepqolzPrXh4PDcJBPOrQyyLGWMTg4YY75ycHj3qtZQ2XhXRorT7VLM8khKNKwUlsfMT/dGDjOSSauNFKDp296/5fgaNp37ljTNQtvE9hdQtbXFs8MnlusxBUPztKkdCPSlht7exuYzcTKXG7Kw7iw3cYOeg9hVBvHUEkIgEN3cNldoJXAQDG0nBJGPxzzkVatbaDVCl2biWKDevnxg/vccfKpPYngHsD3rWdOpTT5ouMeivcIQg5e+9C9dRxWrEHPlK24MDxz0x25z6VHeW0ZsrtrWzhFzKp3sFCl+c4J/D8cVZZnZlmnhgtbSMBYyWGIwCRgDnH+83JxkVZtp4JY5UgkimC4UiMjjg9vxb86w55JX7GUmou1/6/r/gmClk0EkdxNcwRmSJIirnABHoewP51fFtJAr2+pI0iPHh1J5Knqfpg/wn35o1KwF4RJGoNwqFEE2OcrgYPOG647Gs3RnvIJBptyZbiDcoKXS4eMj5mA6jb09PXAra7qR5k9V0/wAvQbbvp/X9f13Llh4f0+zsby0miaaGYKSsgwqKDlVOOc55/CptXubLQdNd5FEdnboFEcK5xzjGO/r+tWL+/SOIzSy8sSWKjLYP8uOM+9c/4ltJdQ0O4sY3QyTLtBPTIIIzx3Hepp89WSdR6N6gn72r0LE2r6dan7QQZZpo12yK2WaMjIB9Ovt0qDTdZvdY1WCzhZbWBnDMw6qBj+Lt0AyOeetY13Cbi0sIYwh+ywLA04GFdh2Hr9a6Pwbp72cEs08P72V/KAOeAOTn269favi8VVzDH5gqMHbD3fvK9pJef4aWR+kU8Pk2UZNLFVIqWMskoyabjKWzUell72qbWidmyto2i2L67Prtta6ho935rxy28RAjmbPJXv5Z6kEAe3FRf8IVHPFKL+5e72uDFG2QkY3FiDjrnP05ro5pFMrFZFeUfMOSV9uT1/D05qpe3E62t1cW1tJNfJEzLArYLEcbf6n9Oa+0pzqQ/hu1/wCv6Z+bxqOT3LtjdI9pEUwk8ahXhQnMeOCDjnjj6etZuq3N/b65FceZ5eleSzTyCME7ifu8Zxg7cY71zHgGOa7vW1C9dzdQRtHMhc4RnPp/u5/Oup1XWdO0ie3i1e58hpcLs2btyg9SMcDP4+lXOj7Gq4xXN8u/b9ClTadlr/X9foYd1ort4juvEt8kVvDb26yRjcrSO4HylscknHP1xzWvoPnSaXbmSN08zDOWznJI+Y46A4JP4fhfsr/Ttb0oXem38d3aCUoV28qw5wUIyPbnHf1q5bxtNvEYkySdnP3iO2fb+tZyxPPDXy+5Cm5J+90/r+vM520udWu/FktrfaM8NuvmfZmeLJCL0d3J4Bwa1lTSdXgmx9i1FVBtiSFZlyD90nkdDyB+NZ3im216/wBL1KwsmFuHATaflZwDyMj1xVHwT4Zm0SK4uL2VXvpF8tBGSURR2zjk59On41o1B0/acyTVkkv6/rzE5Rcbp2ZuRabbiG3sbOcQQwKYVgEPmjacHcQx9c59+cVgal4EuNX124uhq8v2LZHFKjEoqBQOFA4wccL2zmtLSobmS9E93G4SNcHgZY9+prQ1zUki0xZLuVLKxiJZYlcM7e/+0SeMgYGai9SFRKDu/k9X+LYozn9l7jordLSNYLSN0ihXakSddo7Y71yHiP4iwafqVzBb2jOEhTymlgILSkjcGU8FQM8jPQGup0jWftOnuyM8EcZU7ZsBMHtluv14J5p9/Dp2r3cD3cUU8kDjyJJB93Bz17jIPFTFONT97G/f+v6+YU2oO81df16jmgmvNPLXZKLOqu2XKmMlRxnHI/Xt2rzaz1691vVLrwxdWrrdreb7d55DthjRW3bifmYk7SB79RWnFb6xD4hivJFu/PluphMZJMwpBwVVR26nj6V0UNjFdapJeFY1ktwFSQYDKW+8cd/StZ0pUpRlGe2um3a35a9ja8I30u+/b+uxD4bt7y0037NfxQwqrZBjKgt6liOFHpjJPNdDHHPJEzM8WzJ27upPJycjOPesnVryx0m0ubm9nForuYoSBlwTngAHjgfl9araZr9y/gh9X1G0ubt4ss8EDiNnxzuJOcDB5OOg71niJSlB12tL/wBWIcL25VudEjSZG6KORR9595UcHr0/lU8XRWACoTkbcEA9f6g1wjeKdaRYrs/2Z9meAXBtkVXCL/c3kZLAc9See1dXqOtLY6Ot8ITM42qI4goOxhkKxA4AHGcA+9RPDVEo6fF5/wBIiUXsXr3zLK2nns4gZFjLLFGAm8jnGR3PT69fSuKi1jxCmrac0ulxWthcnZIgXcyserHuDjtW54c8UQ+IdQv7NLYBYAFYugZWGehHGec4+ma5/wAbXOrPe3Wj6CLhJIRG7ZBaSYZ6ZxnI3HJJ5A57VvhqUozdKpFX636L+mXTjZuL3/r+v6V+n1W80a21W0k1GW2+3WzeWoIxMqtzjBBOO/IPXtRXNTeEbXUr5Z53lNzLCn2iTzSSW2jJB+oOcn9KKToYVxSqTd0DUY6X+9X/AFN/SgzWVsVDNuhjyDGE3qFGRiM/iGySD0q9aottJFEgcR4wCzB93pnI6AZGccVzR8QzQpo/9n28f2q5ETmNmwDGV4YHryTnnit64Vjp0rr5aSGBkB5j6KWYA44wF7j6HrWXspRjHm2Y6jve239f1/wxRvAL8C4tWBeJMtGT+8ZSRnZz8x5z68ViLc2tmkW+X9wZDHK+SGfIIKgDn1NT+ELp2urnbHlBBkLjbljg/ljocc54rS1m1guIFiukLjfu/dJy3zHnI6ZwD7Y98V26Up+ylsYctnrsXLfULW20+1c3kCRTOttCWbduz8o5YbivGCc59T0qne3+rX/iVNMn+yC0e3aSCZXKlCOWY5ABwQcAnnAAq7Ja27QW4iiglNq6zCJQGEQwuG3dQdvf1PTismXWf7IvbuHULiaYS3CPBGYwpSML1KqxGOwzzxnHOK5Y0lUvyfF+O/p9/dXN6c4wbdtdf6/r5anQ3knn3MjnywXJ3YfBOCOxQZ65BGeTWTff2jaywGCCB7UKQ48rcynJ5+bAOCcNg5HB5ou9bMRDPBiEHl95LfXPbAzW0WUhWA3QqgIYDoD0Kkdeo4qUpUUrx0Odyvql/X9f1sVLV5HsEVo7i1cAKJE2tsA5G4AHnoOcHkZFILQTMYZYkfJDKjIOuOpIGB3zjjrjg1qWzN5iiRcAAL3B54yfXjn6dcVzfiW+W3gtYY3cTzEIkEbneQcnGRjAOOenepp81SfLFWuaRqSS0RuTxNFeyKyAhsGMnONvAAGPujIbP4VX1O3W+0i6hjG5pE+USHqSflwM9cjP0FS26Sx2lu2oDE4QKA+QCeMhcH5x04Gc8nvTTLvuTEnOVwDwM84x9SMe3NRG8XdPb9Cbaa/1/X+RzvhuzmsdRc27Tras22aBt21iOikY6gjhh2FdGqJMds6xy9M7xkHnpjqeemOKufYxdXRs1dBEjbWJOA6qcNj0+YnpndS6ikcNxLC2yKCEH5yixnPVSQDkcdOOR7Hl1cR7Wd+v9fiU3pr/AF/X9eWbcaRplzcmaXTo2aJCuNzfKM88g8mqOmXun3NxeW+nzNI1pJsuA2TlmPUHqccDNbMMiyhZYnGFJAwwGDnP3vc9ucY6c1BptrY2c9z5Vv5ZvCZpmQjOBk+vOcnPGOnHo1Uai1Jt22CNlp/X9f16wzRC7trqzRIpCWAPmnK57n6/ljrWPpdubbW7yCFxNa7tiuepXGSD64xgVr6i09rb3DWsL7mXKll7D0OOSBkf/XrC0+9S01iBi7XUk65H9wZ6SfX8K6KKk4Stt+uhD0egaZ4ljn8UPpKWMsdsVJjuHfLZH8JA4x6Y/WuoOeDNJhFRvnfjaO/v0z+Vc03hCHUJhO13cLHjdbgZLx85wT3wd2Py7V0OsC4i0y6W0DSTi2OzyxuZiMDGPXByPx4qK/snKKpPfe5tzxkkjN+06LqEsccN2JZnORFlkIOMk5IwARzUAD6/ei3sw506Jgk0lvFjrnaoz0JwQGOBzWja6KiH7Zc2xOoSW6i5Y8hWwAT7A9efTtXPTXlnoV/cJbeZHO5WN7lkUKqHkLxgnnbz6AgHmuXF4WWMXsqMnyrddX5Jq1l+LPSy3E0sNKVRK9T7Le0X3tbVrpd2T11sjvtL0AzWqIkYhVELIhAwic5L54+ufzqt4jm07SrOSyedZJ3VXKWo80Ig7MVO1c8HHJ6etYZvNQuvCP8AZN/EZYZrkz+fIzcRKB+6ZP7u4FsM3HHB6Vmp4ens5IZNPkgt4kl85tkJCvxznB+bHy8kd+faKOHnzJSkoxT0Vui29PS33HJKhFuVSvNyk7+d/P117/5GfdeOlSS5HkxCJpVCbFwrKPfscVp6pNJLfBrfP2V8PbyJyrAnoB0/wIPFWbOz0251dJrXT4rh7lyGucGRYj1+RWBCqM859e1a8NgLWBViRAiDGFXy89+BkADOMjAIyRXpVK1GDXJCz8zGVNaW6/1/X5jdNhNraRMbYRXZ3O6quC3HBIBznHXjvWZ4h0+PUCyX1mZbfaNjFApVs9m6gZwCeQOpxjNbEUsb26yG4kmvQGJt0TLtt5I2dPTnJ9qia5uYriS1tVkVWiJScfcViMhSP4ue/HqM1yRnPmco6MmKlFppf1/X/BMPwx4Sg8ONf3jzP9ovVPlxSBU3OueQoPJ57etc+LrXrnVS9hDdrKV+bzX2LkeoPy47fpW7pVhLealBq+p3aXR3qUuIZXlLuo2nhlXCDk4G4jtnmjxPqU0V41vHcxfZcBFkU4jkfGGDOPmYDAxkAE81206qp1GpWbe91ZLy8/w13LUZ1Jvr/X9f8Gxptd6orwQw+QHkAaeeaNnii2j53J3Ywo9c4qC11y3lhgmmeQGXCLC8fzlmAIAx1HOfXBGccCs6a5a7sFSSNpLdBGJLmBwxkVtzMq44K4IDdAcc5q9bafNdaXKsE8AlhV1eWPMskRckb8HAzgcYz93pxXJKCjfp/X9L8X598KFJ0o8610/q39bW01LMmsW1tMjXEBWBGIeXzI5FiA6lwGyOQR3JxwMVUkg0++1ODUt7TzmIrFBIuFCKceZsH3c54yeuTiqVnPa6Da3zjSrfVLSIBJImj8tioIwfRC/GXwT8uBinrcy22nnVhFFJJFcNbkQcxIuzcwYkn1I6luMnBOaiE5Qm0t/u36dxzwNPlfs9O2v59Oj2+S7prSQX1gIp4JfIg/0gRw4BcqPu5657e3Wq3gHXIb22ntodMNrcQJtUs2cjdwSSOo5/UgV1sF3B5y27SLFOpG3ecgscZA3EnoehPY4qeLTorOeaSG2hSWY7pZYwNzHnB+U9zj04zXQ8TH2bpyXpqebKMoLkqLUg1NPMswLWXy7gYYGToOOgOPxqlolisUWSw35yZWG3djuB1A449asaVDMlgZtTwb6cl5YwefYDjaBj1p9raQJPcPuZfP8AmLBm9ONpyMfrnp6VlzckXC/9f5djLlSHajZ2GqQ28V1ZxT/Z5shmPOeO5xjt6g1XUxh3txFBHHtZWjCADBHIxz2zWL4su79Lq0ijhZLURgnph8MclCOuB6nPbqKv+H9SGq2onG+QwMbdHZgWYryBnoGHHByCPQjB1dGUaKk9Y+uxSjJDoPDVnbxW9upYWkX/ACwJCLKM5GXx8oz0/DmrupX8KQRpPMsPmqyxpI+84/PB9eAPpUOv2N3e6FdWlg/l3UowgU7VIGBkL0HU4/TGK4Oz/saLWLa112+v7y9t5hawSPHiMMD8wJzkDdx+tXRp+3TnOV7dEtf6uaU43XNudjp0Ufh1msrOwklcp9omlOWMhbngAckdMnOOetbfmJ52/wAphMQFcuoEuOPlLcbh3659K4XV9SbTNfhK3979ht5D5nloSBnkrkkjHH/6811erahFb2lg1pLEq3I81ZJEUBBjg7emeamtQneMnq5ddQqONkrf1/X+RfF5BB+9keNe+92OWOPfAPHr780Vxd1fGXUHTVHMlxt3RuU3KFz+g460U/qMWryMVGUtl/X3GvozRXGmWV4LJXuVto1ieVCqABQd3AyeCTnrzgVuwz276I/mTTSSFzHHsUpJtGCJCCcE4yQM84wetcdZaneT22ijRLZNR0hoozc3vmSPIsm1Q7fNyCuF4AI4xWhNdOk7+UEm/hleaGRDxGNznA+XnaQQD1rlbhNRbdtna/8AXf8Arp2VMJN/Cv6X5dfx+WistvCyR3LtG87hlEgDHDHcSMfKoGeh7jocVL4q0m2m0Ca6t33ToSwYYb72AclVG04PYf4Vhapo01/4j0jUnnjW1slIks0Z3lbluBgZbOeTxtFdZYYS4gnEs0cbHcWL5UjJ4wCMcj6jqacqipuMoy13t+hzVY6Xv/wP89jnNNsYLKyeaGUzRFPmkMglWRV6KvAIHHRuBjI5rMg0eDWLcXNneWs1q0qmaJpSjrjPBUHnr1wfrXaaiI71JRM0phZQjKvPy4wWGQD6kcnv61zGm6HDpF7Ou+GW7LBkcK+8pj7ypxvAOAQckZ7YrqpYi8ZSbal9/wDX9aBFOpr/AF+v+ZUe0Mk9wqhgtwMMigfIAQM5z3yAO+TXXQS4fZ8zH7gcpyM9iVHf0AHQcinFRM52kOT8zNyMjjAx97PGMjOAOTTbqB7aykuZACoBWNfLKKMk56856k4Fc9St7WyY00tHq/6/rf8A4LpJZCo2Bsv0AIDZOSNxPt6ZNcv4gt7q0kk1ixhWTUB/o0TnHylh9/GPl6kZP+FdNANo8yUbckg8FQ3IxxkkYUDIJ9enNQ6bcpdXUiRWdwDDE0hMj+WMA5GSCCctgEe5qadX2L5kv+D5Fxje7j0/r+vnc55dD1m/uNGeTUw0SAGULHtBYnovQb+gz/Dj256GExvIBb7XBA24YksASMjdyR7Ee/pUEx1GW0vjdTyG5lRlTepRk4YAKP4c5Kjr9TUmi5ube8Nuyi0+RzuViApwIhgEEjGBjvVVK0pRTnZen9fcacilFyve1v6/r7l0ybvxXA+na5Pps7Nd6cp+XYAvBC7l2/Ky7uv6UzT9JSLTbiW0Nzcy3sKTMWIxJgjMgB6A8gZJJqr4W8H6lp2rs15Hbx6YEkJIy3nBsAKodQAR1x97jjOK2/F39pLopGiN/pEGJPK5OYl4+XA6Ac444z3GK6ZOnCapUHo2tf0fz/Mxk46KOhU8FGcyXjEGK3IRiWBTLjPHTPTqOOhroZIysok/c7EJkd/M+ZQByT8uPTkEZHHvXF6bbXuoPbywXTSR3H74zlidoPLAr2YdMd+OM12M0UEds0Nzu8hVHmAgbieoBxxnnAHb0NY4uK9pe+r6fgZap/1/X/B9NOc8HoxvtbukMradJMTbl+jHOS2D2yMA+9aVvobR3zO0zR2vUKIxnLHkD2/Ct2zdBCssIj2gbYwn3EAHAH0x1/xrM13Xba1Z7WaX/TChW2RVDbyV49CMcD36DPNQ61SrUagt/wBP61B3k/6/r+vv5jQZ/Fs0epQ28CcXOYHu48okYyMDdxnp+tdcl9fxabu1E28l4uSXgyI+cbTgcAk+nbNedeDNZubnW4bfU7kM9zIYzHOgcuxBwRu4B3ADpXVBZNVl1GwiUpbW0LNHKiN8joyqR8vXeWx1yNuOlbY+n7Opyyilt/X4dDohS5n72y/r8e/+RDq+qvqGlwTWsxht4Llo3w+xXk7MD1Jx0zyMe9Ytvop1S5c3q3EUT5aUhS/mhcdMZx1rWht9O1aytNN8iaCW1eWTyZXjPmO/LP8ALnaRtVSrdVIwcgg39Fj021DQWl3FPNABvSMkYHUgd3IIAAOOnSihiHTg1TXzt59/67bm9WEILl63+f8AX9dS1eQ3yx2zafFJHFGpmkmREY7920Biep4ACjrknHFVd08upCfzbZriOPyriOJtyhcEsNoGFbnPBwD9KjuNR+yB49UklWOMGbDxgoUKfxAEEDpyuMEcHmoNGks4F0nUYZlmtZx5jSKSrsrNt3HI+UAnBAyeCc1g7xTcl376/wCf9eZvCD5OVvW2m39f15CajYT2Oog2Ept9OugXkt7iRYNzDBDbmI+UcHjPOOOKit7Vp3bW4jdX0Cv5hmWRWiYbtuFXcCWYn5RtILEcDPEul6VqT+HL9r/Tbh9Lhtbm6LOkqxO5YExxSjIZZOhPblhWbqEf2rS47iW3t40ikZokii8tIY19ieCrE85Jxij205ScU1tv16db/LbprfS+1KlBR5W72/4f7t/nc0dM0Q3Kpq08ssklu7M65YnIPCE4zg9yOMZxUs9xMxjurxpbSRJWO2Nf9Yu4H7pHTJI9x06VehjlsBEt1Pvjb5zcFiAi/eJZ8c4GdowTz0qG8tbO31KG3vbtFnucEo8T8/xCUYOFyD/PANNXfu79vQy9qoTftP6/r5/crk2gQy+X9rNs0cFwcGQfu4SccAFzgtnBHAP0qlqT2q6kIIEkWOMRYuGRQSzYGFGOQpyMn72eelNvtPuLqS4u7ZmlurdWSAediFIX++QP7xPDEkk/KSO1KIIvPmvUMUl7dBowWBfzpAvRmzwCcAcdueaXLK/Nf+t/y+7zKhKnz817t/L+u3S29r7WJL9LHTDGNLtzcxfLCXYRoHcnLOBg7RhcrkZ47daNnJcystg9vLdS74xIQzPvuCXZcAHChUJzjjn1qxYxX9zbyArJDlWEewfvJJNpwoUqGxngnn8elReTqCaI9rqqr9tmh+zrMq/NarksgJXnPy5AGPlLE46U3GMFz317Xf5eu5MXGE/Zyh/Wl+1tNLeffUie6ke5dZooJow+8tKokjiG4jk5zgnqGGeMdatadFdeXGt2nMUqS28MQQLGQMtIrqMAYOACMktU82mxaho72V5PJFeTRFHmVFfyM5A5U528Ht3Pc1geBbXXLaR9PvtPeGwto8wySs0ZdyQV2kkbjwcEdO/pWkYRcHK+3f8AT+uvndzPErlsl/X9Pb5aGR43Esy2+pWumi2WIZWNp2k8xupJLEnceuSTnnBrs4LKU2FrBeT3m9Yy7GFwpBcLkEDOSMYz3/Srup2CCNIwnlKm1zujBwBjBxkAnpg+oz2zVg3ME1wu6RHc4fdtJYkdy2cmqniHKEVHZfP8d9b9zzpVefWX9f1+uvnl6fBJFqUipDM8TgPJLKyH5zwO+MEdh0xg81ol3ACuWDMQOoPJHGMfWrscq23zogfaP3e/LAZPUZ+7g8fjzUijKoyFGBUuBtBAHQZ5wAOnpnjmuWdVyd2iOZt3seY+H7e50/U9Ugu78XljAd8g27o2fGcrnGMd8c/zrp/C8j3GnskzR+SDvwP3ahCcAEcZ9e2au2+kWkEt1NbxuTKTycke4U5wcewI7VJpF5Y3uoNpmm3UUl3FzJEjM7IRnswA3cEYA4rsxGJVWLcV219C5Scru2n9f195B4ukurW10tdK84STXCGXy4+FXluVA9Bxk9CfWqN3pthfype28KWN1PcedC/mR+ZKVwAwBGNuOcYBz64roZNVs0uFh3yTTsxLYYnkc8txjPv1rOu/Ddnq3iG0vIp2P2JPNKFvv4OdvpkYOT344rGjV9nFc942u79/+AZwmtmWLGOARPBKIni6yjbgMMDDsxPGcEZx6Ac1i+J40ur8x3kZ+yw/LkYAQKM9ep+8RyPpmptNvJ7q4ZZLpWdGkEiPIXA3cAFBkoN3GDyevQZqa58h74+cgaUurEykZj3HCq4HI+YA9OAR2NOjPlmpvr/X3nTOg4ystf6/r71dGTPoU8kUUkqovAQpJnEWTzg9/cdAOtFb9wJpFntomUyR5YFUbYSOWGT0Iz16duOKK6IYipJfEkck4Pq7f16nhvhS5ni0exSKaVEeVgyqxAYZ7+tev3NtAnivSYFhiWBnctGEAU5Rc5HSiiso/wC50f8ADH8kfT1fgXq/1Oku5HGgxzB2Exm2+Zn5sc8ZqG5+WCLHG0KBjtlVz/M0UV59P4l8z5v/ADX6lj7swUcDzyMD8ao6DNLdW5NzI8x3GTMjFvmyeee/vRRTe4R2l/Xc6SGKP92vlptyeNox90Vk35O9Bk4+QfyooqYfEYP/AC/JjdqybhIoYM0hIYZyR0/maSSxtIdNUQ2sEYwgwkYHYn+fNFFddP4PmjsX+7z/AK6MW4J/t3yM/ufKX93/AA/eHauZu5pbfwfctbyPExnhTKMVO0LJgcdhRRXPQ+H/ALej+RtW+F+i/Nj9C1C8n8M6x593cS+XDE6b5Gba3z8jJ4PA59qPCTs1zZszEsyOzEnkn1PvRRXVD4Kvr+hxdv66nUECK3ikiGxzC0hZeCWw3zZ9fesLVZHfR9GZ3ZmkwzknJYgvgn16UUVy0/8AeYnRH4P+3v0iXPDR32jb/m2zvjPOPnHSrqW8DTTTNDGZg0XzlRu6DvRRW/8Ay8n8/wAzB9P66EgtLbyoZPs8O9ZgVbYMg46g1zliS+oG2c7reW6hWSI8o4IJII6EZ5+tFFXDr6r8zrobf15G/BGkOuWdtCix23ngeUgwnT06V5Z4uAs/iFP9kAgwd37r5ecDnjvRRXTgf4tT0ZFb+JL0f6Ho+u2tumnXESQRLFKB5iBAA/zHqO9aOh2Vr/ZPhy3+zQeQbXmPyxtO5gG46cjg+tFFc1X+Gv8AF/7abr4n8/1MXR9U1Cb9ozxZYTX11JYxW1zFHbvMxjRFVcKFzgAdhXKQRRjTJ4xGgjLsSoAwTuHb8T+dFFeHg/4b/wAP6M9KjvL+v5TLiuriQa55k8rY1eVRucnjawx9McV3njdEa+1ORlUyIgRXI5VQowAfQUUV6mW/xF6P80Y5jvD5/mzkrK5ng8OI8M8sb+cRuRyDzwelXfA8j3FteNcO0rJc4Uud2OT0zRRXqV95/wBdThof5GT4wu7h/BEkr3ErStOqs5cliBnAJ9K3dCkeTQ/DPmOz77IFtxzu2ykLn6DgelFFS/gXr+hfVf12LWkuyy2zKxDMH3EHk/Pjmunt4o4W/dIqfOR8oxxwMflRRXnP4WXjfifz/Mo66iRswjVVB3EhRjJ6Z/KsmIlJFKEqRImMcYoorpo/wzzsV/E+X+Z0ugosusPHKqvGBFhWGQMhSePrToSSZMknAlYZ7EdDRRXHPcyl8aOK1OeZPidolsssi239ly/ugxCfck7dOw/KsuCR7fx+8tu7RSy2avI6HazsY0JJI6nPNFFd+G/hy/wy/wDSmdtfb7v/AG07GKKO30vTVgjSIFyCEULn92T296NNJ8+Q5OWUk+/zY/lRRWc9pf11PPnuyK6uJhq0kAmkEBihYxhjtJMignHTpxVW0lkm8QOssjusgvi4YkhiqYGfXAAx9BRRWUP0/Q9ej8c/RnXWCrE9vHGoRPs8Mm1RgbjHktj1J5zRRRXnYj4jgqfE/Vn/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph in pulmonary capillaritis showing marked broadening of the alveolar septa caused by edema and necrosis. There is a striking infiltration of neutrophils in the alveolar septa (arrows), with many of those cells undergoing fragmentation and appearing pyknotic. The alveolar spaces are packed with red blood cells (diffuse alveolar hemorrhage) as well as some neutrophils.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marvin I Schwarz, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28696=[""].join("\n");
var outline_f28_1_28696=null;
var title_f28_1_28697="Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis";
var content_f28_1_28697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Fibrinolytic (thrombolytic) therapy in acute pulmonary embolism and lower extremity deep vein thrombosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Victor F Tapson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28697/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/1/28697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 29, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic agents activate plasminogen to form plasmin, resulting in the accelerated lysis of thrombi. As a result, thrombolytic agents have been used in a variety of thrombotic disorders including acute myocardial infarction, acute pulmonary embolism (PE), and deep vein thrombosis (DVT).",
"   </p>",
"   <p>",
"    The efficacy, indications, contraindications, and adverse effects of thrombolytic therapy in acute PE and DVT are discussed here. In addition, the types of thrombolytic agents and regimens are reviewed. Alternative treatment modalities and anticoagulation for acute PE and DVT are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link\">",
"     \"Treatment of acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PULMONARY EMBOLISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Typically, only patients in whom the diagnosis of acute PE has been confirmed should be considered for thrombolytic therapy because the adverse effects of thrombolytic therapy can be devastating. For each patient, the indications and potential benefits must be carefully weighed against the risk of adverse events, and the patient's values and preferences should be considered. As an example, is the patient willing to risk intracranial hemorrhage to try a therapy that may only accelerate physiologic improvement?",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of thrombolytic therapy followed by anticoagulant therapy have been compared to those of anticoagulant therapy alone. The evidence indicates that thrombolytic therapy leads to early hemodynamic improvement, but at a cost of increased major bleeding. Thrombolytic therapy has not been proven to improve mortality or reduce the frequency of recurrent thromboembolism [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;No controlled clinical trial or meta-analysis of such trials has been large enough to conclusively demonstrate that thrombolytic therapy improves mortality more than anticoagulant therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. This was best illustrated by a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ] of 11 trials (847 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/5-15\">",
"     5-15",
"    </a>",
"    ] in which systemic thrombolytic therapy caused a non-statistically significant reduction in mortality compared to anticoagulant therapy alone (3.5 versus 6.1 percent, relative risk 0.7, 95% CI 0.37-1.31). Although the estimated effect appears clinically important, the confidence intervals are too wide (ie, there were too few events) to definitively confirm or exclude an effect on mortality.",
"   </p>",
"   <p>",
"    Despite such uncertain data from controlled clinical trials, at least one observational study of unstable patients with acute pulmonary embolism (n = 72,230) found that thrombolytic therapy was associated with lower all-cause mortality (15 versus 47 percent), as well as lower mortality attributable to pulmonary embolism (8.4 versus 42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/16\">",
"     16",
"    </a>",
"    ]. While the reported effect size is large, the observational design of the study and the possible influence of bias and confounding upon the results are such that the study does not serve as definitive proof of the efficacy of thrombolytic therapy in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977537\">",
"    <span class=\"h3\">",
"     Recurrent thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to mortality, no trial or meta-analysis has been large enough to conclusively demonstrate that thrombolytic therapy decreases recurrent thromboembolism more than anticoagulation alone. This was illustrated by a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ] of nine studies (801 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/5-15\">",
"     5-15",
"    </a>",
"    ] in which systemic thrombolytic therapy caused a non-statistically significant reduction in recurrent thromboembolism (4.5 versus 7.4 percent, relative risk 0.7, 95% CI 0.40-1.21). Although the estimated effect appears clinically important, the confidence intervals are too wide (ie, there were too few events) to definitively confirm or exclude an effect on recurrent thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Hemodynamics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic therapy improves pulmonary arterial blood pressure, right ventricular (RV) function, and pulmonary perfusion in the short-term. However, it is uncertain whether these beneficial effects persist because the data are contradictory. This was best illustrated by two studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective, nonrandomized trial of 40 consecutive patients with acute PE, patients who received thrombolytic therapy had improved RV function 12 hours after the initiation of therapy, compared to patients who received anticoagulation alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/17\">",
"       17",
"      </a>",
"      ]. One week later, there was no difference in RV function. This suggests that either the improvement of RV function seen in patients who received thrombolytic therapy was transient and short-lived or that RV function improved later in patients who did not receive thrombolytic therapy. The latter seems more likely.",
"     </li>",
"     <li>",
"      In another trial, 40 patients with acute PE were randomly assigned to receive thrombolysis or anticoagulation alone [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/18,19\">",
"       18,19",
"      </a>",
"      ]. Follow-up two weeks and one year after the initiation of therapy demonstrated more complete resolution of emboli in the group that received thrombolytic therapy (determined by diffusing capacity and pulmonary capillary blood volume) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/18\">",
"       18",
"      </a>",
"      ]. Longer-term follow-up (an average of seven years) revealed that patients who had been treated with thrombolytic therapy had lower pulmonary artery pressure and pulmonary vascular resistance, compared to patients who had received anticoagulant therapy alone, suggesting that the hemodynamic benefits of thrombolytic therapy were persistent [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such hemodynamic improvements associated with thrombolytic therapy have led many clinicians to believe that thrombolysis should be considered on a case-by-case basis, despite the lack of evidence that thrombolysis improves mortality or reduces recurrent thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13978218\">",
"    <span class=\"h3\">",
"     Patients in shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the lack of evidence that systemic thrombolysis improves mortality, most clinicians accept hypotension due to an acute PE (ie, massive PE) as an indication for thrombolysis because successful therapy can be lifesaving [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ]. Few trials have evaluated the effects of thrombolytic therapy in hemodynamically unstable patients, but those that did found a consistent trend toward improved mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/7,9,10,12,13\">",
"     7,9,10,12,13",
"    </a>",
"    ]. A meta-analysis that included those trials did a subgroup analysis of 154 patients with massive PE and found that systemic thrombolytic therapy decreased the composite endpoint of death and recurrent thromboembolism (9.4 versus 19 percent, odds ratio 0.45, 95% CI 0.22-0.92) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13977806\">",
"    <span class=\"h3\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic thrombolytic therapy increases the risk of major bleeding. In a meta-analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ] of 11 studies (847 patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/5-15\">",
"     5-15",
"    </a>",
"    ] that compared systemic thrombolytic therapy to anticoagulation alone in acute PE, thrombolytic therapy increased major bleeding (9.0 versus 5.7 percent, relative risk 1.63, 95% CI 1.00-2.68). There was a large difference in the frequency of major bleeding among patients defined as having a high risk for bleeding versus those defined as having a low risk for bleeding (6.2 versus 0.1 percent). The meta-analysis stratified the risk for bleeding via a clinical score in which a score of zero was considered low risk for bleeding and a score greater than four was considered high risk. Patients were assigned two points if they had a history of recent bleeding, 1.5 points if they had a creatinine &gt;1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    or anemia, and one point if they had a PE, cancer, or were older than 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few studies have sought to identify risk factors for bleeding during thrombolytic therapy. In a retrospective analysis of 104 patients with acute PE who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    , 20 patients (19 percent) had major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/23\">",
"     23",
"    </a>",
"    ]. The principal site of bleeding was unknown in nine patients (45 percent), gastrointestinal in six patients (30 percent), retroperitoneal in three patients (15 percent), intracranial in one patient (5 percent), and splenic in one patient (5 percent). Independent predictors of major hemorrhage were administration of catecholamines for systemic arterial hypotension (odds ratio 115, 95% CI 9.4-1411), malignancy (odds ratio 16, 95% CI 3.2-80), diabetes mellitus (odds ratio 9.6, 95% CI 1.7-54), and an elevated international normalized ratio (INR) (odds ratio 6, 95% CI 1.5-22).",
"   </p>",
"   <p>",
"    Bleeding during thrombolytic therapy occurs most commonly at sites of invasive procedures such as pulmonary arteriography or arterial puncture [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/24\">",
"     24",
"    </a>",
"    ]. Invasive procedures should be minimized when thrombolytic therapy is contemplated and while it is being administered. Bleeding from vascular puncture sites should be controlled with manual compression followed by a pressure dressing.",
"   </p>",
"   <p>",
"    In our practice, patients with significant or refractory bleeding are typically transfused ten units of cryoprecipitate and two units of fresh frozen plasma, then reassessed. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    should be considered to reverse the effect of any",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    that may remain in the patient's plasma. The dose and administration of protamine sulfate is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H22#H22\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most devastating complication associated with systemic thrombolytic therapy is intracranial hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/25\">",
"     25",
"    </a>",
"    ]. Clinical trials suggest that this complication occurs in up to 3 percent of patients who receive thrombolytic therapy for acute PE, which is higher than the rate of intracranial hemorrhage reported after thrombolysis for acute coronary occlusion [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/24,26,27\">",
"     24,26,27",
"    </a>",
"    ]. If intracranial bleeding is suspected clinically, infusion of the thrombolytic agent should be immediately discontinued. Following stabilization, a noncontrast-enhanced computed tomographic scan of the brain and emergent",
"    <span class=\"nowrap\">",
"     neurologic/neurosurgical",
"    </span>",
"    consultation should be obtained.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13978205\">",
"    <span class=\"h3\">",
"     Other adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are adverse effects that are specific for certain thrombolytic agents. As an example, streptokinase is associated with allergic reactions and hypotension:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Streptokinase (SK) is antigenic and can cause immunologic sensitization and allergic reactions, particularly with repeat administration. Major reactions are rare, with anaphylaxis occurring in less than 0.5 percent of patients. However, less severe symptoms such as shivering, pyrexia, or rash may occur in up to 10 percent of patients. The efficacy of SK is not reduced by an allergic reaction; however, anti-SK antibodies remain elevated for up to 7.5 years after treatment, suggesting that a suboptimal response",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      an allergic reaction may occur even if SK is readministered many years later [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/28,29\">",
"       28,29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypotension may occur during streptokinase infusion (particularly if the infusion rate is increased above 500",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per min). The decreased blood pressure usually responds to cessation or slowing of the infusion, intravenous fluids, or vasopressors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, systemic thrombolytic therapy should be considered only after acute PE has been confirmed because the adverse effects of this therapy can be severe. Persistent hypotension (ie, a systolic blood pressure &lt;90 mmHg or a decrease in the systolic blood pressure by &ge;40 mmHg from baseline) due to acute PE is the only widely accepted indication for thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The value of thrombolysis to treat acute PE in the other settings is uncertain and must be determined on a case-by-case basis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ]. The following are situations during which clinicians typically contemplate thrombolysis (",
"    <a class=\"graphic graphic_table graphicRef82171 \" href=\"UTD.htm?1/39/1659\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/26,30-34\">",
"     26,30-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Severe hypoxemia",
"     </li>",
"     <li>",
"      Large perfusion defect on ventilation-perfusion scans",
"     </li>",
"     <li>",
"      Extensive embolic burden on computed tomography (CT)",
"     </li>",
"     <li>",
"      Right ventricular dysfunction",
"     </li>",
"     <li>",
"      Free-floating right atrial or ventricular thrombus",
"     </li>",
"     <li>",
"      Patent foramen ovale",
"     </li>",
"     <li>",
"      Cardiopulmonary resuscitation",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Perhaps the most controversial situation in which thrombolytic therapy is often considered is RV dilation or hypokinesis without systemic hypotension. Although some clinicians advocate thrombolytic therapy in this circumstance because it appears that severe RV dysfunction portends a worse prognosis than mild RV dysfunction, the indication has not gained widespread acceptance and remains highly controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/19,30,35\">",
"     19,30,35",
"    </a>",
"    ]. Clinical trials have not stratified patients based upon RV size or the severity of RV dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=see_link&amp;anchor=H5#H5\">",
"     \"Overview of acute pulmonary embolism\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Case reports and series have reported some success from systemic thrombolytic therapy during cardiopulmonary resuscitation (CPR) when the cardiac arrest is due to an acute PE [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Thrombolysis does not appear to improve outcome when the cardiac arrest manifests as pulseless electrical activity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/38\">",
"     38",
"    </a>",
"    ]. We believe there are insufficient data to argue for or against thrombolytic therapy in patients undergoing CPR due to PE-induced cardiac arrest. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=see_link\">",
"     \"Supportive data for advanced cardiac life support in adults with sudden cardiac arrest\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We believe that the importance of the contraindication depends on the strength of the indication. As an example, we believe that a contraindication is of more concern if the indication for systemic thrombolytic therapy is RV dyskinesis, than if the indication is shock. The risks versus benefits should always be weighed on a case-by-case basis.",
"   </p>",
"   <p>",
"    Contraindications to systemic thrombolytic therapy in acute PE include an intracranial neoplasm, recent (ie, &lt;2 months) intracranial surgery or trauma, active or recent internal bleeding during the prior six months, history of a hemorrhagic stroke, bleeding diathesis, severe uncontrolled hypertension (ie, systolic blood pressure &gt;200 mmHg or diastolic blood pressure &gt;110 mmHg), nonhemorrhagic stroke within the prior two months, surgery within the previous ten days, and thrombocytopenia (ie, &lt;100,000",
"    <span class=\"nowrap\">",
"     platelets/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef71568 \" href=\"UTD.htm?4/28/4555\">",
"     table 2",
"    </a>",
"    ). Thrombolytic therapy may cause moderate bleeding in menstruating women, but it has not been associated with major hemorrhage. Therefore, menstruation is not a contraindication to thrombolytic therapy.",
"   </p>",
"   <p>",
"    As an alternative to thrombolytic therapy, catheter or surgical embolectomy may be warranted if the necessary resources and expertise are available. The decision of whether to pursue one of these approaches should be based on local expertise. Embolectomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of acute pulmonary embolism\", section on 'Embolectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Thrombolytic agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant tissue type plasminogen activator (tPA,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ), streptokinase (SK), and recombinant human urokinase (UK) are the best studied thrombolytic agents for the treatment of acute PE. Other thrombolytic agents include lanoteplase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/39/14966?source=see_link\">",
"     tenecteplase",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/25/30101?source=see_link\">",
"     reteplase",
"    </a>",
"    . The characteristics of SK, tPA, and UK are described briefly here, with greater detail presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=see_link\">",
"     \"Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    tPA is a naturally occurring enzyme produced by a number of tissues including endothelial cells. tPA binds to fibrin, which increases its affinity for plasminogen and enhances plasminogen activation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SK is a polypeptide derived from beta-hemolytic streptococcus cultures. It binds to plasminogen, forming an active enzyme that activates plasmin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/39,42\">",
"     39,42",
"    </a>",
"    ]. Among the thrombolytic agents, it is the least expensive but most commonly associated with adverse effects, including allergic reactions and hypotension. (See",
"    <a class=\"local\" href=\"#H13978205\">",
"     'Other adverse events'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Urokinase is also a plasminogen activator that is normally present in the urine. It is the major activator of fibrinolysis in the extravascular compartment, in contrast to tPA which is largely responsible for initiating intravascular fibrinolysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unnecessary invasive procedures (particularly arterial punctures) should be minimized while thrombolytic therapy is being considered. Once the decision to administer thrombolytic therapy has been made, the thrombolytic agent should be administered via a peripheral intravenous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ]. Anticoagulant therapy is generally discontinued during the thrombolytic infusion (",
"    <a class=\"graphic graphic_table graphicRef79949 \" href=\"UTD.htm?1/20/1355\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Common thrombolytic regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      tPA &ndash; Administer 100 mg intravenously over two hours.",
"     </li>",
"     <li>",
"      Streptokinase &ndash; Administer 250,000 units intravenously over the initial 30 minutes, then 100,000",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      for 24 hours. Monitor closely for hypotension, anaphylaxis, asthma, and allergic reactions. Mild adverse reactions may respond favorably to a decreased infusion rate.",
"     </li>",
"     <li>",
"      Urokinase &ndash; Administer 4400",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      intravenously over the initial 10 minutes, then 4400",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour for 12 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Numerous thrombolytic agents and regimens have been directly compared in randomized trials, but superiority of any thrombolytic agent or regimen over another has not been established. Studied regimens include tPA administration over 15 minutes or two hours, urokinase administration over two hours or 24 hours, and streptokinase administration over two hours, 12 hours, or 24 hours. The evidence suggests that shorter infusions (ie, &le;2 hours) achieve more rapid clot lysis and are associated with lower rates of bleeding than longer infusions (ie, &ge;12 hours) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An activated partial thromboplastin time (aPTT) should be measured when infusion of the thrombolytic therapy is complete.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    should be resumed without a loading dose when the aPTT is less than twice its upper limit of normal. If the aPTT exceeds this value, the test should be repeated every four hours until it is less than twice its upper limit of normal, at which time heparin should be resumed. The administration of heparin to patients with acute PE is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=see_link\">",
"     \"Anticoagulation in acute pulmonary embolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Coagulation assays are unnecessary during infusion of the thrombolytic agent since thrombolytic agents are administered as fixed doses. The one exception is that the thrombin time may be measured four hours after the initiation of SK, since the presence of antibodies to this drug may impair its therapeutic effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Bolus infusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bolus infusion of thrombolytics appear to be effective without excess bleeding complications [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1,43,44\">",
"     1,43,44",
"    </a>",
"    ]. However, it has not been directly compared to a two hour infusion of tPA. Trials comparing the regimens are necessary before routine bolus infusion replaces the more conventional two hour regimen. An exception is that bolus infusion of thrombolytic therapy is indicated for patients with imminent or actual cardiac arrest [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The impact of bolus infusion was illustrated by a double-blind trial in which 58 patients with acute PE were randomly assigned to receive tPA (0.6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over two minutes) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or placebo plus heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/43\">",
"     43",
"    </a>",
"    ]. Patients who received tPA were more likely to have &gt;50 percent clot resolution and increased perfusion within 24 hours, although there were no detectable differences by the seventh day. There was no major bleeding in either group.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Catheter-directed",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic agents have been infused directly into the pulmonary artery via a pulmonary arterial catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/45-50\">",
"     45-50",
"    </a>",
"    ]. There is no evidence that intrapulmonary arterial infusion confers greater benefit than peripheral venous infusion, but it is associated with bleeding at the catheter insertion site.",
"   </p>",
"   <p>",
"    This was illustrated by a clinical trial of 34 patients with persistent hypotension due to acute PE (ie, massive PE), in whom tPA (50 mg) was infused over two hours through either a pulmonary arterial catheter or a peripheral venous catheter [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/49\">",
"     49",
"    </a>",
"    ]. Following the infusion, the severity of the PE (determined by pulmonary angiogram) and the mean pulmonary arterial pressure decreased to a similar extent in both groups. After an additional infusion of tPA (50 mg) over five hours, both outcomes continued to decrease to a similar extent in both groups. Infusion through the pulmonary arterial catheter was associated with bleeding at the catheter insertion site.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     LOWER EXTREMITY DEEP VEIN THROMBOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic therapy is associated with more rapid and complete lysis of lower extremity deep vein thrombosis (DVT), as well as less post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. Despite this, thrombolytic therapy is seldom used in patients with lower extremity DVT because it increases the risk of major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ] and most patients are unwilling to accept the increased risk of death or disability due to bleeding to prevent the post-thrombotic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/53\">",
"     53",
"    </a>",
"    ]. The risk of recurrence and death is low if anticoagulants are started promptly at an appropriate dose [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In this section, we focus on three issues specific to thrombolysis of lower extremity DVT: the outcomes, indications, and regimens. Acute PE and lower extremity DVT are generally considered different manifestations of the same clinical entity; therefore, much of the above discussion regarding acute PE is equally relevant to lower extremity DVT. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Contraindications'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H9\">",
"     'Thrombolytic agents'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13978205\">",
"     'Other adverse events'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombolytic therapy followed by anticoagulation for lower extremity DVT results in less postthrombotic syndrome than anticoagulant therapy alone, although the cost is more major bleeding. This was demonstrated by a meta-analysis of 12 trials that randomly assigned patients with lower extremity DVT to receive thrombolysis followed by anticoagulation or anticoagulant therapy alone [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/54\">",
"     54",
"    </a>",
"    ]. The thrombolysis group had less postthrombotic syndrome (47.5 versus 65 percent, relative risk 0.66, 95% CI 0.47-0.94), but more bleeding complications (10 versus 7.9 percent, relative risk 1.73, 95% CI 1.04-2.88). There were no differences in mortality or pulmonary embolic events.",
"   </p>",
"   <p>",
"    Thrombolysis also leads to more rapid and complete lysis, improving venous patency [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/54-57\">",
"     54-57",
"    </a>",
"    ]. This was demonstrated by the same meta-analysis, which found that thrombolysis followed by anticoagulation led to more complete clot lysis than anticoagulant therapy alone (28.7 versus 7.9 percent, relative risk 4.24, 95% CI 1.22-14.01) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When systemic thrombolytic therapy and catheter-directed thrombolytic therapy are considered separately, catheter-directed thrombolytic therapy appears to reduce postthrombotic syndrome to a greater extent than systemic thrombolytic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Systemic thrombolytic therapy: A meta-analysis of two trials (678 patients) found a trend toward less postthrombotic syndrome among patients with acute DVT who received systemic thrombolytic therapy compared to those who did not (6 versus 10.4 percent, relative risk 0.71, 95% CI 0.49-1.04) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"       1",
"      </a>",
"      ]. There were no differences in mortality or recurrent thromboembolism, although a larger meta-analysis identified a trend toward more nonfatal major bleeding among patients who received thrombolytic therapy (8.4 versus 4.3 percent, relative risk 1.84, 95% CI 0.94-3.59).",
"     </li>",
"     <li>",
"      Catheter-directed thrombolytic therapy: A meta-analysis of two trials (138 patients) found less postthrombotic syndrome at two years among patients who received thrombolytic therapy compared to those who did not (33.8 versus 70 percent, relative risk 0.46, 95% CI 0.00-0.79) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"       1",
"      </a>",
"      ]. There were no significant differences in nonfatal major bleeding (1.3 versus zero percent, relative risk 2.00, 95% CI 0.19-19.46), mortality, or recurrent thromboembolism, although these estimates were severely limited by the small sizes of the included trials. A more recent randomized trial of 209 patients with iliofemoral DVT similarly found less postthrombotic syndrome at two years among patients who received thrombolytic therapy (41 versus 56 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/58\">",
"       58",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Catheter-directed thrombolysis also appears to be superior to systemic thrombolysis with respect to maintaining normal valve function. This is illustrated by a trial that randomly assigned 32 patients with iliofemoral DVT to undergo either systemic or catheter-directed thrombolysis, followed by anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/59\">",
"     59",
"    </a>",
"    ]. Venous valvular competence was preserved in more patients in the catheter-directed group than the systemic thrombolysis group (44 versus 13 percent), with less reflux in both the deep veins (44 versus 81 percent) and superficial veins (25 versus 63 percent). Catheter-directed thrombolysis probably also requires lower doses of thrombolytics than systemic thrombolysis, potentially resulting in fewer bleeding complications. Despite these advantages, recurrent DVT and post-thrombotic syndrome are common following catheter-directed thrombolysis (20 and 37 percent, respectively), according to a study that followed patients for a median of six years after catheter-directed thrombolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A large, randomized, multicenter trial (the ATTRACT trial) is underway [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/61\">",
"     61",
"    </a>",
"    ]. The trial will utilize pharmacomechanical catheter-directed thrombolysis in patients with acute DVT. This approach combines thrombolytic therapy with a catheter-mounted clot removal device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Indication",
"    </span>",
"    &nbsp;&mdash;&nbsp;Massive proximal lower extremity or iliofemoral thrombosis associated with severe symptomatic swelling or limb-threatening ischemia (ie, phlegmasia cerulea dolens) is the only widely accepted indication for thrombolytic therapy for lower extremity DVT. No other indication for thrombolytic therapy to treat lower extremity DVT has gained widespread acceptance because most patients appear unwilling to accept the risk of adverse consequences to prevent the long-term complications of DVT [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/53\">",
"     53",
"    </a>",
"    ]. For most patients, anticoagulant therapy alone is preferred over thrombolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Alternative therapies that may be considered include catheter extraction, catheter fragmentation, and surgical thrombectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unnecessary invasive procedures (particularly arterial punctures) should be minimized while thrombolytic therapy for lower extremity DVT is being considered. Once the decision to administer thrombolytic therapy has been made, the thrombolytic agent should be catheter-directed, if the expertise is available.",
"   </p>",
"   <p>",
"    Common systemic thrombolytic regimens include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      tPA &ndash; Administer 100 mg intravenously over two hours.",
"     </li>",
"     <li>",
"      Streptokinase &ndash; Administer 250,000 units intravenously over the initial 30 minutes, then 100,000",
"      <span class=\"nowrap\">",
"       units/hour",
"      </span>",
"      for 24 to 72 hours. Monitor closely for hypotension, anaphylaxis, asthma, and allergic reactions. Mild adverse reactions may respond favorably to a decreased infusion rate.",
"     </li>",
"     <li>",
"      Urokinase &ndash; Administer 4400",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      intravenously over the initial 10 minutes, then 2200",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour for 12 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regimens for catheter-directed thrombolytic therapy are more variable. Urokinase and tPA are most commonly employed. Infusions of urokinase generally total more than 4 million units and tPA doses generally total approximately 50 to 100 mg. These regimens are generally delivered over 24 hours or longer (often over several days), with or without boluses. The usual dose of tPA is about 2 to 4",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Anticoagulant therapy is generally discontinued during thrombolytic infusion (",
"    <a class=\"graphic graphic_table graphicRef79949 \" href=\"UTD.htm?1/20/1355\">",
"     table 3",
"    </a>",
"    ). When the infusion of the thrombolytic agent is complete, an activated partial thromboplastin time (aPTT) should be measured.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    should be resumed without a loading dose when the aPTT is less than twice its upper limit of normal. If the aPTT exceeds this value, the test should be repeated every four hours until it is less than twice its upper limit of normal, at which time heparin should be resumed. The administration of heparin to patients with lower extremity DVT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link\">",
"     \"Treatment of lower extremity deep vein thrombosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=see_link\">",
"       \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=see_link\">",
"       \"Patient information: Pulmonary embolism (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pulmonary embolism",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombolytic therapy for acute pulmonary embolism (PE) accelerates clot lysis and has short-term hemodynamic benefits (eg, improved pulmonary arterial blood pressure, right ventricular function, and pulmonary perfusion). However, it also increases major bleeding and no clinical trial or meta-analysis has been large enough to demonstrate decreased mortality or reduced recurrent thromboembolism compared to anticoagulation alone. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In most cases, thrombolytic therapy should be considered only after acute PE has been confirmed because the adverse effects of thrombolytic therapy can be severe. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with acute PE who do not have hemodynamic compromise, we recommend AGAINST thrombolytic therapy (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with confirmed acute PE who are persistently hypotensive due to PE (systolic blood pressure &lt;90 mmHg or a drop in systolic blood pressure of &ge;40 mmHg from baseline) and do not have an increased risk of bleeding, we suggest thrombolytic therapy followed by anticoagulation, rather than anticoagulation alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Many patients may not accept the increased risk of major bleeding in order to obtain the potential benefit of more rapid hemodynamic stabilization and clot lysis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For all other patients with acute PE, the decision to pursue thrombolytic therapy should be made on a case-by-case basis after carefully weighing the strength of the indication, the potential benefits, the contraindications, and potential adverse effects. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Once it is decided that thrombolytic therapy is warranted, we suggest that the thrombolytic agent be administered by a peripheral venous catheter, rather than a pulmonary arterial catheter (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a thrombolytic regimen with a short infusion time (ie, &le;2 hours), rather than a regimen with a more prolonged infusion time (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Administration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When there are contraindications to thrombolysis (or thrombolysis fails to induce clinical improvement), catheter or surgical embolectomy may be warranted if the necessary resources and expertise are available. The decision of whether to pursue one of these approaches should be based on local expertise. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Contraindications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=see_link&amp;anchor=H13#H13\">",
"       \"Treatment of acute pulmonary embolism\", section on 'Embolectomy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Lower extremity deep vein thrombosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with lower extremity deep vein thrombosis (DVT), we recommend that thrombolytic therapy NOT be administered (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Indication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with massive iliofemoral or proximal femoral DVT with a high risk of limb gangrene, therapeutic options include thrombolytic therapy, catheter extraction, catheter fragmentation, and surgical thrombectomy. The most appropriate intervention depends upon the institution's expertise. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Indication'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following is applicable to patients in an institution where thrombolytic therapy is the best available option:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients who have massive iliofemoral or proximal femoral DVT with a high risk of limb gangrene, have been symptomatic for 14 or fewer days, do not have an increased risk of bleeding, and accept the risk of bleeding to potentially obtain relief of acute symptoms and reduced post-thrombotic morbidity, we suggest thrombolytic therapy followed by anticoagulation, rather than anticoagulation alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest catheter-directed thrombolysis, rather than systemic thrombolysis (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Indication'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H20\">",
"       'Regimen'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/1\">",
"      Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e419S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/2\">",
"      Thabut G, Thabut D, Myers RP, et al. Thrombolytic therapy of pulmonary embolism: a meta-analysis. J Am Coll Cardiol 2002; 40:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/3\">",
"      Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/4\">",
"      Dong B, Jirong Y, Liu G, et al. Thrombolytic therapy for pulmonary embolism. Cochrane Database Syst Rev 2006; :CD004437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/5\">",
"      The urokinase pulmonary embolism trial. A national cooperative study. Circulation 1973; 47:II1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/6\">",
"      Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol 1992; 20:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/7\">",
"      Dotter CT, Seamon AJ, Rosch J. Streptokinase and heparin in the treatment of acute pulmonary embolism. Vasc Surg 1979; 13:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/8\">",
"      Tissue plasminogen activator for the treatment of acute pulmonary embolism. A collaborative study by the PIOPED Investigators. Chest 1990; 97:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/9\">",
"      Jerjes-Sanchez C, Ram&iacute;rez-Rivera A, Arriaga-Nava R, et al. Streptokinase and Heparin versus Heparin Alone in Massive Pulmonary Embolism: A Randomized Controlled Trial. J Thromb Thrombolysis 1995; 2:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/10\">",
"      Ly B, Arnesen H, Eie H, Hol R. A controlled clinical trial of streptokinase and heparin in the treatment of major pulmonary embolism. Acta Med Scand 1978; 203:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/11\">",
"      Marini C, Di Ricco G, Rossi G, et al. Fibrinolytic effects of urokinase and heparin in acute pulmonary embolism: a randomized clinical trial. Respiration 1988; 54:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/12\">",
"      Tibbutt DA, Davies JA, Anderson JA. Comparison by controlled clinical trial of streptokinase and heparin in treatment of life-threatening pulmonary embolism. BMJ 1974; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/13\">",
"      Urokinase pulmonary embolism trial. Phase 1 results: a cooperative study. JAMA 1970; 214:2163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/14\">",
"      Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res 2010; 125:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/15\">",
"      Fasullo S, Scalzo S, Maringhini G, et al. Six-month echocardiographic study in patients with submassive pulmonary embolism and right ventricle dysfunction: comparison of thrombolysis with heparin. Am J Med Sci 2011; 341:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/16\">",
"      Stein PD, Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med 2012; 125:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/17\">",
"      Konstantinides S, Tiede N, Geibel A, et al. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol 1998; 82:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/18\">",
"      Sharma GV, Burleson VA, Sasahara AA. Effect of thrombolytic therapy on pulmonary-capillary blood volume in patients with pulmonary embolism. N Engl J Med 1980; 303:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/19\">",
"      Come PC. Echocardiographic evaluation of pulmonary embolism and its response to therapeutic interventions. Chest 1992; 101:151S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/20\">",
"      Sharma, GVRK, Folland, ED, McIntyre, KM, et al. Longterm hemodynamic benefit of thrombolytic therapy in pulmonary embolic disease (abstract). J Am Coll Cardiol 1990; 15:65A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/21\">",
"      Wan S, Quinlan DJ, Agnelli G, Eikelboom JW. Thrombolysis compared with heparin for the initial treatment of pulmonary embolism: a meta-analysis of the randomized controlled trials. Circulation 2004; 110:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/22\">",
"      Ru&iacute;z-Gim&eacute;nez N, Su&aacute;rez C, Gonz&aacute;lez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/23\">",
"      Fiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of major hemorrhage following fibrinolysis for acute pulmonary embolism. Am J Cardiol 2006; 97:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/24\">",
"      Meyer G, Gisselbrecht M, Diehl JL, et al. Incidence and predictors of major hemorrhagic complications from thrombolytic therapy in patients with massive pulmonary embolism. Am J Med 1998; 105:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/25\">",
"      Gore JM. Prevention of severe neurologic events in the thrombolytic era. Chest 1992; 101:124S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/26\">",
"      Goldhaber SZ. Modern treatment of pulmonary embolism. Eur Respir J Suppl 2002; 35:22s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/27\">",
"      Kanter DS, Mikkola KM, Patel SR, et al. Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors. Chest 1997; 111:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/28\">",
"      Tsang TS, Califf RM, Stebbins AL, et al. Incidence and impact on outcome of streptokinase allergy in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA in Occluded Coronary Arteries. Am J Cardiol 1997; 79:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/29\">",
"      Squire IB, Lawley W, Fletcher S, et al. Humoral and cellular immune responses up to 7.5 years after administration of streptokinase for acute myocardial infarction. Eur Heart J 1999; 20:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/30\">",
"      Guidelines on diagnosis and management of acute pulmonary embolism. Task Force on Pulmonary Embolism, European Society of Cardiology. Eur Heart J 2000; 21:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/31\">",
"      Dalen JE. The uncertain role of thrombolytic therapy in the treatment of pulmonary embolism. Arch Intern Med 2002; 162:2521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/32\">",
"      Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998; 114:561S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/33\">",
"      Goldhaber SZ. Contemporary pulmonary embolism thrombolysis. Chest 1995; 107:45S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/34\">",
"      Goldhaber SZ. Echocardiography in the management of pulmonary embolism. Ann Intern Med 2002; 136:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/35\">",
"      Grifoni S, Olivotto I, Cecchini P, et al. Short-term clinical outcome of patients with acute pulmonary embolism, normal blood pressure, and echocardiographic right ventricular dysfunction. Circulation 2000; 101:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/36\">",
"      Bail&eacute;n MR, Cuadra JA, Aguayo De Hoyos E. Thrombolysis during cardiopulmonary resuscitation in fulminant pulmonary embolism: a review. Crit Care Med 2001; 29:2211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/37\">",
"      K&uuml;rkciyan I, Meron G, Sterz F, et al. Pulmonary embolism as a cause of cardiac arrest: presentation and outcome. Arch Intern Med 2000; 160:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/38\">",
"      Abu-Laban RB, Christenson JM, Innes GD, et al. Tissue plasminogen activator in cardiac arrest with pulseless electrical activity. N Engl J Med 2002; 346:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/39\">",
"      Anderson HV, Willerson JT. Thrombolysis in acute myocardial infarction. N Engl J Med 1993; 329:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/40\">",
"      van Zonneveld AJ, Veerman H, Pannekoek H. Autonomous functions of structural domains on human tissue-type plasminogen activator. Proc Natl Acad Sci U S A 1986; 83:4670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/41\">",
"      Kalyan NK, Lee SG, Wilhelm J, et al. Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties. J Biol Chem 1988; 263:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/42\">",
"      Marder VJ, Sherry S. Thrombolytic therapy: current status (1). N Engl J Med 1988; 318:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/43\">",
"      Levine M, Hirsh J, Weitz J, et al. A randomized trial of a single bolus dosage regimen of recombinant tissue plasminogen activator in patients with acute pulmonary embolism. Chest 1990; 98:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/44\">",
"      Meneveau N, Schiele F, Metz D, et al. Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. J Am Coll Cardiol 1998; 31:1057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/45\">",
"      Leeper KV Jr, Popovich J Jr, Lesser BA, et al. Treatment of massive acute pulmonary embolism. The use of low doses of intrapulmonary arterial streptokinase combined with full doses of systemic heparin. Chest 1988; 93:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/46\">",
"      Barberena J. Intraarterial infusion of urokinase in the treatment of acute pulmonary thromboembolism: preliminary observations. AJR Am J Roentgenol 1983; 140:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/47\">",
"      Schwarz F, Stehr H, Zimmermann R, et al. Sustained improvement of pulmonary hemodynamics in patients at rest and during exercise after thrombolytic treatment of massive pulmonary embolism. Circulation 1985; 71:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/48\">",
"      The UKEP study: multicentre clinical trial on two local regimens of urokinase in massive pulmonary embolism. The UKEP Study Research Group. Eur Heart J 1987; 8:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/49\">",
"      Verstraete M, Miller GA, Bounameaux H, et al. Intravenous and intrapulmonary recombinant tissue-type plasminogen activator in the treatment of acute massive pulmonary embolism. Circulation 1988; 77:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/50\">",
"      Cuculi F, Kobza R, Bergner M, Erne P. Usefulness of aspiration of pulmonary emboli and prolonged local thrombolysis to treat pulmonary embolism. Am J Cardiol 2012; 110:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/51\">",
"      Goldhaber SZ, Buring JE, Lipnick RJ, Hennekens CH. Pooled analyses of randomized trials of streptokinase and heparin in phlebographically documented acute deep venous thrombosis. Am J Med 1984; 76:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/52\">",
"      Rogers LQ, Lutcher CL. Streptokinase therapy for deep vein thrombosis: a comprehensive review of the English literature. Am J Med 1990; 88:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/53\">",
"      O'Meara JJ 3rd, McNutt RA, Evans AT, et al. A decision analysis of streptokinase plus heparin as compared with heparin alone for deep-vein thrombosis. N Engl J Med 1994; 330:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/54\">",
"      Watson LI, Armon MP. Thrombolysis for acute deep vein thrombosis. Cochrane Database Syst Rev 2004; :CD002783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/55\">",
"      Elsharawy M, Elzayat E. Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg 2002; 24:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/56\">",
"      Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology 1999; 211:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/57\">",
"      Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000; 32:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/58\">",
"      Enden T, Haig Y, Kl&oslash;w NE, et al. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/59\">",
"      Laiho MK, Oinonen A, Sugano N, et al. Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg 2004; 28:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28697/abstract/60\">",
"      Ghanima W, Kleven IW, Enden T, et al. Recurrent venous thrombosis, post-thrombotic syndrome and quality of life after catheter-directed thrombolysis in severe proximal deep vein thrombosis. J Thromb Haemost 2011; 9:1261.",
"     </a>",
"    </li>",
"    <li>",
"     Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis. file://www.clinicaltrials.gov/ct2/results?term=NCT00790335 (Accessed on July 07, 2009).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8259 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-F706DDF602-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28697=[""].join("\n");
var outline_f28_1_28697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PULMONARY EMBOLISM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13977537\">",
"      - Recurrent thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Hemodynamics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13978218\">",
"      - Patients in shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13977806\">",
"      - Bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13978205\">",
"      - Other adverse events",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Thrombolytic agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Bolus infusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Catheter-directed",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      LOWER EXTREMITY DEEP VEIN THROMBOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Outcomes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Indication",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Regimen",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/8259\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/8259|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/39/1659\" title=\"table 1\">",
"      Indication thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?4/28/4555\" title=\"table 2\">",
"      Contraindications to thrombolytic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/20/1355\" title=\"table 3\">",
"      Thrombolytic therapy guidelines",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/5/25690?source=related_link\">",
"      Anticoagulation in acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/27/14778?source=related_link\">",
"      Characteristics of fibrinolytic (thrombolytic) agents and clinical trials in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4456?source=related_link\">",
"      Overview of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/44/12998?source=related_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?2/29/2517?source=related_link\">",
"      Patient information: Pulmonary embolism (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/24/8585?source=related_link\">",
"      Supportive data for advanced cardiac life support in adults with sudden cardiac arrest",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42503?source=related_link\">",
"      Treatment of acute pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_1_28698="Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation";
var content_f28_1_28698=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial chemotherapy for symptomatic multiple myeloma in patients who are NOT candidates for transplantation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28698/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28698/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28698/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28698/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?28/1/28698/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?28/1/28698/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?28/1/28698/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple myeloma (MM) is characterized by the neoplastic proliferation of a single clone of plasma cells producing a monoclonal immunoglobulin. Potential complications include anemia, hypercalcemia, renal insufficiency, infection, and skeletal lesions.",
"   </p>",
"   <p>",
"    When MM is suspected, the diagnosis must be carefully verified. For example, patients who have 10 percent or more clonal plasma cells in the marrow but no evidence of end organ damage that can be attributed to the plasma cell disorder (smoldering multiple myeloma) do not require therapy because there is no proof of clear benefit with currently available therapies, and some of these patients remain stable without treatment over extended periods of time. An exception is that patients with &ge;60 percent clonal plasma cells in the bone marrow who lack end-organ damage are also considered as having MM and are candidates for initiation of therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H2#H2\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Verification of the diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis of MM requires the presence of end organ damage (hypercalcemia, renal failure, anemia, or bone disease) that is thought to be related to the plasma cell proliferative disorder. Once the diagnosis of MM is confirmed, the next step includes testing for those abnormalities that help predict outcome following treatment. Individual cases are stratified into high risk, intermediate risk, or standard risk MM based upon the results of FISH for specific translocations",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    deletions and conventional cytogenetics (",
"    <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Following diagnosis and risk stratification, patients need to be assessed to determine eligibility for autologous hematopoietic cell transplantation (HCT). Although autologous HCT is a standard treatment for patients with MM, a number of patients are not eligible for HCT due to poor performance status",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of comorbid conditions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial treatment of symptomatic standard risk and intermediate risk MM in patients who are not candidates for HCT is discussed here. General treatment indications, risk stratification, transplant eligibility, and the choice of initial treatment options are reviewed separately as are the initial chemotherapy options for high risk MM patients and the initial chemotherapy for patients who are candidates for transplantation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Discussions of relapsed or resistant MM, the treatment of complications of MM (eg, hypercalcemia, renal insufficiency, skeletal lesions), and the use of bisphosphonates are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"     \"Treatment of relapsed or refractory multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=see_link\">",
"     \"Treatment of the complications of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHOICE OF REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the development of effective therapies, median overall survival was less than one year among patients with symptomatic MM, with the majority of patients being standard risk [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/1\">",
"     1",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP), the previous standard chemotherapy for non-transplant candidates, improved median overall survival of such patients to approximately three years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/2\">",
"     2",
"    </a>",
"    ]. The addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    to the MP regimen has resulted in an even longer median overall survival of approximately four years. Besides these MP-based regimens, other options include those in which",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    is used instead of melphalan (eg, bortezomib, cyclophosphamide,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , VCd), and non-alkylator containing regimens such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    and low-dose dexamethasone (Rd).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8888482\">",
"    <span class=\"h2\">",
"     Our preferred approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Our preferred initial treatment for patients with multiple myeloma who are not candidates for transplantation depends on the baseline risk stratification (",
"    <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link\">",
"     \"Determination of initial therapy in patients with multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For standard risk patients who are not candidates for HCT, acceptable treatment options include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Rd) (",
"      <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"       table 2",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and dexamethasone (VCd) (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"       table 3",
"      </a>",
"      ); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (MPT) (",
"      <a class=\"graphic graphic_table graphicRef53179 \" href=\"UTD.htm?9/17/9502\">",
"       table 4",
"      </a>",
"      ). For most patients, we suggest initial treatment with Rd rather than VCd or MPT. This preference places a high value on the relatively low toxicity of this regimen and relies upon the extrapolation of data from trials in patients who were candidates for HCT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For intermediate risk patients who are not candidates for HCT, we recommend initial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen, such as bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (VMP) (",
"      <a class=\"graphic graphic_table graphicRef55107 \" href=\"UTD.htm?27/39/28286\">",
"       table 5",
"      </a>",
"      ) or bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VCd) (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"       table 3",
"      </a>",
"      ). These patients were previously considered to have high risk disease, but treatment with bortezomib-containing regimens have resulted in outcomes approaching that of standard risk patients [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/3,4\">",
"       3,4",
"      </a>",
"      ]. This is discussed in more detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For high risk patients who are not candidates for HCT, we suggest initial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen, such as bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VRd) or bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , dexamethasone (VCd). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These preferred treatment options have not been compared directly with each other in a randomized trial in these patient populations. Data supporting their use come largely from single arm trials or randomized trials comparing these regimens with other regimens. As such, the choice among initial treatment regimens should take into consideration physician preference, risk of neuropathy, risk of thrombosis, and the patient&rsquo;s underlying renal function. In addition, for standard risk patients, the choice of initial therapy varies at least partially by country. Non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -based regimens commonly used in transplant candidates (eg, Rd, VCD) are increasingly used in the United States for patients who are not candidates for transplantation due to high efficacy and lower toxicity rates. Melphalan-based therapy (eg, MPT) is used more commonly in other developed countries.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP) is reserved for patients with contraindications to the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , or those who lack access to these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/5\">",
"     5",
"    </a>",
"    ]. Conditions that make a patient ineligible for thalidomide or lenalidomide therapy include pregnancy, women of childbearing age who are unable to receive adequate contraception, inability to comply with the \"System for Thalidomide Education and Prescribing Safety\" (STEPS) program in the United States,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    a baseline peripheral neuropathy. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Melphalan and prednisone'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5168553\">",
"    <span class=\"h2\">",
"     Lenalidomide plus low-dose dexamethasone (Rd)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (Rd) is an effective oral regimen for the initial therapy of MM. Data regarding its efficacy come from randomized trials comparing Rd with dexamethasone alone and comparing Rd with lenalidomide plus high dose dexamethasone. These trials are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    we recommend consists of lenalidomide 25 mg days 1 through 21 every 28 days with dexamethasone 40 orally once a week (",
"    <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"     table 2",
"    </a>",
"    ). Doses of both drugs are adjusted based on side effects. Therapy is continued for at least one year. Its use in patients with renal impairment and options for thromboembolism prophylaxis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H12#H12\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=see_link&amp;anchor=H32#H32\">",
"     \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\", section on 'Lenalidomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5168648\">",
"    <span class=\"h2\">",
"     Bortezomib, cyclophosphamide, dexamethasone (VCD)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VCD, also called CyBorD) is one of our preferred treatment options for patients with newly diagnosed multiple myeloma (",
"    <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"     table 3",
"    </a>",
"    ). Data regarding the use of VCD come from phase II trials that demonstrated high efficacy and moderate toxicity. Further details are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=see_link&amp;anchor=H4997358#H4997358\">",
"     \"Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation\", section on 'Bortezomib, cyclophosphamide, dexamethasone (VCd)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dosing schedule for VCD used in practice is a modification of that used in clinical trials in order to reduce neurotoxicity and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -related toxicity. We typically use a weekly dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    1.5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    and dexamethasone 40 mg (",
"    <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"     table 3",
"    </a>",
"    ). Treatments are repeated weekly or three weeks out of four as tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/3\">",
"     3",
"    </a>",
"    ]. The weekly schedule minimizes the risk of neuropathy. Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    VCD is administered with antiviral prophylaxis such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    400 mg twice daily throughout treatment. Some clinicians also administer prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    on Monday, Wednesday, and Friday of each week for prevention of Pneumocystis infection. For patients with moderate or severe impairment of hepatic function (serum bilirubin &ge;1.5 times the upper limit of normal), we initiate therapy with a reduced dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (0.7",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5168679\">",
"    <span class=\"h2\">",
"     Melphalan-based therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h3\">",
"     Melphalan, prednisone, and thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;A regimen consisting of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (MPT) is one of the preferred treatment options for initial therapy in patients with MM who are not candidates for HCT (",
"    <a class=\"graphic graphic_table graphicRef53179 \" href=\"UTD.htm?9/17/9502\">",
"     table 4",
"    </a>",
"    ). When compared with MP, MPT is associated with improved progression-free and overall survival, but results in greater toxicity. Studies of melphalan, prednisone, and the thalidomide derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (MPR) are also underway in patients who are not candidates for HCT. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Melphalan, prednisone, and lenalidomide'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    MPT has been compared with MP in several large randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/7-14\">",
"     7-14",
"    </a>",
"    ]. Two large meta-analyses based upon these trials confirmed an improvement in response rate with the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Furthermore, the addition of thalidomide to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    was associated with a significant improvement in progression-free (hazard ratio 0.68, 95% CI 0.56 to 0.81) and overall survival (hazard ratio 0.81; 95% CI 0.70 to 0.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some trials have suggested that the importance of adding",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    to initial therapy may vary depending upon the biology of the tumor. As an example, the total therapy 2 trial that involved a complex regimen of induction, transplant, consolidation, and maintenance with or without the incorporation of thalidomide, reported a distinct survival advantage with the addition of thalidomide for patients with abnormal cytogenetics [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/17\">",
"     17",
"    </a>",
"    ]. It is possible that the mixed results seen in the MP versus MPT trials may reflect a difference in tumor biology and responsiveness to thalidomide.",
"   </p>",
"   <p>",
"    Severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicities associated with MPT include neutropenia (23 to 48 percent), thrombosis or embolism (12 percent), constipation (10 percent), and",
"    <span class=\"nowrap\">",
"     somnolence/fatigue/dizziness",
"    </span>",
"    (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. MPT is also associated with high rates of all stages of peripheral neuropathy (39 percent) and depression (7 percent). Thromboprophylaxis is needed in patients receiving MPT. In one study, the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    40",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    SQ during the first four treatment cycles significantly reduced the rate of thromboembolism from 20 percent (prior to use of low molecular weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ) to 3 percent after its introduction [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/8,18\">",
"     8,18",
"    </a>",
"    ]. Thromboprophylaxis is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link&amp;anchor=H6#H6\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide plus melphalan and prednisone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based on the overall assessment of the data, MPT appears superior to MP, but further follow-up is needed to clarify sub-populations that derive the most benefit from this regimen. (See",
"    <a class=\"local\" href=\"#H8888482\">",
"     'Our preferred approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although it has been given at other doses and schedules, the MPT regimen we recommend is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    given orally for four days repeated every six weeks for a total of 12 cycles with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    100 to 200 mg daily during that time but not continued as maintenance (",
"    <a class=\"graphic graphic_table graphicRef53179 \" href=\"UTD.htm?9/17/9502\">",
"     table 4",
"    </a>",
"    ). We then adjust doses as necessary based upon developing toxicities. However, for older adults (age 75 and older) or those with comorbidities or frailty, initial dose reductions are suggested to minimize toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, when using MPT in older or frail patients, we lower the dose of melphalan to 0.2",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and use thalidomide at a dose not exceeding 100 mg per day [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/10\">",
"     10",
"    </a>",
"    ]. The MPT regimen requires routine thromboprophylaxis in all patients [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/20\">",
"     20",
"    </a>",
"    ]. Options for prophylaxis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link&amp;anchor=H6#H6\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide plus melphalan and prednisone'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    should be discontinued or dose reduced when paresthesias are accompanied by pain or motor deficit, or when they interfere with activities of daily living [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/21\">",
"     21",
"    </a>",
"    ]. The use of thalidomide is subject to the \"System for Thalidomide Education and Prescribing Safety\" (STEPS) program, which attempts to decrease the risk of severe, life-threatening birth defects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=see_link&amp;anchor=H6#H6\">",
"     \"Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues\", section on 'Thalidomide plus melphalan and prednisone'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Thalidomide'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Bortezomib, melphalan, and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (VMP) is an alternative to MPT in patients who are not candidates for transplantation. VMP is one of our preferred treatment regimens for patients with high risk MM. In the VISTA trial (described below), bortezomib was administered twice-weekly during the initial treatment period. However, there is similar efficacy with reduced risk of neuropathy when bortezomib was administered once weekly. Based on these results, the preferred dosing of bortezomib in the VMP regimen for initial therapy in patients ineligible for transplantation is now once weekly (",
"    <a class=\"graphic graphic_table graphicRef55107 \" href=\"UTD.htm?27/39/28286\">",
"     table 5",
"    </a>",
"    ). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A phase III randomized trial (VISTA) compared VMP with MP in the treatment of 682 older adults (median age 71 years) with newly diagnosed MM [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. After a median follow-up of 60 months, when compared with MP, VMP resulted in the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Superior median survival (56.4 versus 43.1 months; hazard ratio [HR] 0.695, 95% CI 0.567-0.852) and five-year survival rates (46 versus 34 percent).",
"     </li>",
"     <li>",
"      Longer median time to next therapy (30.7 versus 20.5 months; HR 0.557, 95% CI 0.462-0.671).",
"     </li>",
"     <li>",
"      Increased acute toxicity, including a higher percentage of patients with grade 3 toxicity (53 versus 44 percent). Side effects of VMP included peripheral sensory neuropathy, which was severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      in 13 percent of patients. After the completion of therapy, peripheral neuropathy improved in 79 percent within a median of 1.9 months and resolved completely in 60 percent within a median of 5.7 months.",
"     </li>",
"     <li>",
"      Similar cumulative incidences of hematologic malignancies (1 percent each) and solid tumors (5 versus 3 percent).",
"     </li>",
"     <li>",
"      The VMP regimen was active and well-tolerated in patients with mild or moderate renal impairment (ie, glomerular filtration rate [GFR] &lt;50",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/24\">",
"       24",
"      </a>",
"      ]. The benefits of VMP compared with MP were seen in patients with both normal and impaired renal function. Furthermore, reversal of renal impairment (ie, improvement in GFR from &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      to &gt;60",
"      <span class=\"nowrap\">",
"       mL/min)",
"      </span>",
"      was more frequent in patients treated with VMP compared with MP (49 of 111 [44 percent] versus 40 of 116 [34 percent]).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, the schedule and route of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (twice weekly intravenous infusion) used in the VISTA trial is associated with a high rate of neuropathy. The use of once weekly subcutaneous bortezomib appears to decrease the risk of neuropathy without compromising efficacy (",
"    <a class=\"graphic graphic_table graphicRef55107 \" href=\"UTD.htm?27/39/28286\">",
"     table 5",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no randomized trials comparing VMP with MPT, or VMP with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    plus low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . However, VMP has been compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (VTP), and with bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    , prednisone, thalidomide (VMPT). As such, the choice of initial therapy for patients with standard risk MM who are not eligible for transplantation depends on physician preference, risk of neuropathy, risk of thrombosis, and the patient&rsquo;s underlying renal function. (See",
"    <a class=\"local\" href=\"#H5168718\">",
"     'Bortezomib, thalidomide, and prednisone'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7\">",
"     'Bortezomib, melphalan, prednisone, and thalidomide'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H8888482\">",
"     'Our preferred approach'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Melphalan, prednisone, and lenalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    derivative",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (MPR) has been investigated in multicenter prospective studies, including one randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a phase III trial of 459 previously untreated patients aged 65 years and older, in which patients were randomly assigned",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP), melphalan, prednisone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    (MPR), or melphalan, prednisone, lenalidomide followed by lenalidomide maintenance (MPR-R) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/27\">",
"     27",
"    </a>",
"    ]. The addition of lenalidomide to induction therapy resulted in a higher percent of patients achieving a very good partial response or better (33 versus 12 percent). However, at a median follow-up of 30 months, MPR did not improve median progression-free survival compared with MP (14 versus 13 months, respectively) or overall survival at three years (62 versus 66 percent). The addition of lenalidomide was also associated with greater hematologic toxicity during induction. The effect of maintenance lenalidomide is discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Maintenance therapy'",
"    </a>",
"    below.) Therefore, MPR induction has not been shown to be superior to MP. We await the results of an ongoing randomized trial comparing MPR with MPT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bortezomib, melphalan, prednisone, and thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of a four-drug regimen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (VMPT), has been compared with the VMP combination. A prospective cooperative group trial of 511 patients older than 65 years with newly diagnosed MM randomly assigned therapy with VMPT or VMP [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. After nine cycles, the patients assigned to VMPT received maintenance therapy with bortezomib and thalidomide; those given VMP did not receive maintenance. After an early protocol amendment, bortezomib was given on a weekly schedule, rather than twice weekly, during all induction cycles on both treatment arms.",
"   </p>",
"   <p>",
"    The response rates for a partial response or better were significantly improved with VMPT compared with VMP (89 versus 81 percent), as was the three-year progression-free survival (56 versus 41 percent). There was no difference in the overall survival rate (89 and 87 percent, respectively). The value of the four-drug combination approach compared with a sequential approach of administering the agents needs further study in order to determine the clinical role of this strategy. A post-hoc analysis designed to assess the impact of the protocol amendment found that long-term efficacy did not appear to be affected by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    schedule, but that the once weekly dosing was associated with significantly less severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    peripheral neuropathy (8 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Melphalan and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     Melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP) has been a well-studied option for the treatment of MM. In general, the oral administration of melphalan and prednisone produces an objective response in 50 to 60 percent of patients and a median survival of two to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Melphalan, prednisone, and thalidomide'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    As previously mentioned, MPT or VMP are preferred to MP among non-transplant candidates. Among those unable to receive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (eg, those not able to tolerate thalidomide or those that lack access to the drug) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , we suggest MP rather than other combination chemotherapy regimens. This is principally based on the findings of a large meta-analysis of 6633 patients from 27 randomized trials that showed similar survival between MP and combination chemotherapy regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, compared with other combination regimens, MP can be given orally, is generally better tolerated, and has been successfully administered for years [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Combination chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We give",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    (0.15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by mouth [8 to 10",
"    <span class=\"nowrap\">",
"     mg]/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (20 mg by mouth three times daily) for seven days; this cycle is repeated every six weeks. Melphalan can also be administered in a dose of 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by mouth (9",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    per day with prednisone (20 mg by mouth three times daily) for four days every four to six weeks, depending upon hematologic tolerance.",
"   </p>",
"   <p>",
"    Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    must be given when the patient is fasting because food reduces its absorption. White cell and platelet counts should be measured every three weeks after beginning each cycle of therapy. The dose of melphalan should be adjusted until modest mid-cycle cytopenia occurs.",
"   </p>",
"   <p>",
"    In patients with a serum creatinine concentration above 2.0",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (177",
"    <span class=\"nowrap\">",
"     micromol/L),",
"    </span>",
"    the initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    should be reduced by 25 percent to prevent severe myelotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/33\">",
"     33",
"    </a>",
"    ]. If myelotoxicity does not occur, increased doses should be administered in the following courses.",
"   </p>",
"   <p>",
"    Unless the disease progresses, at least three courses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    should be given before it is discontinued for lack of effect. The natural course of multiple myeloma is one of progression and, if the patient's pain is alleviated and there is no evidence of progressive disease, the therapeutic regimen is considered beneficial despite the failure to reach an objective response. Furthermore, an objective response may not be achieved for 6 to 12 months or longer in some patients.",
"   </p>",
"   <p>",
"    The benefit of substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    has been explored in a number of randomized trials, all of which showed no advantage for the",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"      melphalan",
"     </a>",
"     /dexamethasone",
"    </span>",
"    combination [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5168718\">",
"    <span class=\"h2\">",
"     Bortezomib, thalidomide, and prednisone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective trial in 260 older adults with newly diagnosed MM randomly assigned treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    , plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (VTP) or VMP, each followed by bortezomib-containing maintenance therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/37\">",
"     37",
"    </a>",
"    ]. After a median follow-up of 32 months, VTP and VMP resulted in similar rates of complete plus near complete response (35 and 32 percent, respectively), median progression-free survival (25 versus 34 months, respectively) and three-year overall survival (65 and 74 percent, respectively). VTP resulted in fewer cases of severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia (22 versus 39 percent) and infections (1 versus 7 percent), but was associated with higher rates of cardiac complications (8 versus 0 percent) and peripheral neuropathy (9 versus 7 percent).",
"   </p>",
"   <p>",
"    In this trial,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    was given twice a week during the first six-week treatment cycle. Subsequently bortezomib was given once weekly rather than the usual twice weekly. This resulted in markedly lower rates of grade 3 or higher neuropathy without loss of efficacy. Based upon these results, a once weekly regimen of bortezomib should be considered a standard alternative to more intensive dosing in the treatment of myeloma. Bortezomib can be administered intravenously or subcutaneously (SC) and, in general, SC is preferred due to a lower risk of neuropathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link&amp;anchor=H18#H18\">",
"     \"Treatment of relapsed or refractory multiple myeloma\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the arrival of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    , many combinations of chemotherapeutic agents were tried. Examples include the M2 protocol (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/39/33399?source=see_link\">",
"     carmustine",
"    </a>",
"    (BCNU),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) and the ABCM regimen (adriamycin, BCNU, cyclophosphamide, and melphalan) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/5,38\">",
"     5,38",
"    </a>",
"    ]. Despite response rates as high as 70 percent, the value of these regimens remains controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/30,39-42\">",
"     30,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis, based upon data from 4930 patients in 20 trials comparing MP with combination chemotherapy (CCT), was performed in 1998 by the Myeloma Trialists' Collaborative Group [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/31\">",
"     31",
"    </a>",
"    ]. Using individual patient data, there was no survival benefit for CCT over MP. The meta-analysis failed to find any category of patients in which CCT had a significantly different mortality rate from that of MP. Specifically, there was no evidence that poor risk patients did better with CCP than with MP, which had been suggested in a prior meta-analysis with fewer trials [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MONITORING DISEASE RESPONSE TO THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be evaluated before each treatment cycle to determine how their disease is responding to therapy. The preferred method is the measurement of monoclonal (M) protein in serum or urine. Free light chain (FLC) measurements are reserved for patients with unmeasurable protein in the serum and urine.",
"   </p>",
"   <p>",
"    Among patients without an M protein in serum or urine and normal FLC ratio, further evaluation includes bone marrow immunohistochemistry or immunofluorescence and plasma cell labeling index. Details on how to determine response to therapy are presented elsewhere (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=see_link\">",
"     \"Evaluating response to treatment of multiple myeloma\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The principal reasons to monitor disease response are to identify when patients enter a plateau phase, experience a relapse, or have resistant disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chemotherapy is usually stopped when patients enter the plateau phase. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Salvage regimens with other chemotherapeutic agents are administered to patients with relapsed or resistant disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=see_link\">",
"       \"Treatment of relapsed or refractory multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately 7 percent of patients will develop a secondary monoclonal gammopathy of undetermined significance (MGUS) defined as a new monoclonal protein that has an isotype (heavy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    light chain) distinct from the original clone (eg, IgM MGUS in a patient with IgG multiple myeloma). This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=see_link&amp;anchor=H62135187#H62135187\">",
"     \"Diagnosis of monoclonal gammopathy of undetermined significance\", section on 'Secondary MGUS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Significance of response to chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relationship between survival and the degree of response (complete versus partial) to initial therapy is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/44\">",
"     44",
"    </a>",
"    ]. Early trials have reported similar survival duration in patients with myeloma who have achieved disease stabilization (either with complete or partial response) following conventional",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    -containing regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/45-48\">",
"     45-48",
"    </a>",
"    ]. However, patients without any objective evidence of response have a relatively poor prognosis. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One series of 243 patients showed that the median survival was similar (42 to 43 months) in patients achieving an objective response, partial response, or complete remission, as well as those with a rapid tumor response [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/45\">",
"       45",
"      </a>",
"      ]; by comparison, the median survival was only 19 months in nonresponders.",
"     </li>",
"     <li>",
"      A retrospective analysis of 1555 patients treated in four SWOG chemotherapy trials confirmed the lack of prognostic significance of the initial response of the monoclonal protein as a predictor of overall or event-free survival [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/49\">",
"       49",
"      </a>",
"      ]. For patients evaluated at either the 6 or 12 month landmark period who had not yet developed disease progression, overall survival was similar (30 to 35 months) in those with &lt;50, 50 to 75, or &gt;75 percent reduction in the calculated tumor mass.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The inability to attain a stringently-defined complete response with conventional regimens may explain these observations, as subsequent studies with intensive chemotherapy have found significantly improved survival in those with such responses [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/50-54\">",
"     50-54",
"    </a>",
"    ]. This was best shown in an ECOG study of 653 previously untreated patients who received treatment with VBMCP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , BCNU,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) alone, or with interferon alfa-2 or high-dose cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/51\">",
"     51",
"    </a>",
"    ]. Overall and complete responses were seen in 67 and 14 percent, respectively. Median durations of post-response survival were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Complete remission, no clonal plasma cells noted &mdash; 6.6 years",
"     </li>",
"     <li>",
"      Complete remission, clonal plasma cells present &mdash; 4.4 years",
"     </li>",
"     <li>",
"      Partial response &mdash; 3.3 years",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Both duration of response and post-response survival were superior among patients achieving CR (absence of monoclonal protein in serum and urine by immunofixation, when compared with those not achieving this status). Although no patient achieved molecular CR (ie, polymerase chain reaction negative status), those whose plasma cells were not clonal on plasma cell labeling studies achieved the best overall survival. Current response criteria can identify patients with no clonal plasma cells present as having a stringent complete response.",
"   </p>",
"   <p>",
"    A survival benefit from attaining negative serum and urine immunofixation was also demonstrated in a retrospective study of 1175 patients with multiple myeloma initially treated on prospective trials with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (MP); melphalan, prednisone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (MPT); melphalan, prednisone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    (VMP); or melphalan, prednisone, bortezomib, thalidomide (VMPT) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/54\">",
"     54",
"    </a>",
"    ]. When compared with those who achieved a very good partial response (VGPR), patients who achieved a CR had significantly higher rates of progression-free (67 versus 27 percent) and overall (91 versus 70 percent) survival at three years. In comparison, patients who achieved a partial response had rates of progression-free and overall survival at three years of 27 and 67 percent, respectively.",
"   </p>",
"   <p>",
"    However, one must be careful when interpreting studies that show improved outcome in responders versus nonresponders (eg, CR versus no CR) since such comparisons have inherent methodologic flaws that cannot be overcome by increasing the sample size. In general, whether a treatment works or not, &ldquo;responders&rdquo; will typically appear to do better than &ldquo;nonresponders&rdquo; [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/55\">",
"     55",
"    </a>",
"    ]. One way of overcoming the bias that exists when comparing responders with nonresponders is to perform landmark analysis at time points that ensure that almost all patients have had time to reach the response level being studied. In studies that employed such landmark analysis (at 12, 18, and 24 months), complete response appeared to improve survival only in the subset of approximately 15 percent of myeloma patients with high risk disease, while in the remaining 85 percent overall survival was similar regardless of whether complete response was achieved or not [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all studies of novel agents have demonstrated a survival benefit with CR. As an example, an unplanned analysis examined the effect of response in the VISTA trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    as front-line therapy for myeloma in patients who are not candidates for transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/53\">",
"     53",
"    </a>",
"    ]. When compared with those who achieved a partial response, patients who achieved a CR had superior time to progression (hazard ratio 0.50), time to next therapy (hazard ratio 0.58), and treatment-free interval (0.50). However, there was no improvement in overall survival for patients who achieved a CR versus those who achieved a PR (hazard ratio 0.89).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Time to disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;More significant than the initial response to treatment is the time to disease progression. In a retrospective analysis of 1555 patients treated in four SWOG chemotherapy trials, overall survival for patients who experienced disease progression at 6 or 12 months was markedly shortened (13 to 15 months) [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/49\">",
"     49",
"    </a>",
"    ]. It was concluded that survival duration was influenced more by the occurrence of progression than by the occurrence of response and that the best indicator of survival was time to first progression. On multivariate analysis, correlates of time to first progression included the following initial patient characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;150,000/microL",
"      </span>",
"     </li>",
"     <li>",
"      Albumin &lt;3",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Age &gt;65 years",
"     </li>",
"     <li>",
"      Beta-2-microglobulin &gt;4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Involvement of more than 3 bones",
"     </li>",
"     <li>",
"      Hemoglobin &lt;10",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many of these characteristics had previously been identified as poor prognostic features. Single or tandem hematopoietic cell transplantation may be a better option than chemotherapy in such patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H36#H36\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MAINTENANCE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial chemotherapy is continued until the patient reaches a plateau phase, which is defined as a stable level of M-protein in the serum and urine and no evidence of progression of myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/57\">",
"     57",
"    </a>",
"    ]. Since all patients eventually develop relapsed disease, trials have investigated the use of chemotherapeutic and biologic agents in an attempt to eliminate residual malignant cells. Until further data in support of maintenance therapy are reported, we suggest observation after the attainment of a plateau phase with treatment at the time of progression rather than the use of maintenance therapy. The use of maintenance therapy following hematopoietic cell transplantation is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H13#H13\">",
"     \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Maintenance'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of maintenance therapy is an area of controversy. The following sections illustrate the potential benefits and harms associated with different maintenance options:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       Lenalidomide",
"      </a>",
"      &mdash; Trials in MM suggest that maintenance lenalidomide prolongs progression-free survival (PFS), but is also associated with substantial rates of severe neutropenia and perhaps second primary cancers. Longer follow-up is needed to evaluate overall survival and long-term toxicities. Most studies of lenalidomide maintenance were performed in patients who underwent HCT. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H13#H13\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Maintenance'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      A double-blind, multicenter, phase III trial of 459 older adults with previously untreated MM who were not candidates for HCT randomly assigned therapy to one of three combinations:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , plus lenalidomide induction followed by lenalidomide maintenance (MPR-R); melphalan, prednisone, plus lenalidomide induction followed by placebo (MPR); or melphalan plus prednisone induction followed by placebo (MP) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/27\">",
"       27",
"      </a>",
"      ]. At a median follow-up of 30 months, MPR-R resulted in a longer median PFS when compared with MPR and MP (31 versus 14 and 13 months, respectively). However, there was no difference in rates of overall survival at three years (70, 62, and 66 percent, respectively). Lenalidomide maintenance was discontinued in 8 percent due to adverse events.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       Thalidomide",
"      </a>",
"      &mdash; Trials in patients with MM have demonstrated that thalidomide maintenance prolongs PFS and may improve overall survival, but is also associated with a significant increase in long-term toxicities, including peripheral neuropathy and thromboembolism [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/58\">",
"       58",
"      </a>",
"      ]. At this time, it is not clear whether routine thalidomide maintenance offers adequate clinical benefit to overcome these toxicities. Most studies of thalidomide maintenance were performed in patients who underwent HCT. In patients who are not candidates for HCT, two studies discussed below have shown some benefit. In addition, other reports have suggested that the thalidomide plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      <span class=\"nowrap\">",
"       (thal/dex)",
"      </span>",
"      regimen may be associated with excess toxicity in older patient populations [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/59\">",
"       59",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=see_link&amp;anchor=H13#H13\">",
"       \"Autologous hematopoietic cell transplantation in multiple myeloma\", section on 'Maintenance'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H3\">",
"       'Melphalan, prednisone, and thalidomide'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A prospective trial in 103 patients with de novo (older adults) or relapsing MM randomly assigned maintenance therapy with either thalidomide plus dexamethasone",
"      <span class=\"nowrap\">",
"       (thal/dex)",
"      </span>",
"      versus interferon plus dexamethasone after initial treatment with thalidomide, dexamethasone, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/13/10458?source=see_link\">",
"       pegylated liposomal doxorubicin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/60\">",
"       60",
"      </a>",
"      ]. Patients assigned to",
"      <span class=\"nowrap\">",
"       thal/dex",
"      </span>",
"      had significantly better rates of PFS (63 versus 32 percent) and overall survival (84 versus 68 percent) at two years when compared with those assigned to interferon plus dexamethasone. Common, mostly mild, adverse events seen with",
"      <span class=\"nowrap\">",
"       thal/dex",
"      </span>",
"      included constipation (52 percent), peripheral neuropathy (31 percent), fatigue (27 percent), and anorexia (19 percent). This study used initial therapy that was not standard for patients who are not candidates for HCT and needs further confirmation.",
"      <br/>",
"      <br/>",
"      In a Spanish trial, 178 older adults with previously untreated MM who had completed induction therapy with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen were randomly assigned maintenance with bortezomib plus thalidomide (VT) or bortezomib plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (VP) [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/61\">",
"       61",
"      </a>",
"      ]. The complete response rate increased from 24 percent following induction to 46 and 39 percent following VT and VP, respectively. When compared with VP, VT resulted in a longer median PFS (39 versus 32 months). Rates of overall survival at five years were 69 and 50 percent, a difference that did not reach statistical significance. Severe (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      peripheral neuropathy was more common following VT maintenance (9 versus 3 percent). Since the trial did not have a control arm without maintenance, and there were differences in induction regimens between the two arms, it is difficult to interpret the role of maintenance from this trial.",
"     </li>",
"     <li>",
"      <strong>",
"       Interferon",
"      </strong>",
"      &mdash; Most randomized trials of interferon demonstrate an improvement in progression-free survival but minimal, if any, benefit in overall survival [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/62,63\">",
"       62,63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Corticosteroids",
"      </strong>",
"      &mdash; Corticosteroids can prolong the duration of response but their effect on survival is unclear [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/36,64\">",
"       36,64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Chemotherapy",
"      </strong>",
"      &mdash; Continuing chemotherapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (MP) after the attainment of a plateau state is associated with increased toxicity and no improvement in survival. This was best demonstrated in a trial of 185 patients in plateau phase who were randomly assigned to continued MP therapy until relapse or to stop treatment and resume therapy at the time of relapse [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/65\">",
"       65",
"      </a>",
"      ]. Maintenance was associated with toxicity (eg, myelosuppression) and no improvement in median survival. In addition, continued chemotherapy with alkylating agents may lead to a greater number of myeloma cells becoming resistant to chemotherapy or to the development of myelodysplasia or acute leukemia [",
"      <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/30,60,66\">",
"       30,60,66",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Together, these trials suggest that maintenance therapy prolongs PFS, but data are limited to determine if there is meaningful improvement in OS. Of the available options,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    appears to be associated with the lowest rate of severe side effects. However, the benefits of improved PFS must be balanced against the lack of improvement in OS [",
"    <a class=\"abstract\" href=\"UTD.htm?28/1/28698/abstract/27\">",
"     27",
"    </a>",
"    ], increased rate of severe (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia, risk of second cancers and other toxicities, the cost, and the possibility that the PFS advantage may be neutralized by the use of lenalidomide at time of first relapse in the observation arm. Given these uncertainties, we suggest observation with retreatment at the time of progression rather than the use of maintenance therapy. If clinical circumstances dictate the use of lenalidomide to treat residual disease (such treatment is typically not considered maintenance), then the risk of second cancers must be discussed with the patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=see_link\">",
"       \"Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=see_link\">",
"       \"Patient information: Multiple myeloma treatment (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior to initiating treatment, patients with multiple myeloma (MM) should be distinguished from patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) who do not need therapy (",
"      <a class=\"graphic graphic_table graphicRef57627 \" href=\"UTD.htm?41/38/42603\">",
"       table 6",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H4#H4\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Multiple myeloma'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H25#H25\">",
"       \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Diagnosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with MM are stratified based upon cytogenetic findings at the time of diagnosis into three main risk categories (standard risk, intermediate risk, and high risk) (",
"      <a class=\"graphic graphic_table graphicRef78344 \" href=\"UTD.htm?24/32/25099\">",
"       table 1",
"      </a>",
"      ). This risk stratification has considerable prognostic value and also helps guide the selection of initial therapy (",
"      <a class=\"graphic graphic_algorithm graphicRef79012 \" href=\"UTD.htm?24/59/25534\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The choice of initial chemotherapy for patients with MM depends greatly on whether or not the patient is felt to be a candidate for hematopoietic cell transplantation (HCT). The principal characteristics that determine eligibility for HCT are age, performance status,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the presence and severity of certain comorbid conditions. This is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"       \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For standard risk patients who are not candidates for HCT, reasonable options for initial treatment include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      plus low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (Rd) (",
"      <a class=\"graphic graphic_table graphicRef56451 \" href=\"UTD.htm?25/61/26589\">",
"       table 2",
"      </a>",
"      );",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and dexamethasone (VCd) (",
"      <a class=\"graphic graphic_table graphicRef50061 \" href=\"UTD.htm?32/43/33470\">",
"       table 3",
"      </a>",
"      ); or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      (MPT) (",
"      <a class=\"graphic graphic_table graphicRef53179 \" href=\"UTD.htm?9/17/9502\">",
"       table 4",
"      </a>",
"      ). The choice among these should take into consideration physician preference, risk of neuropathy, risk of thrombosis, and the patient&rsquo;s underlying renal function. For most patients, we suggest the use of Rd rather than VCd or MPT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This preference places a high value on the relatively low toxicity of this regimen.",
"     </li>",
"     <li>",
"      Among patients with intermediate risk MM who are not candidates for autologous HCT, we recommend the use of a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      containing regimen (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Of these, we usually administer bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (VMP). Bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      would be an acceptable alternative. (See",
"      <a class=\"local\" href=\"#H8888482\">",
"       'Our preferred approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For high risk patients who are not candidates for HCT, we suggest initial treatment with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -containing regimen, such as bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VRd) or bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , dexamethasone (VCd). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link\">",
"       \"Initial chemotherapy for patients with high risk multiple myeloma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Among non-transplant candidates with contraindications to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      or who lack access to these drugs, we suggest administering",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (MP) rather than combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Melphalan and prednisone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Initial chemotherapy should be continued until the patient reaches a plateau phase, which is defined as a stable M-protein in the serum and urine and no evidence of progression of MM. For most patients, we suggest observation with treatment at the time of progression rather than the use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"       lenalidomide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      maintenance therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Maintenance therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/1\">",
"      Osgood EE. The survival time of patients with plasmocytic myeloma. Cancer Chemother Rep 1960; 9:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/2\">",
"      Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208:1680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/3\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/4\">",
"      Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/5\">",
"      MacLennan IC, Chapman C, Dunn J, Kelly K. Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults. Lancet 1992; 339:200.",
"     </a>",
"    </li>",
"    <li>",
"     United States Food and Drug Administration file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm198424.htm (Accessed on February 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/7\">",
"      Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma. Cancer 2005; 104:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/8\">",
"      Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/9\">",
"      Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007; 370:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/10\">",
"      Hulin C, Facon T, Rodon P, et al. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial. J Clin Oncol 2009; 27:3664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/11\">",
"      Waage A, Gimsing P, Fayers P, et al. Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 2010; 116:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/12\">",
"      Gulbrandsen N, Waage A, Gimsing P, et al. A randomized placebo controlled study with melphalan/prednisone/thalidomide: quality of life and toxicity (abstract). Haematologica 2008; 93:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/13\">",
"      Wijermans P, Schaafsma M, Termorshuizen F, et al. Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 Study. J Clin Oncol 2010; 28:3160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/14\">",
"      Beksac M, Haznedar R, Firatli-Tuglular T, et al. Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group. Eur J Haematol 2011; 86:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/15\">",
"      Kapoor P, Rajkumar SV, Dispenzieri A, et al. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia 2011; 25:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/16\">",
"      Fayers PM, Palumbo A, Hulin C, et al. Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 2011; 118:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/17\">",
"      Barlogie B, Pineda-Roman M, van Rhee F, et al. Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 2008; 112:3115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/18\">",
"      Palumbo A, Bringhen S, Liberati AM, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood 2008; 112:3107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/19\">",
"      Palumbo A, Bringhen S, Ludwig H, et al. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN). Blood 2011; 118:4519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/20\">",
"      Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008; 22:414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/21\">",
"      Palumbo A, Facon T, Sonneveld P, et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 2008; 111:3968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/22\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/23\">",
"      Mateos MV, Richardson PG, Schlag R, et al. Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 2010; 28:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/24\">",
"      Dimopoulos MA, Richardson PG, Schlag R, et al. VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27:6086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/25\">",
"      San Miguel JF, Schlag R, Khuageva NK, et al. Persistent overall survival benefit and no increased risk of second malignancies with bortezomib-melphalan-prednisone versus melphalan-prednisone in patients with previously untreated multiple myeloma. J Clin Oncol 2013; 31:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/26\">",
"      Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. J Clin Oncol 2007; 25:4459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/27\">",
"      Palumbo A, Hajek R, Delforge M, et al. Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 2012; 366:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/28\">",
"      Palumbo A, Bringhen S, Rossi D, et al. Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. J Clin Oncol 2010; 28:5101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/29\">",
"      Bringhen S, Larocca A, Rossi D, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116:4745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/30\">",
"      Oken MM, Harrington DP, Abramson N, et al. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479. Cancer 1997; 79:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/31\">",
"      Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol 1998; 16:3832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/32\">",
"      Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/33\">",
"      Carlson K, Hjorth M, Knudsen LM, Nordic Myeloma Study Group. Toxicity in standard melphalan-prednisone therapy among myeloma patients with renal failure--a retrospective analysis and recommendations for dose adjustment. Br J Haematol 2005; 128:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/34\">",
"      Hern&aacute;ndez JM, Garc&iacute;a-Sanz R, Golvano E, et al. Randomized comparison of dexamethasone combined with melphalan versus melphalan with prednisone in the treatment of elderly patients with multiple myeloma. Br J Haematol 2004; 127:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/35\">",
"      Facon T, Mary JY, P&eacute;gourie B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood 2006; 107:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/36\">",
"      Shustik C, Belch A, Robinson S, et al. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol 2007; 136:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/37\">",
"      Mateos MV, Oriol A, Mart&iacute;nez-L&oacute;pez J, et al. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial. Lancet Oncol 2010; 11:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/38\">",
"      Case DC Jr, Lee DJ 3rd, Clarkson BD. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol. Am J Med 1977; 63:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/39\">",
"      Boccadoro M, Marmont F, Tribalto M, et al. Multiple myeloma: VMCP/VBAP alternating combination chemotherapy is not superior to melphalan and prednisone even in high-risk patients. J Clin Oncol 1991; 9:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/40\">",
"      Blad&eacute; J, San Miguel JF, Alcal&aacute; A, et al. Alternating combination VCMP/VBAP chemotherapy versus melphalan/prednisone in the treatment of multiple myeloma: a randomized multicentric study of 487 patients. J Clin Oncol 1993; 11:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/41\">",
"      Crowley J, Jacobson J, Alexanian R. Standard-dose therapy for multiple myeloma: The Southwest Oncology Group experience. Semin Hematol 2001; 38:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/42\">",
"      Kyle RA, Jacobus S, Friedenberg WR, et al. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase III Eastern Cooperative Oncology Group Study E5A93. Cancer 2009; 115:2155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/43\">",
"      Gregory WM, Richards MA, Malpas JS. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 1992; 10:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/44\">",
"      Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28:2612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/45\">",
"      Blad&eacute; J, L&oacute;pez-Guillermo A, Bosch F, et al. Impact of response to treatment on survival in multiple myeloma: results in a series of 243 patients. Br J Haematol 1994; 88:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/46\">",
"      Riccardi A, Mora O, Tinelli C, et al. Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocol. Eur J Cancer 2003; 39:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/47\">",
"      Oivanen TM, Kellokumpu-Lehtinen P, Koivisto AM, et al. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study. Eur J Haematol 1999; 62:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/48\">",
"      Dingli D, Pacheco JM, Nowakowski GS, et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25:4933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/49\">",
"      Durie BG, Jacobson J, Barlogie B, Crowley J. Magnitude of response with myeloma frontline therapy does not predict outcome: importance of time to progression in southwest oncology group chemotherapy trials. J Clin Oncol 2004; 22:1857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/50\">",
"      Alexanian R, Weber D, Giralt S, et al. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma. Bone Marrow Transplant 2001; 27:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/51\">",
"      Kyle RA, Leong T, Li S, et al. Complete response in multiple myeloma: clinical trial E9486, an Eastern Cooperative Oncology Group study not involving stem cell transplantation. Cancer 2006; 106:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/52\">",
"      Lahuerta JJ, Mateos MV, Mart&iacute;nez-L&oacute;pez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26:5775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/53\">",
"      Harousseau JL, Palumbo A, Richardson PG, et al. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood 2010; 116:3743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/54\">",
"      Gay F, Larocca A, Wijermans P, et al. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 2011; 117:3025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/55\">",
"      Tannock I, Murphy K. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results. J Clin Oncol 1983; 1:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/56\">",
"      Haessler J, Shaughnessy JD Jr, Zhan F, et al. Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007; 13:7073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/57\">",
"      UK myeloma forum. British Committee for Standards in Haematology. Diagnosis and management of multiple myeloma. Br J Haematol 2001; 115:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/58\">",
"      Ludwig H, Durie BG, McCarthy P, et al. IMWG consensus on maintenance therapy in multiple myeloma. Blood 2012; 119:3003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/59\">",
"      Ludwig H, Hajek R, T&oacute;thov&aacute; E, et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009; 113:3435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/60\">",
"      Offidani M, Corvatta L, Polloni C, et al. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study. Br J Haematol 2009; 144:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/61\">",
"      Mateos MV, Oriol A, Mart&iacute;nez-L&oacute;pez J, et al. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial. Blood 2012; 120:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/62\">",
"      Myeloma Trialists' Collaborative Group. Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 2001; 113:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/63\">",
"      Fritz E, Ludwig H. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. Ann Oncol 2000; 11:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/64\">",
"      Berenson JR, Crowley JJ, Grogan TM, et al. Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 2002; 99:3163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/65\">",
"      Belch A, Shelley W, Bergsagel D, et al. A randomized trial of maintenance versus no maintenance melphalan and prednisone in responding multiple myeloma patients. Br J Cancer 1988; 57:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?28/1/28698/abstract/66\">",
"      Govindarajan R, Jagannath S, Flick JT, et al. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996; 95:349.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6650 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-202.43.93.2-77D3A94D3A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28698=[""].join("\n");
var outline_f28_1_28698=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHOICE OF REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8888482\">",
"      Our preferred approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5168553\">",
"      Lenalidomide plus low-dose dexamethasone (Rd)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5168648\">",
"      Bortezomib, cyclophosphamide, dexamethasone (VCD)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5168679\">",
"      Melphalan-based therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      - Melphalan, prednisone, and thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Bortezomib, melphalan, and prednisone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Melphalan, prednisone, and lenalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bortezomib, melphalan, prednisone, and thalidomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Melphalan and prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5168718\">",
"      Bortezomib, thalidomide, and prednisone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MONITORING DISEASE RESPONSE TO THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Significance of response to chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Time to disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MAINTENANCE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6650\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6650|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?24/59/25534\" title=\"algorithm 1\">",
"      Therapy approach MM II",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6650|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/32/25099\" title=\"table 1\">",
"      Risk stratification of myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/61/26589\" title=\"table 2\">",
"      Rd for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/43/33470\" title=\"table 3\">",
"      VCd CyBorD for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/17/9502\" title=\"table 4\">",
"      MPT for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/39/28286\" title=\"table 5\">",
"      VMP for multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/38/42603\" title=\"table 6\">",
"      Diagnostic criteria for myeloma MGUS and SMM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/47/31482?source=related_link\">",
"      Autologous hematopoietic cell transplantation in multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41738?source=related_link\">",
"      Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15290?source=related_link\">",
"      Diagnosis of monoclonal gammopathy of undetermined significance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31526?source=related_link\">",
"      Evaluating response to treatment of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/54/18282?source=related_link\">",
"      Initial chemotherapy for symptomatic multiple myeloma in patients who are candidates for transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?12/16/12547?source=related_link\">",
"      Patient information: Multiple myeloma symptoms, diagnosis, and staging (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/40/31366?source=related_link\">",
"      Patient information: Multiple myeloma treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/57/29594?source=related_link\">",
"      Thrombotic complications following treatment of multiple myeloma with thalidomide and its analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/15/37114?source=related_link\">",
"      Treatment of relapsed or refractory multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/13/23769?source=related_link\">",
"      Treatment of the complications of multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f28_1_28699="Stages of ABPA";
var content_f28_1_28699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76368&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Stages of allergic bronchopulmonary aspergillosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Classification",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"       <td class=\"subtitle1\">",
"        Radiographic infiltrates",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total serum IgE",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        Acute",
"       </td>",
"       <td>",
"        Upper lobes or middle lobe",
"       </td>",
"       <td>",
"        Markedly elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        II",
"       </td>",
"       <td>",
"        Remission",
"       </td>",
"       <td>",
"        No infiltrate; off prednisone &gt;6 mo",
"       </td>",
"       <td>",
"        Elevated or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        III",
"       </td>",
"       <td>",
"        Exacerbation",
"       </td>",
"       <td>",
"        Upper lobes or middle lobe",
"       </td>",
"       <td>",
"        Markedly elevated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV",
"       </td>",
"       <td>",
"        Corticosteroid-dependent asthma",
"       </td>",
"       <td>",
"        Infiltrates absent or only intermittent",
"       </td>",
"       <td>",
"        Elevated or normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        V",
"       </td>",
"       <td>",
"        End stage",
"       </td>",
"       <td>",
"        Fibrotic, bullous or cavitary lesions",
"       </td>",
"       <td>",
"        May be normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Patterson, R, Greenberger, PA, Radin, RC, Roberts, M. Allergic Bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med 1982;96 286.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28699=[""].join("\n");
var outline_f28_1_28699=null;
var title_f28_1_28700="Diagnosis criteria pericarditis";
var content_f28_1_28700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F74376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F74376&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Diagnostic criteria for acute pericarditis and myopericarditis in the clinical setting",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Acute pericarditis (at least 2 criteria of 4 should be present)*:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Typical chest pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Pericardial friction rub",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Suggestive ECG changes (typically widespread ST segment elevation)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. New or worsening pericardial effusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Myopericarditis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1. Definite diagnosis of acute pericarditis,",
"        <strong>",
"         PLUS",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2. Suggestive symptoms (dyspnea, palpitations, or chest pain) and ECG abnormalities beyond normal variants, not documented previously (ST/T abnormalities, supraventricular or ventricular tachycardia or frequent ectopy, atrioventricular block),",
"        <strong>",
"         OR",
"        </strong>",
"        focal or diffuse depressed LV function of uncertain age by an imaging study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3. Absence of evidence of any other cause",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4. One of the following features: evidence of elevated cardiac enzymes (creatine kinase-MB fraction, or troponin I or T),",
"        <strong>",
"         OR",
"        </strong>",
"        new onset of focal or diffuse depressed LV function by an imaging study,",
"        <strong>",
"         OR",
"        </strong>",
"        abnormal imaging consistent with myocarditis (MRI with gadolinium, gallium-67 scanning, anti-myosin antibody scanning)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Case definitions for myopericarditis include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Suspected myopericarditis:",
"        </strong>",
"        criteria 1 plus 2 and 3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Probable myopericarditis:",
"        </strong>",
"        criteria 1, 2, 3, and 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         Confirmed myopericarditis",
"         <sup>",
"          &bull;",
"         </sup>",
"         :",
"        </strong>",
"        histopathologic evidence of myocarditis by endomyocardial biopsy or on autopsy",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pericardial effusion confirms the clinical diagnosis but its absence does not exclude it.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      In clinical practice a confirmed diagnosis would require an endomyocardial biopsy that is not warranted in self-limited cases with predominant pericarditis.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Imazio M, Trinchero R. Triage and management of acute pericarditis. Int J Cardiol 2006, doi:10.1016/j.ijcard.2006.07.100. Copyright &copy; 2006 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28700=[""].join("\n");
var outline_f28_1_28700=null;
var title_f28_1_28701="Types of lipid altering drugs";
var content_f28_1_28701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77498&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Adult dosing, side effects, and drug interactions of lipid lowering drugs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosing",
"       </td>",
"       <td class=\"subtitle1\">",
"        Major side effects and drug interactions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Statins (HMG CoA reductase inhibitors)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lovastatin",
"       </td>",
"       <td>",
"        20-80 mg/day",
"       </td>",
"       <td>",
"        IR take with evening meal. BID with meals&nbsp;if dose &gt;20 mg/day. XR take any time.",
"       </td>",
"       <td rowspan=\"8\">",
"        Headache; nausea; sleep disturbance; elevations in hepatocellular enzymes and alkaline phosphatase. Myositis and rhabdomyolysis, primarily when given with gemfibrozil or cyclosporine; myositis is also seen with severe renal insufficiency (CrCl &lt;30 mL/min). Lovastatin, atorvastatin, rosuvastatin, and simvastatin potentiate effect of warfarin; this interaction is not seen with pravastatin, fluvastatin, or pitavastatin. Most statins can also affect digoxin metabolism and levels.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pravastatin",
"       </td>",
"       <td>",
"        10-80 mg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Simvastatin",
"       </td>",
"       <td>",
"        5-40 mg/day",
"       </td>",
"       <td>",
"        Take in the evening",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Fluvastatin",
"       </td>",
"       <td>",
"        20-80 mg/day",
"       </td>",
"       <td rowspan=\"2\">",
"        IR take in the evening; if dose &gt;40 mg/day take morning and evening. XR take any time.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        80 mg XR/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atorvastatin",
"       </td>",
"       <td>",
"        10-80 mg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rosuvastatin",
"       </td>",
"       <td>",
"        5-40 mg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pitavastatin",
"       </td>",
"       <td>",
"        1-4 mg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Gemfibrozil",
"        </strong>",
"       </td>",
"       <td>",
"        600 mg BID",
"       </td>",
"       <td>",
"        30 to 60 min before meals",
"       </td>",
"       <td>",
"        Potentiates warfarin action. Absorption of gemfibrozil diminished by bile acid sequestrants.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Fenofibrate",
"        </strong>",
"       </td>",
"       <td>",
"        <p>",
"         Nanocrystal 145 mg/day",
"        </p>",
"        <p>",
"         Micronized 160-200 mg/day",
"        </p>",
"       </td>",
"       <td>",
"        Micronized taken with meals. Use lower doses with renal insufficiency.",
"       </td>",
"       <td>",
"        Skin rash, gastrointestinal (nausea, bloating, cramping) myalgia; lowers blood cyclosporine levels; potentially nephrotoxic in cyclosporine treated patients. Avoid in patients with CrCl &lt;30 mL/min.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Nicotinic acid",
"        </strong>",
"       </td>",
"       <td>",
"        1-12 g/day",
"       </td>",
"       <td>",
"        Given with meals. Start with 100 mg BID and titrate to 500 mg TID. After&nbsp;six weeks, check lipids, glucose, liver function, and uric acid. Increase dose as needed.",
"       </td>",
"       <td>",
"        Prostaglandin-mediated cutaneous flushing, headache, warm sensation, and pruritus; hyperpigmentation (particularly in intertriginous regions); acanthosis nigricans; dry skin; nausea; vomiting; diarrhea; and myositis",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Bile acid sequestrants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholestyramine",
"       </td>",
"       <td>",
"        4-24 g/day",
"       </td>",
"       <td rowspan=\"2\">",
"        Take within 30 min of a meal. A double dose with dinner produces same lipid-lowering effect as BID dosing.",
"       </td>",
"       <td rowspan=\"2\">",
"        Nausea, bloating, cramping, and constipation; elevations in hepatic transaminases and alkaline phosphatase. Impaired absorption of fat soluble vitamins, digoxin, warfarin, thiazides, &beta;-blockers, thyroxine, and phenobarbital.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colestipol",
"       </td>",
"       <td>",
"        5-30 g/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Colesevelam",
"       </td>",
"       <td>",
"        3.75 g/day",
"       </td>",
"       <td>",
"        Take with meals QD or divided BID",
"       </td>",
"       <td>",
"        Similar",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cholesterol absorption inhibitors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ezetimibe",
"       </td>",
"       <td>",
"        10 mg/day",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Increased transaminases in combination with statins",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Neomycin",
"        </strong>",
"       </td>",
"       <td>",
"        1 g BID",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Ototoxicity; nephrotoxicity",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Probucol",
"        </strong>",
"       </td>",
"       <td>",
"        500 mg BID",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Loose stools; eosinophilia; QT prolongation; angioneurotic edema",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BID: twice daily; QD: daily; TID: three times daily; IR: immediate release; XR: extended release; CrCl: creatinine clearance.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28701=[""].join("\n");
var outline_f28_1_28701=null;
var title_f28_1_28702="Valve surgery nonischemic MR";
var content_f28_1_28702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F51845%7ECARD%2F71650%7ECARD%2F86954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F51845%7ECARD%2F71650%7ECARD%2F86954&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in patients with nonischemic mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement mitral valve surgery is indicated in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Symptomatic severe acute MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Severe symptomatic chronic MR (NYHA class II-IV) in the absence of severe left ventricular dysfunction (left ventricular ejection fraction [LVEF] less than 30 percent or end-systolic dimension greater than 55 mm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic severe chronic MR with LVEF of 30 to 60 percent and/or end-systolic dimension &ge;40 mm.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Among patients with severe chronic MR who require surgery, mitral valve repair is preferred to mitral valve replacement in the majority of patients and the patients should be referred to surgical centers experienced in mitral valve repair.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of mitral valve surgery in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mitral valve repair in experienced surgical centers in asymptomatic severe chronic MR with preserved left ventricular function (LVEF &gt;60 percent and end-systolic dimension less than 40 mm) if the estimated likelihood of successful repair without residual MR is greater than 90 percent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic patients with severe chronic MR and preserved left ventricular function who have new onset atrial fibrillation or pulmonary hypertension defined as a pulmonary artery systolic pressure &gt;50 mmHg at rest or &gt;60 mmHg with exercise.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; If mitral valve repair is highly likely, severe chronic MR due to a primary abnormality in the mitral valve apparatus (ie, not functional MR), NYHA class III-IV symptoms, and severe left ventricular dysfunction (LVEF less than 30 percent or end-systolic dimension greater than 55 mm).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the usefulness of mitral valve surgery in patients with MR in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Mitral valve repair for severe MR due to severe left ventricular dysfunction (LVEF &lt;30 percent) in patients with persistent NYHA class III-IV symptoms despite optimal therapy for heart failure, including biventricular pacing if warranted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that mitral valve surgery is not useful in patients with MR in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Isolated mitral valve surgery for mild to moderate MR.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Asymptomatic patients with preserved left ventricular function (LVEF &gt;60 percent and end-systolic dimension less than 40 mm) if there is significant doubt about the feasibility of repair.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Mitral valve surgery (repair or valve replacement) in adolescents or young adults with congenital mitral regurgitation (MR)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement mitral valve surgery is indicated in adolescents or young adults with congenital MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Symptomatic severe MR with NYHA class III-IV symptoms.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Asymptomatic severe MR and left ventricular dysfunction, defined as a left ventricular ejection fraction (LVEF) &le;60 mmHg.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Mitral valve repair in experienced surgical centers in asymptomatic severe MR and preserved left ventricular function (LVEF &gt;60 percent) if the estimated likelihood of successful repair without residual MR is greater than 90 percent.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIb - The weight of evidence or opinion is less well established for the usefulness of mitral valve surgery in adolescents or young adults with congenital MR in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Asymptomatic severe and preserved left ventricular function (LVEF &gt;60 percent) if valve replacement is highly likely.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    European Society of Cardiology guideline recommendations for mitral valve surgery in patients with severe primary mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"70%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"10%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Class*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Levels",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle1\">",
"        Ref",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Mitral valve repair should be the preferred technique when it is expected to be durable.",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery is indicated in symptomatic patients with LVEF &gt;30 percent and LVESD &lt;55 mm.",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        B",
"       </td>",
"       <td>",
"        1,2",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery should be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk and flail leaflet and LVESD &ge;40 mm.",
"       </td>",
"       <td>",
"        I",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery should be considered in patients with severe LV dysfunction (LVEF &lt;30 percent and/or LVESD &gt;55 mm) refractory to medical therapy with high likelihood of durable repair and low comorbidity.",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery is indicated in asymptomatic patients with LV dysfunction (LVESD &ge;45 mm and/or LVEF &le;60 percent).",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery should be considered in asymptomatic patients with preserved LV function and new onset of atrial fibrillation or pulmonary hypertension (systolic pulmonary pressure at rest &gt;50 mmHg).",
"       </td>",
"       <td>",
"        IIa",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery may be considered in patients with severe LV dysfunction (LVEF &lt;30 percent and/or LVESD &gt;55 mm) refractory to medical therapy with low likelihood of durable repair and low comorbidity.",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Surgery may be considered in asymptomatic patients with preserved LV function, high likelihood of durable repair, low surgical risk, and:",
"        <ul>",
"         <li>",
"          Left atrial dilatation (volume index &ge;60 ml/m",
"          <sup>",
"           2",
"          </sup>",
"          BSA) and sinus rhythm, or",
"         </li>",
"         <li>",
"          Pulmonary hypertension on exercise (SPAP &ge;60 mmHg at exercise).",
"         </li>",
"        </ul>",
"       </td>",
"       <td>",
"        IIb",
"       </td>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    1. Haan CK, Cabral CI, Conetta DA, Coombs LP, Edwards FH. Selecting patients with mitral regurgitation and left ventricular dysfunction for isolated mitral valve surgery. Ann Thorac Surg 2004;78:820&ndash;825.",
"    <br>",
"     2. Enriquez-Sarano M, Tajik AJ, Schaff HV, Orszulak TA, McGoon MD, Bailey KR, Frye RL. Echocardiographic prediction of left ventricular function after correction of mitral regurgitation: results and clinical implications. J Am Coll Cardiol 1994;24:1536&ndash;1543.",
"     <div class=\"footnotes\">",
"      BSA: body surface area; LV: left ventricle; LVEF: left ventricular ejection fraction; LVESD: left ventricular end-systolic diameter; SPAP: systolic pulmonary artery pressure.",
"      <br>",
"       * Class of recommendation.",
"       <br>",
"        <font class=\"bullet\">",
"         &bull;",
"        </font>",
"        Level of evidence.",
"        <br>",
"         &Delta; Reference(s) supporting class I (A + B) and IIa + IIb (A + B) recommendations.",
"        </br>",
"       </br>",
"      </br>",
"     </div>",
"     <div class=\"reference\">",
"      From: Vahanian A, Alifieri O, Andreotti F, et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33:2451. By permission of European Society of Cardiology. Copyright &copy; 2012 Oxford University Press.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28702=[""].join("\n");
var outline_f28_1_28702=null;
var title_f28_1_28703="Estimated prevalence of non-acid reflux";
var content_f28_1_28703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57581&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Estimated prevalence of non-acid reflux",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 316px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Estimated prevalence of GERD symptoms, persistent symptoms on PPI, and symptomatic non-acid reflux in the United States population (60-40 rule). Epidemiologic studies estimate that approximately 40 percent&nbsp;of the adult population in the United States experiences reflux symptoms at least once a week. Large clinical trials evaluating the efficacy of acid suppressive therapy in the treatment of GERD indicate that approximately 40 percent&nbsp;of GERD patients treated with PPI have persistent symptoms on therapy. Clinical investigations evaluating the association between persistent symptoms on PPI therapy with reflux episodes indicate that approximately 40 percent of patients have symptoms preceded by non-acid reflux. Based on this proportion, we estimate that roughly 19 million adults in the United States have symptomatic non-acid reflux.",
"    <div class=\"footnotes\">",
"     %: percent; GERD: gastroesophageal reflux disease; PPI: proton pump inhibitor.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f28_1_28703=[""].join("\n");
var outline_f28_1_28703=null;
